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General introduction 
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CHRONIC OBSTRUCTIVE PULMONARY DISEASE 
Chronic Obstructive Pulmonary Disease (COPD) is defined as ‘a common, preventable 
and treatable disease that is characterised by persistent respiratory symptoms and 
airflow limitation that is due to airway and/or alveolar abnormalities usually caused by 
significant exposure to noxious particles or gases’1. COPD is an umbrella term for small 
airways disease (obstructive bronchiolitis) and parenchymal destruction (emphysema), 
conditions resulting in chronic airflow limitation1. The most important factor for the 
development and progression of COPD is tobacco smoke2. However, in the last decade 
growing evidence suggests that risk factors other than smoking also contribute to the 
pathophysiology of COPD. Outdoor, occupational and indoor air pollution, lung devel-
opment abnormalities (e.g. respiratory infections during childhood, history of pulmo-
nary tuberculosis), genetics and socioeconomic status account for a substantial propor-
tion of cases worldwide3, 4. 
In subjects with respiratory symptoms, the diagnosis of COPD is confirmed by the pres-
ence of persistent airflow limitation assessed by spirometry, with a ratio of post-
bronchodilator forced expiratory volume in 1 second (FEV1) and forced vital capacity 
(FVC) below 0.701. Recently, it became clear that the burden of COPD is not adequately 
reflected by the severity of airflow limitation, but also by the impact of the disease on 
patient’s health status, perceived respiratory symptoms and the frequency of exacerba-
tions (defined as an acute worsening of disease symptoms)1. Therefore, the updated 
Global initiative for chronic Obstructive Lung Disease (GOLD) recommends not only to 
use the degree of airflow obstruction for classifying patients with COPD, but to integrate 
also the level of patient’s symptoms and exacerbation risk1. 
BURDEN OF COPD 
COPD is a life-threatening lung disease, expected to be the third leading cause of death 
worldwide by 20305. The economic burden is significant, including costs directed at the 
diagnoses of COPD, as well as costs related with the management of COPD, especially 
exacerbations and the presence of comorbidities6. Furthermore, COPD impacts enor-
mously on a patient’s life. Characteristic symptoms of COPD are dyspnoea, cough and 
sputum production, which vary during the day and the week, and are associated with 
problems in performing basic daily activities7, 8. Additionally, patients with COPD are 
susceptible for respiratory infections and prone for exacerbations, which have a detri-
mental impact on a patients’ wellbeing and the underlying disease. Although many 
overlap is present, it is important to differentiate between both disease conditions, as 
they cover a different pathophysiology. 
Chapter 1 
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RESPIRATORY INFECTIONS 
Respiratory infections include among others community acquired pneumonia (CAP), 
which is a major health problem worldwide as it affects all age categories and has a high 
mortality rate9, 10. CAP is characterised by an acute infection of the lung parenchyma 
with onset in the out-of-hospital setting11. Several risk prediction scores exist to predict 
severity and mortality of CAP, to guide CAP management (e.g. determine the level of 
care and treatment intensity)12. CAP in patients with COPD was observed to be more 
severe as compared to non-COPD patients13-16. This was reflected by higher risk predic-
tion scores and more pronounced disturbances in gas exchange. As far as mortality is 
concerned, there is no clear consensus, as some authors report increased short- and 
long-term mortality rates in patients with COPD13, 14, 17, while others observed no differ-
ences compared to non-COPD patients15, 16, 18. Though, COPD has frequently been ob-
served as underlying cause of death17, 19. 
The mechanisms behind the increased CAP risk in patients with COPD are yet to be 
revealed. Possibly, smoking-related effects play a role, as smoking is the most important 
risk factor for developing COPD2, but has also been associated with an increased risk of 
CAP in general11, 20. In contrast, current smoking status was not associated with CAP 
incidence in a cohort of patients with COPD21. Furthermore, variability of smoking status 
is common, as many need to undergo several quit attempts before really stopping 
smoking22. The impact of this variability has not been taken into account in former re-
search23. Yet, smoking cessation has been related to a significant decreased CAP risk in 
the general population24. 
In order to optimise the management of CAP it is mandatory to know the pathogens 
involved. Streptococcus pneumoniae is the most frequently identified pathogen in CAP 
in general9, 25. In contrast, Haemophilus influenzae, Pseudomonas aeruginosa and 
Moraxella catarrhalis are bacterial pathogens frequently detected in patients with 
COPD26. Whether this pattern is also reflected in COPD patients with CAP is currently 
not sufficiently clear. However, it is necessary to clarify this point, as knowledge of anti-
biotic susceptibility patterns is needed to guide treatment and avoid inadequate treat-
ment contributing to antibiotic resistance27. This is especially true in patients with 
COPD, as pathogen detection may also represent colonisation. The latter remains a 
huge challenge, as isolated pathogens in stable condition are comparable to those iso-
lated during infection. This makes it difficult to differentiate between both conditions in 
clinical practice. Additionally, it is currently unknown whether possible differences in 
the bacterial aetiology have consequences for short- and long-term mortality. 
1
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EXACERBATIONS 
Exacerbations are defined as ‘an acute worsening of respiratory symptoms that result in 
additional therapy’1. They contribute to the overall severity in individual patients, with a 
large heterogeneity between patients28, negatively impacting on patient’s wellbeing, 
disease outcomes and prognosis29. Exacerbations occur more frequently than CAP in 
patients with COPD30,31. The presence of exacerbations has been related to the severity 
of COPD, although patients with mild-to-moderate disease also experience exacerba-
tions28,32. The same pattern is seen for hospitalisation, as the proportion of exacerbating 
patients who are hospitalised increase by severity of COPD32. A history of exacerbations 
is the best predictor for an exacerbation32, but still relatively little is known about de-
terminants. This is also due to the fact that exacerbations are thought to be underre-
ported.  
Treatment of exacerbations is challenging, as exacerbations might involve bacterial or 
viral infection and environmental pollution33. Consequently, prevention of exacerba-
tions is a key component of COPD-management. Prevention and reduction of exacerba-
tions is mostly derived by active immunisation, including influenza and pneumococcal 
vaccination. Additionally, pulmonary rehabilitation is a promising intervention to pre-
vent exacerbations, especially by increasing self-management skills to early recognize 
symptoms and react adequately34. Furthermore, pulmonary rehabilitation has favoura-
ble effects on exercise capacity and health status35, factors affected by exacerbations. 
Nevertheless, a subset of patients with COPD does not respond to36, or complete pul-
monary rehabilitation37. Exacerbations are often described as cause38, while evidence is 
limited. 
RESPIRATORY MICROBIOME 
Respiratory infections and exacerbations are acute events in patients with COPD. Until 
now it is unclear whether the pathogen detected by culture is really the infectious trig-
ger. Colonisation might play a role, with pathogens already present in stable state. On 
the other hand, former research showed that isolation of a new strain of a pathogen 
was associated with acute exacerbations39. Bacterial load seemed not to be related to 
the presence of exacerbations, when compared to the bacterial load observed in stable 
state40. These results strengthen the use of quantitative assessment of sputum cultures, 
instead of semi quantitative sputum cultures, which are not useful in determining the 
etiologic role of the isolated pathogen. Overall, a better understanding of the host-
pathogen interaction that underlies exacerbations and infections of COPD is necessary, 
as this interaction is more complicated than simple changes in concentrations of bacte-
ria26,40. As such, it is clear that assessing the microbiology and its relation with disease 
Chapter 1 
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status is complex. Clearly, more insight is needed into the pathogen distribution in sta-
ble state in patients with COPD and the presence of pathogens in the lungs of healthy 
individuals, as well as the contribution of infections during disease state. The respiratory 
microbiome can potentially contribute to these issues, and might overcome limitations 
of traditional culture methods. 
For a long time, the lungs of healthy individuals were considered to be sterile, while the 
lungs of patients with COPD were believed to be colonised41,42. This assumption is re-
voked, as it was demonstrated that the lungs of healthy individuals are not sterile, but 
inhabited by communities of microorganisms, also called the respiratory microbiome41-
43. Research concerning the respiratory microbiome is primarily focussing on the bacte-
riome (bacteria), while the virome (viruses) and mycobiome (fungi) are also part of it. 
The precise role of the respiratory microbiome and the possible contribution to, or 
protection from disease is unknown and needs further assessment. 
Until now, microbiome research was mainly performed by using invasive sampling tech-
niques, which are not applicable in daily routine. Sputum wasn’t assumed to be repre-
sentative for the respiratory microbiome, showing an overrepresentation of the oro-
pharyngeal flora, representing a different bronchial compartment than bronchoalveolar 
lavage samples44. In contrast, a lot of respiratory microbiome research has been per-
formed using sputum samples45-49, with the advantage that it is a non-invasive proce-
dure, allowing multiple sampling periods, to assess the microbiome over time. Insight 
into different sample types is necessary, in order to determine the optimal sample type 
for respiratory microbiome analysis in clinical practice. 
AIMS OF THIS THESIS 
CAP and exacerbations are complex concepts in patients with COPD, which have a tre-
mendous impact on a patient’s life. A better understanding of these concepts may con-
tribute to improved disease management. The respiratory microbiome is promising in 
determining the microbial aetiology of COPD in both stable and acute condition. There-
fore, the aims of this thesis were to: 
- Study the impact of COPD on CAP severity and mortality. 
- Determine the bacterial aetiology of CAP in patients with and without COPD; and to 
study the association between the bacterial aetiology, empirical antibiotic treat-
ment, serum markers and mortality. 
- Evaluate the association between COPD and CAP by smoking status. 
- Compare clinical characteristics and health status of spontaneous sputum producers 
with a positive culture, negative culture and non-sputum producers in a cohort of 
patients with COPD referred for pulmonary rehabilitation. 
1
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- Investigate the impact of acute exacerbations on adherence and outcomes of pul-
monary rehabilitation in patients with COPD. 
- Determine the optimal sample type for respiratory microbiome analysis by the IS-
pro technology. 
OUTLINE OF THIS THESIS 
Chapter 2 provides more insight in differences between CAP patients with and without 
COPD concerning severity of CAP and short- and long-term mortality in CAPNETZ, a 
multi-centre observational study. 
Chapter 3 describes the bacterial aetiology of CAP in patients with and without COPD, 
and possible associations with the empirical antibiotic treatment, serum markers and 
short- and long-term mortality in CAPNETZ. 
Chapter 4 includes data from the Clinical Practice Research Datalink GOLD (CPRD), a 
population-based cohort study in the UK, exploring the influence of smoking on risk of 
CAP in patients with and without COPD. 
Chapter 5 provides more insight into differences between sputum producers with a 
positive culture, negative culture and non-sputum producers on clinical characteristics 
and health status at the start of pulmonary rehabilitation, in the Chance study, an ob-
servational mono-center study. 
Chapter 6 explores the impact of acute exacerbations on dropout and response of pul-
monary rehabilitation, stratified by exacerbation severity, in the Chance study. 
Chapter 7 determines which sample type is valid for assessing the respiratory microbi-
ome in patients with COPD in clinical practice. 
Chapter 8 discusses the previous chapters and future directions for research and clinical 
practice. 
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Increased severity and mortality  
of CAP in COPD: 
Results from the German 
Competence Network, CAPNETZ 
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ABSTRACT 
Background: Mortality of community acquired pneumonia (CAP) remains high despite 
significant research efforts. Knowledge about comorbidities including Chronic Obstruc-
tive Pulmonary Disease (COPD) might help to improve management and ultimately, 
survival. The impact of COPD on CAP severity and mortality remains a point of discus-
sion. 
Objectives: Assess the prevalence and clinical characteristics of COPD in the observa-
tional German Competence Network for CAP, CAPNETZ, and to study the impact of 
COPD on CAP severity and mortality. 
Methods: 1307 consecutive patients with CAP (57.0% males, age 59.0±18.5), classified 
as CAP-only (n=1043; 78.0%) and CAP-COPD (n=264; 20.2%) were followed up for 180 
days. Associations between CAP, COPD and mortality were evaluated by univari-
ate/multivariate and Kaplan-Meier survival analyses. 
Results: CAP-COPD patients were older, more often males, current/former smokers, 
with higher confusion-urea-respiratory rate-blood pressure (CURB) scores. Length of 
hospital stay, urea, glucose and leucocytes plasma levels, and arterial carbon dioxide 
tension (PaCO2) were significantly increased in CAP-COPD. Thirty, 90- and 180-day mor-
tality rates were significantly increased in CAP-COPD (p=0.046, odds ratio [OR]=2.48, 
95% confidence interval [CI] 1.015-6.037; p=0.003, OR=2.80, 95%CI 1.430-5.468; 
p=0.001, OR=2.57, 95%CI 1.462-4.498; respectively). Intensive care unit (ICU)-admission 
and age, but not COPD, were identified as independent predictors of short-and long-
term mortality. 
Conclusion: Severity as well as mortality was significantly higher in COPD patients with 
CAP. To improve CAP management with the aim to decrease its still-too-high mortality, 
underlying comorbidities, particularly COPD, need to be assessed. 
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INTRODUCTION 
Community acquired pneumonia (CAP) is a major cause of morbidity and mortality 
worldwide1. Chronic Obstructive Pulmonary Disease (COPD) is a common comorbidity in 
these patients. Older age, being male and having other comorbidities have been associ-
ated with more severe CAP in COPD patients compared with CAP in patients without 
COPD2,3. 
Conflicting evidence exists regarding mortality rates. Some studies suggested higher 
mortality rates in COPD patients with CAP2-4, while others did not confirm this5-8. The 
association between confusion-urea-respiratory rate-blood pressure (CURB) severity 
scores9, COPD and mortality, has been studied sparsely. Myint et al.10 stated that CURB 
scores were useful in predicting CAP mortality, but did not specify this in COPD patients. 
The same was reported by others, when comparing different severity scores for CAP11. 
When adding age ≥65 years as a component of the severity score (CURB-65), Snijders et 
al.5 did not find any differences between CAP patients with and without COPD in severi-
ty scoring and 30-day mortality. Crisafulli et al.7 reported that CURB-65 scores were 
significantly higher in CAP-COPD patients, but did not investigate any possible associa-
tion with mortality. A recent meta-analysis observed no significant association between 
COPD and increased 30-day mortality in patients with CAP12. Less data is available on 
long-term mortality. 
Moreover, information about clinical parameters and their association with CAP and 
COPD is limited, sometimes contradicting and difficult to compare. The latter may be 
related to the context, as some investigators described the association between clinical 
parameters and mortality in CAP-COPD patients3,6, while others looked at differences in 
clinical parameters between CAP-COPD patients and CAP-only patients7,8. Factors found 
to be associated with CAP-COPD are respiratory rate ≥30/min and increased arterial 
carbon dioxide tension (PaCO2)
8. Others, however, did not confirm this7. Mortality in 
CAP-COPD was found to be related to a PaCO2 ≥45 mmHg
3, an arterial oxygen concen-
tration (PaO2) ≤60 mmHg
3 and a respiratory rate ≥30/min.3,6. 
The aims of this study were to assess the prevalence of COPD in a well-characterized 
cohort of CAP patients, represented in the German Competence Network for CAP 
(CAPNETZ) and to determine clinical characteristics of these patients compared with 
CAP-only patients. Also, the impact of COPD on CAP severity and mortality and its de-
terminants were prospectively studied. 
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MATERIALS AND METHODS 
Data were derived from a multi-center observational study initiated by CAPNETZ13. 
Methodological details such as sampling techniques, microbiological diagnostics and 
laboratory processing of this study were previously published14. The study design was 
approved by the local ethics committees of all participating centers. All patients gave 
written, informed consent. 
Study population 
CAPNETZ included 1788 CAP patients between December 2009 and June 2012. Patients 
were eligible to be included in CAPNETZ when age was ≥18 years, having a new pulmo-
nary infiltrate on chest x-ray and 1 or more clinical symptoms consisting of cough, puru-
lent sputum, positive auscultation or fever. Patients were excluded when hospitalized 
during the previous 28 days, chronically immunosuppressed, HIV-infected or having 
active tuberculosis. Follow-up included a structured interview on outcome parameters 
at 30 and 180 days.  
The presence of COPD in CAP patients was assessed from the medical record, based on 
post-bronchodilator forced expiratory volume in 1 second (FEV1) and forced vital capac-
ity (FVC) in the previous six months15. COPD was defined as FEV1/FVC ratio <0.7
16. Study 
physicians assessed spirometric data, confirmed diagnosis and staged patients accord-
ing to the Global initiative for chronic Obstructive Lung Disease (GOLD) guidelines. No 
direct spirometric data was available, only the diagnosis and staging made by study 
physicians. Patients were excluded from the current study when no data on COPD diag-
nosis was available. Moreover, cigarette smoke exposure and appraisal of inhalation 
medication was used in order to identify COPD patients. 
Study procedures 
CURB scores were calculated based on the sum of points, with 1 point assigned for the 
presence of each criterion (confusion, urea >7 mmol/l, respiratory rate ≥30/minutes, 
and blood pressure) on admission to the hospital9,17-19. CURB scores were assessed 
instead of CURB-65 scores, as age was included as a possible confounder. 
Date and cause of death was assessed from an autopsy report and/or the medical rec-
ord. Cause of death was specified as pneumonia including sepsis, cardiac cause, pulmo-
nary embolism, other, or unknown. Overall mortality and groups-specific mortality were 
analysed, with 30-, 90- and 180-day mortality calculated by subtracting the date of 
examination from the date of death. COPD severity and comorbidities were taken as 
additional factors possibly contributing to mortality in the CAP-COPD group. The pres-
ence of comorbid diseases was recorded from the medical records of patients. 
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To avoid possible misdiagnosis of undetected COPD in smoking, non-COPD patients, 
additional analyses were performed by excluding current and former smokers from the 
CAP-only group (Supplemental material). 
Statistical analysis 
Data analyses were performed using SPSS for Windows version 20.0. Variables were 
tested on normality by the Kolmogorov-Smirnov and Sapiro-Wilk test. Continuous data 
are presented as mean±standard deviation (SD) or median (interquartile range) and 
categorical data as counts and percentages. To compare baseline characteristics and 
clinical parameters of CAP-only and CAP-COPD patients, Mann Whitney U-test, Chi-
square test or Fisher’s Exact test were performed, as appropriate. Chi-square tests and 
Kaplan-Meier survival curves were assessed to analyse mortality. A Cox Model was 
computed, with COPD as covariate and hospitalization as strata, to analyse mortality. 
Odds ratio (OR) and independent predictors of mortality were assessed by logistic re-
gression analyses. The value of p<0.05 was considered to be statistically significant. 
RESULTS 
In total, 1788 CAP patients were included in the CAPNETZ study. Of these, 1307 CAP 
patients (73.1%) matched the inclusion criteria of the current study. A total of 264 pa-
tients (20.2%) fulfilled the diagnostic criteria for COPD. 
Table 1 shows the baseline characteristics of the CAP-only and CAP-COPD patients. CAP-
COPD patients were significantly older, more frequently male and had a higher mean 
pack years of smoking compared to CAP-only patients. The proportion of patients using 
long-term oxygen therapy (LTOT) was significantly increased in CAP-COPD patients. 
Comorbidities were more often present in CAP-COPD patients, especially chronic heart 
failure and other chronic respiratory/lung diseases.  
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Table 1. Baseline characteristics 
 CAP-only  
(n=1043) 
CAP-COPD  
(n=264) 
p-value 
Age (years) 57.0 (41.0-72.0) 71.0 (63.0-77.0) <0.001 
Gender 
Male 
Female 
 
575 (55.1) 
468 (44.9) 
 
170 (64.4) 
94 (35.6) 
 
0.007 
Smoking 
Never smoked 
Stopped smoking 
Current smoking 
 
561 (54.7) 
194 (18.9) 
270 (26.3) 
 
78 (29.8) 
104 (39.7) 
80 (30.5) 
 
<0.001 
 
 
Pack years 0.0 (0.0-15.0) 25.0 (0.0-40.0) <0.001 
GOLD 
I 
II 
III 
IV 
 
- 
- 
- 
- 
 
55 (20.8) 
92 (34.8) 
71 (26.9) 
46 (17.4) 
 
- 
BMI (kg/m2) 25.4 (22.2-29.4) 24.8 (22.4-28.9) ns. 
LTOT 14 (1.3) 63 (23.9) <0.001 
Vaccination 
Influenza 
Influenza A/H1N1 
Pneumococcal 
Pertussis 
 
268 (25.8) 
53 (9.7) 
71 (6.9) 
109 (11.1) 
 
134 (51.0) 
22 (15.4) 
63 (24.0) 
11 (4.3) 
 
<0.001 
ns. 
<0.001 
0.001 
Co-morbidities 
0 
1 
2 
>2 
Chronic heart failure 
Chronic renal disease 
Chronic liver disease 
Cerebrovascular disease 
Diabetes mellitus 
Chronic respiratory/ lung disease 
Asthma 
Bronchiectasis 
Lung fibrosis 
Sarcoidosis 
Bronchial/lung cancera 
Sleep apnoea 
Other 
 
191 (37.7) 
202 (39.8) 
77 (15.2) 
37 (7.3) 
121 (11.6) 
81 (7.8) 
23 (2.2) 
36 (3.5) 
133 (12.8) 
151 (14.5) 
97 (9.3) 
9 (0.9) 
9 (0.9) 
2 (0.2) 
5 (0.5) 
12 (1.2) 
21 (2.0) 
 
41 (23.0) 
76 (42.7) 
38 (21.3) 
23 (12.9) 
64 (24.2) 
26 (9.8) 
12 (4.5) 
18 (6.8) 
49 (18.6) 
74 (28.0) 
19 (7.2) 
4 (1.5) 
4 (1.5) 
1 (0.4) 
8 (3.0) 
11 (4.2) 
31 (11.7) 
 
<0.001 
 
 
 
0.002 
ns. 
ns. 
ns. 
ns. 
<0.001 
<0.001 
ns. 
ns. 
ns. 
0.028 
ns. 
<0.001 
Patient from nursing home 17 (1.6) 9 (3.4) ns. 
Patient hospitalised 825 (79.1) 214 (81.1) ns. 
Length of stay (days) 9.0 (7.0-12.0) 11.0 (8.8-14.0) <0.001 
ICU-admission 65 (7.9) 19 (8.9) ns. 
Notes: Data are presented as median (interquartile range) or n (%). a Currently no radiation or chemotherapy. 
Abbreviations: CAP, community acquired pneumonia; COPD, Chronic Obstructive Pulmonary Disease; BMI, 
body mass index; LTOT, long-term oxygen therapy; ICU, intensive care unit. 
2Severity and mortality of CAP in COPD 
 23 
Laboratory data, clinical parameters and CURB-scores are shown in Table 2. Significantly 
increased plasma levels of urea, glucose and leucocytes were observed in CAP-COPD 
patients. In addition, higher proportions of CAP-COPD patients were hypercapnic and 
had acidosis. PaO2 and O2 saturations were significantly lower and respiratory rates 
significantly higher in CAP-COPD patients, compared with CAP-only patients. CAP-COPD 
patients scored significantly higher on the CURB index, indicating more severe CAP. 
Table 2. Laboratory data, clinical parameters and severity scores 
 CAP-only (n=1043) CAP-COPD (n=264) p-value 
Urea (mg/dl) 13.6 (10.2-19.3) 16.9 (11.9-25.0) <0.001 
CRP (mg/dl) 100.0 (27.8-200.0) 116.0 (22.0-208.9) ns. 
Glucose (mg/dl) 112.0 (95.0-136.0) 124.0 (102.0-153.9) <0.001 
Leucocytes (x109/l) 10.7 (7.8-14.8) 12.3 (9.5-16.3) <0.001 
PaO2 (mmHg) 65.0 (57.0-76.0) 61.0 (55.0-70.0) 0.001 
PaCO2 (mmHg) 
≤ 45 mmHg 
> 45 mmHg 
34.0 (31.0-38.0) 
619 (94.5) 
36 (5.5) 
37.0 (33.0-43.0) 
153 (78.5) 
42 (21.5) 
<0.001 
<0.001 
pH 
≤ 7.35 
> 7.35 
7.5 (7.4-7.5) 
12 (1.8) 
645 (98.2) 
7.4 (7.4-7.5) 
16 (8.2) 
179 (91.8) 
<0.001 
<0.001 
O2 saturation (%) 94.0 (92.0-96.0) 92.0 (89.3-95.0) <0.001 
Respiratory rate 
≥ 30/min 
20.0 (18.0-24.0) 
56 (5.6) 
21.0 (18.0-25.0) 
27 (10.3) 
<0.001 
0.007 
CURB 
0 
1 
2 
3 
4 
 
548 (57.3) 
320 (33.4) 
83 (8.7) 
6 (0.6) 
- 
 
114 (44.7) 
89 (34.9) 
48 (18.8) 
3 (1.2) 
1 (0.4) 
 
<0.001 
Notes: Data are presented as median (interquartile range) or n (%). Abbreviations: CAP, community acquired 
pneumonia; COPD, Chronic Obstructive Pulmonary Disease; CRP, C-reactive protein; CURB, Confusion, Urea, 
Respiratory rate, and Blood pressure. 
Comparisons between CAP-COPD patients and non-smoking, CAP-only patients (to 
avoid possible misdiagnosis of undetected COPD in smoking, CAP-only patients), are 
shown in Tables S1 and S2 (Supplemental material). Results of baseline characteristics 
were comparable. Only bronchial/lung cancer was no longer significant when excluding 
former and current smokers of the CAP-only group. No differences in results were ob-
served when excluding former and current smokers from the CAP-only group concern-
ing laboratory data, clinical parameters and severity scores. 
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Mortality 
During the whole study period, 55 patients (4.2%) died. Table 3 provides an overview of 
the mortality rates specified for CAP-only and CAP-COPD patients. A significant differ-
ence in 30-, 90- and 180- day mortality (p=0.046, OR=2.48; p=0.003, OR=2.80; p=0.001, 
OR=2.57; respectively) was observed. Cause of death was not significantly different 
between CAP-only and CAP-COPD patients at the different time points. Table S3 (Sup-
plemental material) shows the mortality rates and cause of death of non-smoking, CAP-
only patients compared with CAP-COPD patients. 
Table 3. Mortality rates and cause of death 
 Total 
(n=1307) 
CAP-only 
(n=1043) 
CAP-COPD 
(n=264) 
p-value OR (95% CI) 
t = 30 days 21 (1.6) 13 (1.2) 8 (3.0) 0.046 2.48 (1.015-6.037) 
Cardiac 
Pneumonia (incl. sepsis) 
Other 
Unknown 
 1 (7.7) 
7 (53.8) 
2 (15.4) 
3 (23.1) 
1 (12.5) 
3 (37.5) 
3 (37.5) 
1 (12.5) 
ns.  
t = 90 days 37 (2.8) 22 (2.1) 15 (5.7) 0.003 2.80 (1.430-5.468) 
Cardiac 
Pneumonia (incl. sepsis) 
Other  
Unknown 
 3 (13.6) 
7 (31.8) 
8 (36.4) 
4 (18.2) 
1 (6.7) 
4 (26.7) 
7 (46.7) 
3 (20.0) 
ns.  
t = 180 days 55 (4.2) 34 (3.3) 21 (8.0) 0.001 2.57 (1.462-4.498) 
Cardiac 
Pneumonia (incl. sepsis) 
Other  
Unknown 
 5 (14.7) 
11 (32.4) 
12 (35.3) 
6 (17.6) 
1 (4.8) 
8 (38.1) 
8 (38.1) 
4 (19.0) 
ns.  
Notes: Data are presented as n (%). Abbreviations: CAP, community acquired pneumonia; COPD, Chronic 
Obstructive Pulmonary Disease; OR, odds ratio; CI, confidence interval. 
In accordance with Table 3, a Kaplan-Meier survival analysis showed an increased 30-, 
90- and 180-day mortality in CAP-COPD patients (Figure 1, Log Rank 11.762, p=0.001). A 
Kaplan-Meier survival analysis of long-term mortality in non-smoking, CAP-only and 
CAP-COPD patients is shown in Figure S1 (Supplemental material). 
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Figure 1. Long-term mortality in CAP patients with and without COPD 
Kaplan Meier survival curve (t=180 days) for CAP patients with the presence of COPD (- - - -; n=264) and 
without (  ̶  ̶ ̶  ; n=1043) the presence of COPD. 
 
Most patients who died, were hospitalized patients. When stratified for COPD, a signifi-
cant difference was found for short- and long-term mortality in hospitalized patients, 
compared to outpatient mortality (Table 4). The Kaplan-Meier survival analysis supports 
these findings (Figure 2). Moreover, a Cox Model showed a hazard ratio of 2.47 
(p=0.001; 95%CI 1.432-4.251). 
Table 4. Mortality stratified for hospitalisation and COPD 
 Outpatient Hospitalised p-value 
 CAP-only 
(n=214) 
CAP-COPD 
(n=49) 
CAP-only 
(n=825) 
CAP-COPD 
(n=214) 
 
t = 30 days - - 13 (1.6) 8 (3.7) 0.015 
t = 90 days 1 (0.5) 1 (2.0) 21 (2.5) 14 (6.5) 0.002 
t = 180 days 1 (0.5) 2 (4.1) 33 (4.0) 19 (8.9) <0.001 
Notes: Data are presented as n (%). Abbreviations: CAP, community acquired pneumonia; COPD, Chronic 
Obstructive Pulmonary Disease. 
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Figure 2. Long-term mortality in outpatient and hospitalised CAP patients with and without COPD 
Kaplan Meier survival curve (t=180 days) for outpatient CAP patients without COPD (. . . . .; n=214), hospitalised 
CAP patients without COPD (  ̶  ̶ ̶  ; n=825), outpatients CAP patients with COPD (-_- -_-; n=49), hospitalised CAP 
patients with COPD (- - -; n=214) (Log Rank 19.314; p<0.001). 
 
Table 5 shows short- and long-term mortality rates per CURB-score for both CAP-COPD 
and CAP-only patients. Mortality rates are low, but increase with more severe CAP ac-
cording to CURB-scores. 
Table 5. Short- and long-term mortality per CURB-scores in CAP-only and CAP-COPD patients 
 CAP-only CAP-COPD 
CURB-
scores 
n 30-day 90-day 180-day n 30-day 90-day 180-day 
0 114 - 2 (1.8) 4 (3.5) 548 3 (0.5) 6 (1.1) 10 (1.8) 
1 89 5 (5.6) 6 (6.7) 7 (7.9) 320 5 (1.6) 10 (3.1) 17 (5.3) 
2 48 1 (2.1) 5 (10.4) 8 (16.7) 83 2 (2.4) 3 (3.6) 4 (4.8) 
3 3 1 (33.3) 1 (33.3) 1 (33.3) 6 1 (16.7) 1 (16.7) 1 (16.7) 
4 1 1 (100.0) 1 (100.0) 1 (100.0) 0 - - - 
Notes: Data are presented as n (%). Abbreviations: CAP, community acquired pneumonia; COPD, Chronic 
Obstructive Pulmonary Disease; CURB, Confusion, Urea, Respiratory rate, and Blood pressure. 
Therapy 
Therapy initiated when CAP was diagnosed, could have influenced the outcomes. A 
significant difference between CAP-only and CAP-COPD patients was found for mono-
therapy with macrolides, combination therapy of penicillin and macrolides, and combi-
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nation therapy of penicillin and fluorchinolone (Table S4, Supplemental material). 
Mono-therapy with macrolide and combination therapy of penicillin and macrolide was 
more often initiated in CAP-only patients, while a combination therapy of penicillin and 
fluorchinolone was more often initiated in CAP-COPD patients. When comparing de-
ceased and survived COPD-patients, survived patients were more frequently treated 
with fluorchinolone mono-therapy (Table S5, Supplemental material). In CAP-only pa-
tients, deceased patients were more often treated with penicillin mono-therapy, while 
survived patients were more often treated with a combination therapy of penicillin and 
macrolides (Table S6, Supplemental material). Analysing therapeutic failure, no differ-
ences were observed in change of therapy after 14 days, comparing CAP-only with CAP-
COPD patients (32.4% versus 26.2%, p>0.05). 
Predictors of mortality 
Logistic regression analyses were conducted to predict short-term mortality in CAP-
patients by including age, gender, smoking status, LTOT, vaccination status, comorbidi-
ties other than COPD, ICU-admission and COPD as predictors. Test of the full model 
against a constant-only model was statistically significant (Goodness-of-fit: Chi-
square=0.008, Hosmer and Lemeshow-test=0.389). Age was a significant predictor 
(p=0.008, OR=1.1, 95%CI 1.021-1.149), as well as ICU admission (p=0.047, OR=4.2, 
95%CI 1.022-17.669). 
For long-term mortality, a logistic regression analysis was conducted by including age, 
gender, smoking status, LTOT, vaccination status, co-morbidities other than COPD, 
CURB, COPD, ICU-admission, therapy change and GOLD-stage as possible predictors. 
Test of the full model against a constant only model was statistically significant for 90- 
and 180-day mortality (Goodness-of-fit: Chi-square=0.003, Hosmer and Lemeshow-
test=0.828; Chi-square=0.002, Hosmer and Lemeshow-test=0.360; respectively). Age 
was a significant predictor for long-term mortality (p=0.014, OR=1.2, 95%CI 1.035-
1.359; p=0.035, OR=1.1, 95%CI 1.008-1.259; respectively). Moreover, ICU-admission 
was predictive for long-term mortality (90-day mortality p=0.008, OR=16.0, 95%CI 
2.087-121.878; 180-day mortality p=0.018, OR=9.6, 95%CI 1.483-62.797). 
When excluding current and former smokers from the CAP-only group, results of logistic 
regression analysis were nearly comparable (Table S7, Supplemental material). 
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DISCUSSION 
The present multi-center prospective study has several important findings. COPD is a 
common comorbidity of CAP and associated with increased short- and long-term mor-
tality. Age and ICU-admission, and not COPD per se, were independent risk factors for 
CAP mortality. Additionally, CAP in COPD patients is related to increased severity of 
pneumonia and prolonged hospitalization. The clinical presentation of CAP in COPD 
patients is different as compared to CAP-only patients. 
In accordance with previous CAPNETZ publications20,21, overall CAP mortality rates were 
low in the present population. There are several explanations for this observation. First, 
it should be noted that the average age of the study population was lower than in most 
registry studies, which partly explains the lower mortality rates. Moreover, signed in-
formed consent was obligatory for participation in CAPNETZ, while in population-based 
studies, this is not the case22. Thus, possibly less critically ill patients were included in 
the present study, as more critically ill patients were not able to provide written in-
formed consent. 
Despite the low mortality rates, COPD patients had more than twice as high a risk of 
dying due to CAP than CAP-only patients. Other authors observed no differences in 
short-term mortality comparing CAP-COPD patients with CAP-only5-8. The discrepancies 
found can possibly be due to inclusion of ICU patients with very severe pneumonia2, 
differences in severity of airflow limitation in COPD patients, variability in other pa-
tients’ characteristics, such as age and comorbidities3,4,6,8, and the initiated therapy. 
To our knowledge, this is the first study prospectively addressing 180-day mortality. 
Others found contradicting results. Restrepo et al.4 found a significantly higher 90-day 
mortality rate for CAP-COPD patients, whereas Crisafulli et al.7 did not find differences 
in 90-day, as well as 1-year mortality. 
Finding significant differences when comparing CAP-only and CAP-COPD patients in 
univariate analysis, suggested that COPD could be of influence on mortality rates in CAP 
patients. However, when adjusting for other characteristics, COPD was no independent 
predictor of short-and long-term mortality. This is in line with a recent meta-analysis, in 
which COPD didn’t affect mortality in patients with CAP (OR=1.44, 95%CI 0.97-2.16)12. 
By our knowledge, Restrepo et al.4 were the only ones who assessed the relationship 
between COPD and long-term mortality in multivariate analyses. They observed an 
association between COPD and 90-day mortality. It is worth noticing that, all referred 
studies used different characteristics to adjust for, which could have influenced the 
results. 
Predictors of short- and long-term CAP mortality in the present study were age and ICU-
admission. Age as an independent risk factor is not surprising, as older age itself is asso-
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ciated with increased mortality. In addition to age, ICU-admission was associated with 
an increased risk of both short-and long-term mortality. Comparable results of ICU-
admission between CAP-COPD and CAP-only patients were observed by others3,6,8. ICU-
admission was identified as a significant predictor of CAP-mortality by others, which did 
not sustain when adjusted for other confounders3,6. In contrast, Restrepo et al.4 ob-
served increased ICU-admission in CAP-COPD patients, which did not result in differ-
ences in 30- and 90-day mortality rates comparing COPD and non-COPD patients who 
needed ICU-admission. Rello et al.2 observed a higher ICU mortality in CAP-COPD pa-
tients, compared with non-COPD patients. 
The length of hospital stay was increased in CAP-COPD patients. Pifarre et al.8 showed 
comparable results in CAP-COPD patients, while others did not find this association3,5,7. 
Differences can partly be explained by the criteria used to discharge patients, which 
differ between hospitals, the attending physician and different health care systems. 
However, longer hospital stays could be anticipated24,25, as CAP-COPD patients suffered 
from more severe CAP. 
The question arose if including former and current smokers in the CAP-only group could 
have influenced the outcomes, as there is a possibility that smoking, CAP-only patients 
are in fact CAP-COPD patients. Results of baseline characteristics, laboratory data, clini-
cal parameters, severity scores and mortality rates were almost comparable to the 
results stated above (Supplemental material). Overall, it could be stated that smoking 
status of CAP-only patients was not of influence on characteristics of group comparisons 
and mortality-rates. 
A limitation of the present study is that the primary outcome of the initial CAPNETZ-
study was not to describe mortality rates in CAP-COPD patients, although mortality in 
CAP patients was one of the objectives. Assessment of COPD as a comorbidity was add-
ed to the study starting in December 2009. Due to the study design, this assessment 
relied on medical reports because patients were included during the acute phase of 
their pneumonia. Hereby, there was no structured extensive baseline assessment of 
COPD severity. However, lung function results, together with cigarette smoke exposure 
and appraisal of inhalation medication, were used to identify COPD patients. Study 
physicians assessed the most recent lung function results and defined the appropriate 
GOLD stage. This resulted in data concerning COPD diagnosis and severity. We chose 
this concept in order to keep the extensive database manageable with the drawback of 
lacking specific lung function data. 
A strength of the present study is the extensive manner and accurate characterization 
of CAP patients systematically including chest x-ray. Using a combination of chest x-ray 
and clinical symptoms to diagnose pneumonia, provides a more objective way of diag-
nosis, as compared to using only physical examination, clinical characteristics, or chest 
x-ray alone2,4. Moreover, CAPNETZ has a prospective design and is possibly the largest 
Chapter 2 
 30 
cohort on CAP worldwide. It is a multi-center study, with centers in 5 different Europe-
an countries, including both in- and outpatients, which makes the results also relevant 
for the general population. The cohort is representative of patients with CAP in more 
economically developed countries26.  
In conclusion, COPD is common in patients with CAP and results in increased severity of 
pneumonia. Moreover, age and ICU-admission are important risk factors for mortality in 
CAP. Further study of ICU-admission as a risk factor seems warranted. To us, there is no 
clear therapeutic pattern which could conclusively explain the differences in mortality 
discussed above. Although COPD itself was not an independent risk factor for mortality, 
this group is at higher risk of dying due to CAP, with generally a higher age and more 
severe CAP. Further research is necessary to identify specific COPD characteristics asso-
ciated with mortality, which can possibly contribute to better management of CAP-
COPD patients. 
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SUPPLEMENTAL MATERIAL 
Table S1. Baseline characteristics of non-smoking CAP-only vs. CAP-COPD patients 
 CAP-only  
(n=561) 
CAP-COPD  
(n=264) 
p-value 
Age (years) 60.0 (41.0-74.0) 71.0 (63.0-77.0) <0.001 
Gender  
Male 
Female 
 
253 (45.1) 
308 (54.9) 
 
170 (64.4) 
94 (35.6) 
 
<0.001 
Smoking  
Never smoked 
Stopped smoking 
Current smoking  
 
561 (100) 
- 
- 
 
78 (29.8) 
104 (39.7) 
80 (30.5) 
 
<0.001 
 
 
Pack years  - 25.0 (0.0-40.0) - 
BMI (kg/m2) 25.2 (22.3-29.7) 24.8 (22.4-28.9) ns. 
LTOT  11 (2.0) 63 (23.9) <0.001 
Vaccination 
Influenza 
Influenza A/H1N1 
Pneumococcal  
Pertussis  
 
152 (27.1) 
31 (10.4) 
41 (7.4) 
57 (10.8) 
 
134 (51.0) 
22 (15.4) 
63 (24.0) 
11 (4.3) 
 
<0.001 
ns. 
<0.001 
0.003 
Co-morbidities 
0 
1 
2 
>2 
Congestive heart failure 
Chronic renal disease 
Chronic liver disease 
Cerebrovascular disease 
Diabetes mellitus 
Chronic respiratory/ lung disease 
Asthma 
Bronchiectasis 
Lung fibrosis 
Sarcoidosis 
Bronchial/lung cancera 
Sleep apnoea 
Other 
 
99 (37.9) 
97 (37.2) 
49 (18.8) 
16 (6.1) 
66 (25.3) 
42 (16.1) 
10 (3.8) 
16 (6.1) 
69 (26.4) 
83 (14.8) 
55 (67.1) 
8 (9.8) 
5 (6.1) 
2 (2.4) 
4 (4.9) 
6 (7.3) 
10 (12.2) 
 
41 (23.0) 
76 (42.7) 
38 (21.3) 
23 (12.9) 
64 (36.0) 
26 (14.6) 
12 (6.7) 
18 (10.1) 
49 (27.5) 
74 (28.0) 
19 (25.7) 
4 (5.4) 
4 (5.4) 
1 (1.4) 
8 (10.8) 
11 (14.9) 
31 (41.9) 
 
0.007 
 
 
 
0.016 
ns. 
ns. 
ns. 
ns. 
<0.001 
<0.001 
ns. 
ns. 
ns. 
ns. 
ns. 
<0.001 
Patient from nursing home 10 (1.8) 9 (3.4) ns. 
Patient hospitalised 435 (77.8) 214 (81.4) ns. 
Length of stay (days) 9.0 (7.0-11.0) 11.0 (8.8-14.0) <0.001 
ICU-admission 24 (4.3) 19 (8.9) ns. 
Notes: Data are presented as median (interquartile range) or n (%). a Currently no radiation or chemotherapy. 
Abbreviations: CAP, community acquired pneumonia; COPD, Chronic Obstructive Pulmonary Disease; BMI, 
body mass index; LTOT, long-term oxygen therapy; ICU, intensive care unit. 
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Table S2. Laboratory data, clinical parameters and severity scores of non-smoking CAP-only patients versus 
CAP-COPD patients 
 CAP-only (n=561) CAP-COPD (n=264) p-value 
Urea (mg/dl) 13.5 (10.2-19.5) 16.9 (11.9-25.0) <0.001 
CRP (mg/dl) 98.0 (30.0-183.9) 116.0 (22.0-208.9) ns. 
Glucose (mg/dl) 113.4 (95.0-140.0) 124.0 (102.0-153.9) 0.004 
Leucocytes (x109/l) 10.1 (7.3-14.1) 12.3 (9.5-16.3) <0.001 
PaO2 (mmHg) 66.0 (58.0-75.0) 61.0 (55.0-70.0) <0.001 
PaCO2 (mmHg) 
≤ 43 mmHg 
> 43 mmHg 
34.0 (31.0-37.0) 
316 (94.3) 
19 (5.7) 
37.0 (33.0-43.0) 
153 (78.5) 
42 (21.5) 
<0.001 
<0.001 
pH 
≤ 7.35 
> 7.35 
7.5 (7.4-7.5) 
3 (0.9) 
335 (99.1) 
7.4 (7.4-7.5) 
16 (8.2) 
179 (91.8) 
<0.001 
<0.001 
O2 saturation (%) 95.0 (92.0-96.0) 92.0 (89.3-95.0) <0.001 
Respiratory rate 
≥ 30/min 
20.0 (18.0-23.0) 
26 (4.8) 
21.0 (18.0-25.0) 
27 (10.3) 
0.001 
0.004 
CURB 
0 
1 
2 
3 
4 
 
299 (58.2) 
172 (33.5) 
42 (8.2) 
1 (0.2) 
- 
 
114 (44.7) 
89 (34.9) 
48 (18.8) 
3 (1.2) 
1 (0.4) 
 
<0.001 
Notes: Data are presented as median (interquartile range) or n (%). Abbreviations: CAP, community acquired 
pneumonia; COPD, Chronic Obstructive Pulmonary Disease; CRP, C-reactive protein; CURB, Confusion, Urea, 
Respiratory rate, and Blood pressure. 
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Table S3. Mortality rates and cause of death of non-smoking CAP-only patients versus CAP-COPD patients 
 Total 
(n=825) 
CAP-only 
(n=561) 
CAP-COPD 
(n=264) 
p-value OR (95% CI) 
t = 30 days 16 (1.9) 8 (1.4) 8 (3.0) ns. 2.160 (0.802-5.820) 
Cardiac 
Pneumonia (incl. sepsis) 
Other 
Unknown 
 1 (12.5) 
3 (37.5) 
1 (12.5) 
3 (37.5) 
1 (12.5) 
3 (37.5) 
3 (37.5) 
1 (12.5) 
ns.  
t = 90 days 27 (3.3) 12 (2.1) 15 (5.7) 0.010 2.756 (1.271-5.975) 
Cardiac 
Pneumonia (incl. sepsis) 
Other  
Unknown 
 2 (16.7) 
3 (25.0) 
3 (25.0) 
4 (33.3) 
1 (6.7) 
4 (26.7) 
7 (46.7) 
3 (20.0) 
ns.  
t = 180 days 36 (4.4) 15 (2.7) 21 (8.0) 0.001 3.146 (1.594-6.207) 
Cardiac 
Pneumonia (incl. sepsis) 
Other  
Unknown 
 3 (20.0) 
3 (20.0) 
4 (26.7) 
5 (33.3) 
1 (4.8) 
8 (38.1) 
8 (38.1) 
4 (19.0) 
ns.  
Notes: Data are presented as n (%). Abbreviations: CAP, community acquired pneumonia; COPD, Chronic 
Obstructive Pulmonary Disease; OR, odds ratio; CI, confidence interval. 
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Table S4. Initiated therapy when diagnosed with CAP 
 CAP-only (n=1043) CAP-COPD (n=264) p-value 
Therapy unknown 34 (3.3) 7 (2.7) ns. 
Penicillin 394 (37.8) 109 (41.3) ns. 
Cephalosporin 155 (14.9) 44 (16.7) ns. 
Macrolide 58 (5.6) 6 (2.3) 0.027 
Fluorchinolone 125 (12.0) 40 (15.2) ns. 
Other 12 (1.2) 2 (0.8) ns. 
Penicillin and Cephalosporin 2 (0.2) - ns. 
Penicillin and Macrolide 145 (13.9) 21 (8.0) 0.010 
Penicillin and Fluorchinolone 19 (1.8) 14 (5.3) 0.001 
Penicillin and other 1 (0.1) 1 (0.4) ns. 
Cephalosporin and Macrolide 90 (8.6) 16 (6.1) ns. 
Cephalosporin and Fluorchinolone 4 (0.4) 2 (0.8) ns. 
Cephalosporin and other 2 (0.2) - ns. 
Macrolide and Fluorchinolone 1 (0.1) - ns. 
Macrolide and other - - - 
Fluorchinolone and other - 1 (0.4) ns. 
Penicillin and Cephalosporin and Macrolide 1 (0.1) 1 (0.4) ns. 
Notes: Data are presented as n (%). Abbreviations: CAP, community acquired pneumonia; COPD, Chronic 
Obstructive Pulmonary Disease 
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Table S5. Initiated therapy of survived versus deceased CAP-COPD patients 
 Survived (n=243) Deceased (n=21) p-value 
Therapy unknown 7 (2.9) - ns. 
Penicillin 97 (39.9) 12 (57.1) ns. 
Cephalosporin 39 (16.0) 5 (23.8) ns. 
Macrolide 6 (2.5) - ns. 
Fluorchinolone 40 (16.5) - 0.044 
Other 2 (0.8) - ns. 
Penicillin and Cephalosporin - - - 
Penicillin and Macrolide 20 (8.2) 1 (4.8) ns. 
Penicillin and Fluorchinolone 12 (4.9) 2 (9.5) ns. 
Penicillin and other 1 (0.4) - ns. 
Cephalosporin and Macrolide 15 (6.2) 1 (4.8) ns. 
Cephalosporin and Fluorchinolone 2 (0.8) - ns. 
Cephalosporin and other - - - 
Macrolide and Fluorchinolone - - - 
Macrolide and other - - - 
Fluorchinolone and other - - - 
Penicillin and Cephalosporin and Macrolide 1 (0.4) - ns. 
Notes: Data are presented as n (%). Abbreviations: CAP, community acquired pneumonia; COPD, Chronic 
Obstructive Pulmonary Disease. 
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Table S6. Initiated therapy of survived versus deceased CAP-only patients 
 Survived (n=1009) Deceased (n=34) p-value 
Therapy unknown 34 (3.4) - ns. 
Penicillin 375 (37.2) 19 (55.9) 0.027 
Cephalosporin 146 (14.5) 9 (26.5) ns. 
Macrolide 58 (5.7) - ns. 
Fluorchinolone 121 (12.0) 4 (11.8) ns. 
Other 12 (1.2) - ns. 
Penicillin and Cephalosporin 2 (0.2) - ns. 
Penicillin and Macrolide 145 (14.4) - 0.017 
Penicillin and Fluorchinolone 19 (1.9) - ns. 
Penicillin and other 1 (0.1) - ns. 
Cephalosporin and Macrolide 88 (8.7) 2 (5.9) ns. 
Cephalosporin and Fluorchinolone 4 (0.4) - ns. 
Cephalosporin and other 2 (0.2) - ns. 
Macrolide and Fluorchinolone 1 (0.1) - ns. 
Macrolide and other - - - 
Fluorchinolone and other - - - 
Penicillin and Cephalosporin and Macrolide 1 (0.1) - ns. 
Notes: Data are presented as n (%). Abbreviations: CAP, community acquired pneumonia; COPD, Chronic 
Obstructive Pulmonary Disease. 
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Table S7. Independent predictors of short- and long-term mortality in CAP-patients (including non-smoking 
CAP-only patients and CAP-COPD patients) 
 OR p-value 95% CI 
30-day mortalitya 
Age 
LTOT 
 
1.1 
10.5 
 
0.006 
0.011 
 
1.037-1.235 
1.706-64.442 
90-day mortalityb 
Age 
ICU-admission 
 
1.1 
14.5 
 
0.005 
0.006 
 
1.024-1.144 
2.140-98.251 
180-day mortalityb 
Age 
ICU-admission 
 
1.1 
9.6 
 
0.004 
0.018 
 
1.025-1.138 
1.483-62.797 
Notes: a Adjusted for age, gender, LTOT, being vaccinated or not, having co-morbidities besides COPD, CURB 
and COPD for 30-day mortality (Goodness-of-fit: Chi-square=0.000, Hosmer and Lemeshow-test=0.712). b 
Adjusted for age, gender, LTOT, being vaccinated or not, having co-morbidities besides COPD, CURB, COPD, 
ICU-admission, therapy change and GOLD stage for 90- and 180-day mortality (Goodness-of-fit: Chi-
square=0.003, Hosmer and Lemeshow-test=0.828; Chi-square=0.002, Hosmer and Lemeshow-test=0.360; 
respectively). Abbreviations: CAP, community acquired pneumonia; COPD, Chronic Obstructive Pulmonary 
Disease; OR, odds ratio; CI, confidence interval; LTOT, long-term oxygen therapy; ICU, intensive care unit. 
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Figure S1. Long-term mortality in non-smoking, CAP-only and CAP-COPD patients 
Kaplan Meier survival curve (t=180 days) for CAP patients with the presence of COPD ( - - - - ; n=264) and 
without (  ̶  ̶ ̶  ; n=1043) the presence of COPD. 
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ABSTRACT 
Background: Community acquired pneumonia (CAP) is a major cause of morbidity and 
mortality, and Chronic Obstructive Pulmonary Disease (COPD) is a frequent comorbidity. 
The bacterial aetiology of CAP-COPD and its possible associations with serum markers 
and mortality are incompletely understood. 
Objectives: 1) To assess the bacterial aetiology of CAP-only and CAP-COPD, and 2) to 
study the association between bacterial aetiology, empirical antibiotic treatment, serum 
markers and mortality. 
Methods: Of 1288 patients with CAP (57.0% males, age 59.0 years ± 18.5), 262 (20.3%) 
fulfilled the diagnostic criteria for COPD. Differences between subgroups were investi-
gated using univariate analyses and corrected for multiple comparisons. 
Results: Streptococcus pneumoniae was the most common pathogen (30.8% CAP-only 
vs. 26.0% CAP-COPD, not significant). Haemophilus influenzae was significantly more 
frequent in CAP-COPD (5.6% CAP-only vs. 26.0% CAP-COPD, p<0.001). The number 
given adequate empirical antibiotic treatment was comparable (83.3% CAP-only vs. 
83.6% CAP-COPD, p>0.05). The CAP-COPD group had worse CURB-65 and partial pres-
sure of arterial oxygen levels than the CAP-only group (p<0.001). Partial pressure of 
arterial carbon dioxide levels were increased in CAP-COPD patients without pathogen 
detection (p<0.001). Short- (p=0.011) and long-term mortality (p=0.006) were highest in 
CAP-COPD without pathogen detection. 
Conclusion: It is important to identify COPD patients with CAP. In particular, those with-
out bacterial pathogen detection have more severe CAP and are at higher risk of dying. 
Better understanding of the aetiology could contribute to improved management and 
treatment of CAP in COPD patients. 
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INTRODUCTION 
Community acquired pneumonia (CAP) has an important socio-economic impact, with 
an incidence ranging from 3 to 10 per 1000 adults per year1. Chronic Obstructive Pul-
monary Disease (COPD) is a frequent comorbidity of CAP, associated with increased 
severity and mortality rates2. 
Studies investigating bacterial patterns in CAP with or without COPD have suggested the 
presence of different pathogens. It is known that Streptococcus pneumoniae is the most 
frequently detected pathogen in CAP1,3–7, whereas Haemophilus influenzae has been 
reported to be the most common pathogen in COPD patients with CAP8. Moreover, 
Pseudomonas aeruginosa and Moraxella catarrhalis, which are rarely detected in CAP, 
are important pathogens in COPD, particularly in more severe disease9–13. 
However, no studies have been specifically designed to study potential differences in 
the bacterial aetiology of CAP in patients with or without COPD and to investigate 
whether these differences have consequences for short- and long-term mortality. 
Moreover, the concordance of empirical antibiotic treatment and pathogens detected 
has not yet been investigated, but may have significant effects on clinical outcome. 
Serum markers of inflammation might be associated with bacterial aetiology. C-reactive 
protein (CRP) has been proposed to be a helpful tool in the detection of classical bacte-
rial aetiology in CAP, compared to atypical or viral CAP3. However, CRP was not predic-
tive for individual differentiation of the bacterial aetiology14. A possible relationship 
between the bacterial aetiology and other serum markers and clinical parameters 
should be further analysed. 
Against this background, we hypothesised that differences in microbiology between CAP 
subjects without co-existing COPD (CAP-only) and CAP subjects with co-existing COPD 
(CAP-COPD) are related to mortality. The objectives of the present study were 1) to in-
vestigate possible differences in the bacterial aetiology of CAP between subjects with 
and those without co-existing COPD; 2) to assess empirical antibiotic treatment in rela-
tion to bacterial aetiology; 3) to examine the relationship between serum markers and 
clinical parameters and bacterial aetiology; and 4) to study the relationship between 
bacterial aetiology, empirical antibiotic treatment, serum markers and mortality in CAP. 
MATERIALS AND METHODS 
Data were derived from a multicentre observational study initiated by CAPNETZ (CAP 
network)15. The study design has been published elsewhere15, and was approved by the 
ethics committees of all local clinical centres. All patients provided written informed 
consent. 
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Study population 
Between December 2009 and June 2012, CAPNETZ included 1788 CAP patients. Inclu-
sion criteria were age ≥18 years, new pulmonary infiltrate on chest X-ray, clinical symp-
toms of cough, purulent sputum, positive auscultation or fever. Patients were excluded 
if they had been hospitalised in the previous 28 days, if they were chronically immuno-
suppressed, human immunodeficiency virus infected or had active tuberculosis. Follow-
up included a structured interview on outcome parameters, including death, at 30 and 
180 days. 
The presence of COPD was assessed based on post-bronchodilator forced expiratory 
volume in the first second (FEV1) and forced vital capacity (FVC) in the previous 6 
months16. COPD was defined as FEV1/FVC ratio <0.7
17. Study physicians interpreted 
spirometric data, confirmed diagnosis and categorised patients according to GOLD 
(Global Initiative for Chronic Obstructive Lung Disease) stages16, as previously pub-
lished2. Patients were excluded from the present study when no data on COPD diagno-
sis were available (n=481) and when no samples had been collected for microbial analy-
sis (n=19). A cohort of 1288 eligible CAP patients with COPD data was available for the 
present analyses, divided into two subgroups: 1) CAP patients without COPD (CAP-only); 
2) CAP patients with COPD (CAP-COPD). 
Study procedures and definitions 
The methodological details of the microbiological diagnostic techniques and laboratory 
processing in this study have been published previously3,18. Briefly, serum, sputum, 
tracheobronchial secretions, bronchoalveolar lavage fluid and punctate samples were 
obtained for microbiological analysis according to routine local procedures. Urine sam-
ples were collected and tested for Legionella pneumophila and S. pneumoniae using an 
antigen test. Samples were routinely collected within <72 h of presentation at the 
emergency department. Respiratory samples were cultured and gram-stained as soon 
as clinical routine allowed after they had been obtained. Respiratory samples and blood 
cultures were plated on blood agar, McConkey-agar and chocolate agar. All samples 
included were adequate for analysis. Inadequate samples were not processed by the 
local laboratory and were not reported in the database. 
Enterobacteriaceae were clustered, including Citrobacter spp., Enterobacter spp., Esche-
richia coli, Klebsiella pneumoniae, K. oytoca, Pantoea agglomerans, Proteus mirabilis, 
Rahnella aquatilis and Serratia marcescens. Other bacteria included Acinetobacter spp., 
Moraxella catarrhalis and Stenothrophomonas maltophilia, among others. Both CAP-
only and CAP-COPD patients were stratified according to culture result (positive vs. 
negative bacterial culture). No data were available on viral pathogens. 
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The empirical antibiotic treatment given was recorded. A respiratory physician retro-
spectively assessed the empirical treatment based on typical antibiotic susceptibility 
patterns to assess whether the treatment was adequate for the bacterial aetiology. 
Changes in treatment were assessed. 
Overall mortality and group-specific mortality rates were analysed, with 30-, 90- and 
180-day mortality calculated by subtracting the date of examination from the date of 
death. 
CURB-65 (Confusion of new onset, defined as an abbreviated mental test score of ≤8, 
blood Urea nitrogen >7 mmol/l [19 mg/dl]), Respiratory rate of ≥30 breaths/min, Blood 
pressure <90 mmHg systolic or diastolic blood pressure ≤60 mmHg, age ≥65 years) 
scores were calculated based on the sum of points, with one point assigned for the 
presence of each criterion5,19,20. 
Statistical analysis 
Data analyses were performed using the Statistical Package for the Social Sciences, 
version 20.0 (IBM Corp, Armonk, NY, USA). Variables were tested for normality using 
the Kolmogorov-Smirnov and Shapiro-Wilk test. Continuous data are presented as me-
dians (interquartile range) and categorical data as counts (percentages). To compare 
the bacterial aetiology of CAP-only and CAP-COPD, the χ2 test was performed. Baseline 
characteristics, serum markers and clinical parameters assessed between subgroups 
were performed using Kruskal Wallis test for 2- and κ-independent samples, as well as 
the χ2 test. χ2 tests were also assessed to analyse mortality in relation to bacterial aeti-
ology. p<0.05 was considered statistically significant; analyses were corrected for multi-
ple comparisons using Bonferroni correction. 
RESULTS 
A total of 1288 patients met the inclusion criteria, with 262 classified as COPD (20.3%). 
Of these, 55 (21.0%) were characterised as mild (GOLD I), 91 (34.7%) as moderate (GOLD 
II), 70 (26.7%) as severe (GOLD III) and 46 (17.6%) as very severe COPD (GOLD IV). 
Bacterial aetiology 
Bacterial aetiology could be determined in 271 patients (21.0%). Pathogens were identi-
fied significantly more frequently in CAP-COPD than in CAP-only patients: 73 CAP-COPD 
(27.9% of all CAP-COPD) vs. 198 CAP-only (19.3% of all CAP-only patients). Table 1 gives an 
overview of the identified pathogens, with S. pneumoniae being the most frequent patho-
gen in CAP-only, while H. influenzae and S. pneumoniae were identified most frequently in 
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CAP-COPD. H. influenzae detection rates differed significantly between the groups, being 
more frequent in CAP-COPD. Low rates of P. aeruginosa were found in both groups. 
Baseline characteristics of CAP-only and CAP-COPD, stratified by culture result, showed 
that CAP-COPD patients were in general older, more often former smokers and with 
more pack-years than CAP-only patients (Table S1, Supplemental material). CAP-COPD 
patients were also more frequently vaccinated against influenza and pneumococci. CAP-
COPD patients with negative bacterial culture results were more likely to have underly-
ing chronic heart failure than CAP-only patients with negative bacterial culture, while 
CAP-only patients had significantly more frequent asthma than CAP-COPD. 
Table 1. Bacterial aetiology of CAP-only vs. CAP-COPD patients* 
 CAP-only 
(n=1026) 
n (%) 
CAP-COPD 
(n=262) 
n (%) 
p-value 
Bacterial aetiology 198 (19.3) 73 (27.9) 0.002 
Typical bacterial pathogens    
Streptococcus pneumoniae 61 (30.8) 19 (26.0) NS 
Staphylococcus aureus 25 (12.6) 6 (8.2) NS 
Other gram-positive cocci (not further specified) 14 (7.1) 2 (2.7) NS 
Haemophilus influenzae 11 (5.6) 19 (26.0) <0.001 
H. parainfluenzae 25 (12.6) 6 (8.2) NS 
Pseudomonas aeruginosa 6 (3.0) 1 (1.4) NS 
Enterobacteriaceae† 33 (16.7) 16 (21.9) NS 
Atypical pathogens    
Legionella pneumophila 9 (4.5) 1 (1.4) NS 
Other bacteria‡ 3 (1.5) 3 (4.1) NS 
Mixed infection 11 (5.6) - NS 
* Corrected for multiple comparisons (p<0.005). 
† Including Citrobacter spp., Enterobacter spp., Escherichia coli, Klebsiella pneumoniae, K. oytoca, Pantoea 
agglomerans, Proteus mirabilis, Rahnella aquatilis and Serratia marcescens. 
‡ Including, among others, Acinetobacter spp., Moraxella catarrhalis and Stenothrophomonas maltophilia. 
CAP = community acquired pneumonia; COPD = Chronic Obstructive Pulmonary Disease; NS = not significant. 
Empirical antibiotic treatment 
Empirical antibiotic treatment was started in 19 CAP-only (1.9%) and 3 CAP-COPD 
(1.2%) patients before sampling. Most patients started treatment on the same day as 
sampling (40.3% of CAP-only vs. 37.5% of CAP-COPD patients).  
Empirical antibiotic treatment was started in almost all patients with positive bacterial 
culture, (94.9% CAP-only vs. 97.3% CAP-COPD, p>0.05). Figure 1 shows the proportion 
of patients with adequate treatment, comparable between CAP-only and CAP-COPD 
patients with positive bacterial culture (83.3% CAP-only vs. 83.6% CAP-COPD, p>0.05). 
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Antibiotic treatment was changed in 12 CAP-only (33.3%) and 5 CAP-COPD (41.7%) 
patients. Reasons for the change were inadequate coverage (n=8, 47.1%), resistance 
(n=4, 23.5%) and de-escalation (n=2, 11.8%). This change in treatment was adequate for 
two thirds of CAP-only patients (n=8, 66.7%) and for all CAP-COPD patients. 
 
 
Figure 1. Percentage of patients with adequate/inadequate empirical antibiotic treatment. 
CAP = community acquired pneumonia; COPD = Chronic Obstructive Pulmonary Disease. 
Serum markers and clinical parameters 
Serum markers and clinical parameters of CAP-only and CAP-COPD stratified by culture 
result are shown in Table 2. No differences were observed between CAP-COPD with 
negative and positive bacterial culture. CRP levels were statistically significantly differ-
ent between CAP-only patients, with higher levels in CAP-only patients with positive 
bacterial culture (CRP 136.0 mg/dl [IQR 53.0–233.5] vs. 89.2 mg/dl [IQR 21.0–189.6], 
p<0.001). Leucocyte levels were statistically significantly higher in CAP-COPD patients 
with negative bacterial culture than in CAP-only patients with negative bacterial culture 
(12.2 x 109/l [IQR 9.5–16.1] vs. 10.5 x 109/l [IQR 7.7–14.6], p<0.001). Moreover, CAP-
COPD patients with negative bacterial culture had higher levels of urea (16.9 mg/dl [IQR 
12.0–25.0]) and partial pressure of arterial carbon dioxide (PaCO2) (38.0 mmHg [IQR 
34.0–44.0]) than CAP-only patients, independent of bacterial aetiology. CAP-COPD pa-
tients suffered more frequently from acidosis (<pH) than CAP-only patients. Body tem-
perature was highest in CAP-only patients with positive bacterial culture (38.2°C [IQR 
37.0–38.8]), indicating fever, than CAP-COPD and CAP-only patients with negative bac-
terial culture. CAP severity, as measured by CURB-65, was higher in CAP-COPD than in 
CAP-only patients, with no differences based on culture result (Table 2). 
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Mortality 
Short- and long-term mortality rates were lowest in CAP-only patients, while COPD 
patients in general had the highest mortality rates (Table 3; Figure 2). Both short- and 
long-term mortality rates differed significantly between CAP-only patients with negative 
bacterial culture and CAP-COPD patients with negative bacterial culture. No differences 
in mortality rates were observed between CAP-only patients with negative and positive 
bacterial culture results, and CAP-COPD patients with negative and positive bacterial 
culture results. 
Table 3. Short- and long-term mortality rates for CAP-only and CAP-COPD patients stratified by culture result* 
 CAP-only (n=1026)  CAP-COPD (n=262) 
Mortality Bacterial aetiology 
negative culture 
(n=828) 
n (%) 
Bacterial aetiology 
positive culture 
(n=198) 
n (%) 
 Bacterial aetiology 
negative culture 
(n=189) 
n (%) 
Bacterial aetiology 
positive culture 
(n=73) 
n (%) 
30-day 10 (1.2) 2 (1.0)  8 (4.2)† - 
90-day 19 (2.3) 2 (1.0)  13 (6.9)†‡ 2 (2.7) 
180-day 27 (3.3) 6 (3.0)  16 (8.5)† 5 (6.8) 
* Corrected for multiple comparisons (p≤0.003). 
† p≤0.003 compared to CAP-only negative culture. 
‡ p≤0.003 compared to CAP-only positive culture. 
CAP = community acquired pneumonia; COPD = Chronic Obstructive Pulmonary Disease. 
 
 
Figure 2. Survival of CAP-only and CAP-COPD patients stratified by culture result. 
Kaplan-Meier survival curve (t=180 days) for CAP-only with negative culture (— ; n=828), CAP-only patients 
with positive culture (. . .. . .; n=198), CAP-COPD patients with negative culture (- - -; n=189) and CAP-COPD 
patients with positive culture (._. ._.; n=73); log-rank 12.691; p=0.005. CAP = community acquired pneumonia; 
COPD = Chronic Obstructive Pulmonary Disease. 
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Enterobacteriaceae were frequently detected (n=5, 45.5%) in deceased patients. No 
further analyses could be performed to investigate possible associations of specific 
bacterial aetiology and serum markers with mortality due to the small number of de-
ceased patients. On comparing the antibiotic treatment administered with the patho-
gen detected and known antibiotic resistance patterns, three deceased patients (27.8%) 
had received inadequate empirical antibiotic treatment. However, all of these patients 
had been prescribed adequate changes to their treatment. 
DISCUSSION 
The main results of the present study were as follows: S. pneumoniae was the most 
common pathogen in both groups, whereas H. influenzae was significantly more fre-
quent in CAP-COPD patients. In general, CAP-COPD patients had more severe CAP than 
CAP-only patients and, in particular, CAP-COPD patients with negative culture had sig-
nificantly more frequent signs of respiratory failure and higher mortality rates than CAP-
only patients. 
Bacterial aetiology 
Results of the present study confirm that S. pneumonia is the most frequent pathogen 
identified in CAP-only9–11,13,21 and CAP-COPD9–13 patients. H. influenzae was observed to 
be significantly more frequent in CAP-COPD patients. Other studies have also observed 
that CAP-COPD was often associated with an infection attributable to P. aeruginosa9–13. 
In the present study, no difference was observed in the prevalence of P. aeruginosa in 
CAP-only and CAP-COPD patients. This might be due to less severe COPD in our popula-
tion. 
The presence of H. influenzae varies in study populations, ranging from approximately 
1% to 8%6. In the current population, H. influenzae was observed in 11.1% of all CAP 
patients in whom a pathogen was identified. This overall figure is in accordance with 
Welte et al.1, who reported that the proportion varied between 2.9% and 14.6% in Eu-
rope. The fact that H. influenzae, together with S. pneumoniae, was most frequently 
identified in CAP-COPD patients, and significantly more often than in CAP-only patients, 
is not surprising. A higher proportion of H. influenzae pneumonia in COPD patients was 
also reported by Torres et al.4, Rello et al.10 and Restrepo et al.9 (9.2%, 11.4% and 
15.1%, respectively). Respiratory physicians should keep this in mind when choosing 
their antibiotic treatment, as H. influenzae is often not susceptible to standard empirical 
penicillin treatment. However, it is clinically very difficult to distinguish H. influenzae 
infection from colonisation22. 
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Enterobacteriaceae were identified more often in CAP-COPD patients, although this 
difference was not statistically significant. Conflicting results have been reported, with 
lower incidence of Enterobacteriaceae in both total and CAP-COPD patients9,10,12,13,21. 
This discrepancy can partly be explained by the definition of Enterobacteriaceae in the 
different studies. The more pathogens grouped into Enterobacteriaceae, the higher the 
incidence observed. von Baum et al.18 also noticed that Enterobacteriaceae were asso-
ciated with older age and comorbid conditions, factors that are more frequently associ-
ated with COPD11,23. 
Serum markers and clinical parameters 
In general, CAP-COPD patients had more severe CAP than CAP-only patients. CURB-65 
scores were higher, a finding in line with previous research13. Moreover, CAP-COPD 
patients were frequently hypoxic, which has been previously associated with COPD in 
CAP24,25. The observed differences in CURB-65 and hypoxaemia were not associated 
with bacterial aetiology. 
In CAP-COPD patients with negative bacterial culture, elevated levels of PaCO2 were 
observed. Molinos et al. also observed more patients with hypercapnia in COPD than 
non-COPD CAP, with both hypercapnia and hypoxaemia independently related to 30-
day mortality21. Hypercapnia has been associated with a poor prognosis even in stable 
COPD26. 
CRP levels in CAP-only patients were statistically significantly higher in patients with 
positive bacterial culture. This finding is not surprising, as CRP is a marker for bacterial 
infection3. However, given the high levels in all subgroups, the clinical relevance of the 
observed differences might be limited. 
Mortality 
Mortality rates were highest in CAP-COPD patients with negative bacterial culture. As 
mentioned before, these patients also appeared to have more severe CAP. Respiratory 
viral infections might be important triggers in these patients. Vaccination status did not 
differ between CAP-COPD patients with and without positive bacterial culture. The fact 
that no bacterial aetiology was obtained in these patients does not exclude the possibil-
ity of bacterial infection. In COPD patients, this may be of importance, as it is known 
that such patients are more likely to be infected and colonised with bacteria that are 
not susceptible to standard antibiotics. 
Failure of pathogen detection is common in CAP27, possibly leading to difficulties in 
creating treatment strategies, with the antibiotic treatment initiated usually being em-
pirical. In addition, viral infections account for a substantial proportion of CAP cases7,28, 
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with a lack of treatment options29. It is also well known that viral infections in COPD are 
associated with worse outcomes, such as prolonged symptom recovery from a COPD 
exacerbation30. 
Enterobacteriaceae were the most frequently bacterial pathogens detected in deceased 
patients. Earlier research showed mortality rates of around five times higher in CAP 
patients identified with Enterobacteriaceae18. The present results emphasise the im-
portance of using sputum analysis as a possible tool in the assessment of CAP, and ad-
vanced culture or sequencing techniques, in particular, might lead to targeted treat-
ment strategies and better outcomes31. 
Strengths and limitations 
This study has several limitations. No data were available on viral pathogens. As samples 
were collected only during disease state, information on colonisation is lacking. Sample 
sizes for subgroup analysis were small, which may have influenced outcomes. Moreo-
ver, treatment adequacy was assessed retrospectively, based on typical antibiotic sus-
ceptibility patterns. Ideally, resistance patterns of the specific aetiology should be as-
sessed to guide antibiotic treatment. 
A strength of the present study is the systematic use of a new pulmonary infiltrate on 
chest X-ray to confirm CAP diagnosis32. As other studies used clinical symptoms only to 
diagnose CAP, the current study is therefore able to add important information33–35. 
Moreover, CAPNETZ has a prospective design and is possibly the largest CAP cohort 
worldwide, including both in- and out-patients. This makes the results also relevant for 
a more general population. 
Conclusion 
It is important to identify COPD patients with CAP, especially those without detected 
bacterial pathogens, as such patients have more severe CAP and are at higher risk of 
dying. This highlights the role of pathogen testing, which is currently not recommended 
in standard care, but may be relevant in this patient population due to higher mortality 
rates. A better understanding of the specific aetiology could contribute to improved 
management and treatment of CAP in COPD, which might change the outcome. 
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SUPPLEMENTAL MATERIAL 
Table S1. Baseline characteristics of CAP-only and CAP-COPD patients stratified by culture result* 
 CAP-only (n=1026)  CAP-COPD (n=262) 
 Bacterial aetiology 
negative culture
(n=828) 
n (%) 
Bacterial aetiology 
positive culture 
(n=198) 
n (%)
Bacterial aetiology 
negative culture 
(n=189) 
n (%) 
Bacterial aetiology 
positive culture 
(n=73) 
n (%) 
Age, years, median [IQR] 57.0 [41.0–71.0] 59.0 [43.0–75.0] 71.0 [62.5–77.0]†‡ 72.0 [65.0–77.5]†‡ 
Sex 
Male 
Female 
 
452 (54.6) 
376 (45.4) 
 
114 (57.6) 
84 (42.4) 
 
125 (66.1) 
64 (33.9) 
 
44 (60.3) 
29 (39.7) 
Smoking status 
Never smoker 
Ex-smoker 
Current smoker  
 
449 (55.3) 
159 (19.6) 
204 (25.1) 
 
102 (52.0) 
34 (17.3) 
60 (30.6) 
 
52 (27.8)†‡ 
77 (41.2) 
58 (31.0) 
 
26 (35.6)† 
26 (35.6) 
21 (28.8) 
Pack-years, median [IQR 0.0 [0.0–15.0] 0.0 [0.0–18.0] 30.0 [0.0–43.0]†‡ 20.0 [0.0–40.0]†‡ 
GOLD stage 
1 
2 
3 
4 
 
- 
 
- 
 
36 (19.0) 
65 (34.4) 
51 (27.0) 
37 (19.6) 
 
19 (26.0) 
26 (35.6) 
19 (26.0) 
9 (12.3) 
Vaccination 
Influenza 
Influenza A/H1N1 
Pneumococcal  
 
216 (26.2) 
43 (10.0) 
54 (6.6) 
 
46 (23.4) 
7 (6.4) 
15 (7.7) 
 
102 (54.0)†‡ 
17 (16.3) 
42 (22.2)†‡ 
 
32 (43.8)†‡ 
5 (13.2) 
21 (28.8)†‡ 
Co-morbidities 
Chronic heart failure§
Chronic renal disease§ 
Chronic liver disease§ 
Cerebrovascular disease§ 
Diabetes mellitus§ 
Asthma¶ 
Bronchiectasis¶ 
Lung fibrosis¶ 
Sarcoidosis¶ 
Bronchial/lung cancer¶# 
Sleep apnoea¶ 
 
95 (23.7) 
63 (15.7) 
18 (4.5) 
27 (6.7) 
98 (24.4) 
73 (67.0) 
6 (5.5) 
8 (7.3) 
1 (0.9) 
3 (2.8) 
10 (9.2) 
 
25 (26.0) 
15 (15.6) 
5 (5.2) 
8 (8.3) 
34 (35.4) 
24 (66.7) 
3 (8.3) 
1 (2.8) 
1 (2.8) 
1 (2.8) 
2 (5.6) 
 
51 (39.2)* 
18 (13.8) 
5 (3.8)
14 (10.8) 
40 (30.8) 
13 (25.5)†‡ 
1 (2.0)
4 (7.8)
1 (2.0)
6 (11.8) 
8 (15.7) 
 
12 (26.1) 
8 (17.4) 
6 (13.0) 
4 (8.7) 
8 (17.4) 
6 (27.3)†‡ 
3 (13.6) 
- 
- 
2 (9.1) 
3 (13.6) 
Inhaled corticosteroids - - 101 (53.4) 39 (53.4) 
* Corrected for multiple comparisons (p<0.001). 
† p≤0.001 compared to CAP-only negative culture. 
‡ p≤0.001 compared to CAP-only positive culture. 
§ Missing: CAP-only bacterial aetiology NO: n=427; CAP-only bacterial aetiology YES: n=102; CAP-COPD bacte-
rial aetiology NO: n=59; CAP-COPD bacterial aetiology YES: n=27. 
¶ Missing: CAP-only bacterial aetiology NO: n=719; CAP-only bacterial aetiology YES: n=162; CAP-COPD bacte-
rial aetiology NO: n=138; CAP-COPD bacterial aetiology YES: n=51. 
# Currently no radiation or chemotherapy. 
CAP = community acquired pneumonia; COPD = Chronic Obstructive Pulmonary Disease; IQR = interquartile 
range; GOLD = Global Initiative for Chronic Obstructive Lung Disease. 
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ABSTRACT 
Background: Smoking increases the risk of community acquired pneumonia (CAP) and is 
associated with the development of COPD. Until now, it is unclear whether CAP in COPD 
is due to smoking-related effects, or due to COPD pathophysiology itself. 
Objective: To evaluate the association between COPD and CAP by smoking status. 
Methods: In total, 62,621 COPD and 191,654 control subjects, matched by year of birth, 
gender and primary care practice, were extracted from the Clinical Practice Research 
Datalink (2005–2014). Incidence rates (IRs) were estimated by dividing the total number 
of CAP cases by the cumulative person-time at risk. Time-varying Cox proportional haz-
ard models were used to estimate the hazard ratios (HRs) for CAP in COPD patients 
versus controls. HRs of CAP by smoking status were calculated by stratified analyses in 
COPD patients versus controls and within both subgroups with never smoking as refer-
ence. 
Results: IRs of CAP in COPD patients (32.00/1,000 person-years) and controls 
(6.75/1,000 person-years) increased with age and female gender. The risk of CAP in 
COPD patients was higher than in controls (HR 4.51, 95% CI: 4.27–4.77). Current smok-
ing COPD patients had comparable CAP risk (HR 0.92, 95% CI: 0.82–1.02) as never smok-
ing COPD patients (reference), whereas current smoking controls had a higher risk (HR 
1.23, 95% CI: 1.13–1.34) compared to never smoking controls. 
Conclusion: COPD patients have a fourfold increased risk to develop CAP, independent 
of smoking status. Identification of factors related with the increased risk of CAP in 
COPD is warranted, in order to improve the management of patients at risk. 
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INTRODUCTION 
Community acquired pneumonia (CAP) is characterized by an acute infection of the 
pulmonary parenchyma with onset in the out-of-hospital setting1. CAP incidence in-
creases with age, smoking and the presence of comorbidities1,2, varying between 1.5 
and 11.0 per thousand adult population3,4. In COPD, high incidence rates (IRs) of CAP, 
up to 22.4 per 1000 person-years, have been reported5. Worse outcomes i.e., higher 
mortality rates6,7 and longer length of hospital stay6 were observed, as well as more 
pronounced hypoxemia7, hypercapnia6,7, tachypnea6 and increased symptoms such as 
dyspnea and purulent sputum7. 
Smoking individuals have a twofold increased CAP risk1,4. Besides, smoking has been 
associated with increased susceptibility to infections in healthy subjects8 and COPD 
patients, triggering exacerbations9. Until now, it is unclear whether CAP development in 
COPD is due to smoking-related increased susceptibility to infections, or due to COPD 
pathophysiology itself. Müllerova et al5 observed no association between current smok-
ing and CAP incidence in COPD. 
As smoking has been identified as a risk factor for both COPD and CAP, it is important to 
compare COPD patients to smoking and non-smoking controls, to assess smoking-
related effects, and distinguish possibly from additional risks associated with COPD and 
its pathophysiology. Particularly, it is important to take changes in smoking status over 
time into account, since smokers are known to undertake several attempts to quit 
smoking10,11. Therefore, the aim of the present study was to evaluate the association 
between COPD and CAP by smoking status. 
METHODS 
Source population 
A population-based cohort study, with data derived from the world’s largest primary 
care database, Clinical Practice Research Datalink (CPRD), was conducted. CPRD con-
tains computerized medical records of 674 primary care practices in the UK, collected 
since January 1987, representative for the total population12. Coded data are collected 
on demographics, prescription details, clinical events, preventive care provided, tests, 
immunizations, specialist referrals, hospital admissions, discharge summaries and de-
tails regarding death12. The period of data collection for the present study included the 
period in which the quality and outcomes framework (QOF) was effective (January 
2005–January 2014)13. CPRD data have been widely used to study CAP14,15, COPD16,17 
and other respiratory diseases18,19. CPRD data have been shown to be accurate and 
valid20. 
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Study population 
Two cohorts were extracted. Cohort I: patients aged ≥40 years with a first ever recorded 
COPD read code, assigned by the general practitioner (Table S1, Supplemental materi-
al). COPD diagnosis defined start of follow-up (index date). Cohort II: randomly selected 
controls, without COPD diagnosis, matched by year of birth, gender and practice, using 
incidence density sampling. Controls were assigned the index date of their matched 
COPD patient. Controls with lung medication or lung function with Tiffenau index <0.7 
before start of follow-up were excluded21. From both cohorts, individuals with history of 
asthma, history of pneumonia 3 months prior to index date, active tuberculosis or use 
of tuberculosis medication and unknown smoking status were excluded. 
Outcome 
The primary outcome was physician-recorded pneumonia diagnosis, identified by read 
codes (Table S2, Supplemental material). All patients were followed from index date to 
end of data collection, date of transfer out of the practice, patient’s death or outcome 
of interest, whichever came first. Follow-up time was divided into fixed intervals of 90 
days. 
Exposure of interest 
Smoking status was determined prior to each interval (90-day) and stratified into three 
subcategories: never, current and former smoking. Smoking was defined by read codes 
(Table S3, Supplemental material), which have provided valid estimates for the prevalence 
of current and never smoking22. When the most recent smoking status was “never”, and 
the patient had quit smoking, his status was classified as former smoking. 
Potential confounders 
Potential confounders were time-dependently assessed, except for gender and body 
mass index (BMI). Time-dependent potential confounders were collected at the start of 
each time interval (90-day): age, history of pneumonia, cerebrovascular disease, de-
mentia, malignancy (excluding non-melanoma skin cancer), chronic renal disease, dia-
betes mellitus (use of insulin and/or blood glucose lowering medicines), cardiovascular 
diseases (heart failure, ischemic heart disease, coronary artery disease, myocardial 
infarction) and chronic liver disease. Moreover, proxies of the underlying severity of 
COPD, including number of exacerbations in the year before, and use of the following 
drugs 6 months before, were collected: short-acting beta-2 agonists, long-acting beta-2 
agonists, inhaled corticosteroids, xanthine derivatives, short-acting inhaled anticholin-
ergics, long-acting anticholinergics, cromoglycates, oxygen or systemic glucocorti-
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coids23. Analyses were adjusted for exposure to antipsychotics, acid suppressants or 
immunosuppressants in the past 6 months, as well as influenza or pneumococcal vac-
cination the year before. The most recent forced expiratory volume in 1 second (FEV1), 
forced vital capacity (FVC) and Tiffenau index (ratio FEV1/FVC) were reviewed in the 
time frame ever before. 
Statistical analysis 
Data analyses were performed using SAS 9.3. IRs were estimated by dividing the total 
number of CAP cases by cumulative person-time at risk. Cox proportional hazard models 
estimated hazard ratios (HRs) of CAP in COPD patients versus controls. Analyses were 
stratified to gender, age and smoking status during follow-up. 
Determinants of CAP within COPD were evaluated during follow-up: age, gender, smok-
ing status and most recently recorded FEV1. HRs were estimated within each smoking 
status stratified for most recent level of airflow obstruction. HRs of CAP stratified by 
time-varying smoking status were assessed within COPD patients and controls separate-
ly. Never smoking was used as reference. 
All analyses used time-varying Cox regression analysis. HRs were adjusted for gender 
and time-varying age and potential confounders (specified in previous section). Con-
founders were entered into the final model when independently changing the beta 
coefficient for current smoking by at least 5%, or when consensus was reached within 
the research team, supported by clinical evidence from literature. A test of interaction 
was performed to compare effects between the defined stratifications24. The study 
protocol was approved by Independent Scientific Advisory Committee, 14_055. 
RESULTS 
In total, 254,277 subjects were included in the present analysis (Figure 1). Of these, 
62,621 had COPD. Table 1 describes baseline characteristics: almost half were female, 
mean age was 67 years, follow-up time on average was 3.6–4.0 years. At baseline, 
smoking status differed: COPD patients were frequently former or current smokers, 
while controls were more often never smokers. FEV1 data were available for <50% of 
COPD patients, most classified as mild-to-moderate airflow obstruction. 
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Figure 1. Flow chart. 
*Subjects can have more than one exclusion criteria. 
  
Index date before January 2005:- 98,343 COPD patients- 192,887 matched controls
Index date incorrectly defined:- 2 COPD patients 
(first record after index date)- 4,518 matched controls 
(COPD record before index date)
Exclusion criteria*:- 52,595 COPD patients
- 38,332 Asthma
- 16,186 Pneumonia 3 months prior 
to index date
- 2,808 Tuberculosis
- 2,707 Unknown smoking status- 47,532 matched controls
- 22,247 Asthma
- 6,187 Pneumonia 3 months prior 
to index date
- 3,373 Tuberculosis
- 22,864 Lung medication
- 2,333 Tiffenau index <0.7
- 8,557 Unknown smoking status
No follow-up:- 117 matched controls
COPD patients:
213,561
Matched controls:
436,708
COPD patients:
213,561
COPD patients:
213,559
COPD patients:
115,216
COPD patients:
62,621
Matched controls:
436,591
Matched controls:
432,073
Matched controls:
239,186
Matched controls:
191,654
Study population:
650,269
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Table 1. Baseline characteristics of patients with COPD and matched controls 
 COPD patients Matched controls 
Characteristics n=62 621 n=191 656 
Mean follow-up time (years) 3.6±2.5 4.0±2.5 
Females 28 044 (44.8) 91 511 (47.8) 
Age at index date (years) 67.8±11.2 67.4±11.5 
BMI at index date (kg/m2) 26.8±6.0 27.3±5.2 
Underweight (BMI <18.5 kg/m2) 
Normal weight (BMI 18.5-<25 kg/m2) 
Overweight (BMI 25-<30 kg/m2) 
Obese (BMI ≥30 kg/m2) 
Unknown 
3 335 (5.3) 
21 513 (34.4)
19 649 (31.4)
15 927 (25.4)
2 197 (3.5) 
2 998 (1.6) 
59 054 (30.8) 
71 236 (37.2) 
45 481 (23.7) 
12 887 (6.7) 
Smoking status at index date   
Never 
Current 
Former  
7 033 (11.2) 
30 938 (49.4)
24 650 (39.4)
100 987 (52.7) 
36 989 (19.3) 
53 680 (28.0) 
Drug use (<6 months)   
SABAs 
LABAs 
SAMAs 
LAMAs 
ICS 
Systemic glucocorticoids 
Xanthine derivatives 
Oxygen 
Antipsychotics 
Acid suppressants 
Immunosuppressants 
Influenza vaccination 
Pneumococcal vaccination 
27 001 (43.1)
10 022 (16.0)
4 607 (7.4) 
6 308 (10.1) 
13 148 (21.0)
8 850 (14.1) 
417 (0.7) 
239 (0.4) 
684 (1.1) 
18 631 (29.8)
264 (0.4) 
6 093 (9.7) 
1 052 (1.7) 
0 
0 
0 
0 
0 
0 
0 
0 
1 368 (0.7) 
36 640 (19.1) 
291 (0.2) 
17 088 (8.9) 
2 707 (1.4) 
History of co-morbidities   
Coronary artery diseasea 
Heart failure 
Diabetes Mellitus 
Cerebrovascular disease 
Dementia 
Malignancy (excl. non-melanoma skin cancer) 
Chronic renal disease 
Chronic liver disease 
Pneumonia b 
11 187 (17.9)
2 171 (3.5) 
5 039 (8.1) 
4 113 (6.6) 
910 (1.5) 
9 068 (14.5) 
646 (1.0) 
231 (0.4) 
34 519 (55.1)
22 779 (11.9) 
2 768 (1.4) 
15 908 (8.3) 
9 290 (4.9) 
3 355 (1.8) 
26 350 (13.8) 
1 522 (0.8) 
288 (0.2) 
78 667 (41.1) 
FEV1 %pred.
c (most recent) 67.8±22.2 93.9±18.0 
≥80 %pred. 
≥50 - <80 %pred. 
≥30 - <50 %pred. 
<30 %pred. 
6 573 (28.6) 
11 330 (49.3)
4 264 (18.6) 
818 (3.6) 
3 689 (80.1) 
867 (18.8) 
48 (1.0) 
4 (0.1) 
FVC %pred. (most recent) 84.6±20.7 94.7±18.6 
Tiffenau index (FEV1/FVC) (most recent) 65.2±14.2 80.9±6.7 
Acute exacerbation of COPD (<1 year) 444 (0.7) 0 
Notes: Data are presented as mean±SD or n (relative %). a Including: ischemic heart disease, myocardial infarc-
tion and coronary artery disease. b History of pneumonia >3 months prior to index date. c COPD n=22,985 
(36.7%); matched controls n=4,608 (2.4%). Abbreviations: %pred, percentage of predicted; BMI, body mass 
index; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; ICS, inhaled corticosteroids; 
LABAs, long-acting beta-2 agonists; LAMAs, long-acting muscarinic antagonists; SABAs, short-acting beta-2 
agonists; SAMAs, short-acting muscarinic antagonists. 
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CAP incidence 
Around 3.04% (n=7,730) of the total population was diagnosed with CAP during follow-
up: 3,819 (6.10%) COPD patients and 3,911 (2.04%) controls. Table S4 shows IRs of CAP 
in COPD patients (32.00 per 1000 person-years) and controls (6.75 per 1000 person-
years). IRs increased with age and female gender. In COPD patients, IR was highest in 
never smokers (39.51 per 1000 person-years), while former smokers had the lowest IR 
(28.31 per 1000 person-years). In controls, IR was highest in current smokers (7.82 per 
1000 person-years). 
CAP risk in COPD patients versus controls 
COPD patients had a fourfold increased CAP risk compared to controls (fully adjusted 
[adj.] HR 4.51 [4.27–4.77]; Figure 2; Table S4, Supplemental material). Stratum-specific 
CAP risk in COPD was significantly higher (test of interaction HR 1.22 [1.03–1.45]) in 
younger patients (aged 40–59; fully adj. HR 4.97 [4.40–5.62]), then in elderly patients 
(aged ≥80; fully adj. HR 4.08 [3.61–4.60]). After stratification to smoking status, the HR 
of CAP was five times higher in never smoking COPD patients, compared to never smok-
ing controls (fully adj. HR 5.25 [4.75–5.80]). The same for current smoking COPD pa-
tients versus current smoking controls (fully adj. HR 4.94 [4.65–5.26]). Former smoking 
COPD patients had a fourfold increased CAP risk compared to former smoking controls 
(fully adj. HR 4.26 [4.00–4.55]). 
 
  
Figure 2. Stratum-specific risk of CAP in patients with COPD compared to matched controls, stratified by age, 
gender and smoking status. 
Notes: Adjusted for age, gender, BMI, antipsychotics, acid suppressants, immunosuppressants, influenza 
vaccination, pneumococcal vaccination, ICS, coronary artery disease, heart failure, diabetes mellitus, cerebro-
vascular disease, dementia, malignancy, chronic renal disease, chronic liver disease and smoking status. 
Abbreviations: BMI, body mass index; CAP, community-acquired pneumonia; ICS, inhaled corticosteroids. 
3.5 4.0 4.5 5.0 5.5 6.0
COPD vs. Non-COPD
40-59 years
60-79 years
80+ years
Males
Females
Never smoking
Current smoking
Former smoking
Fully adjusted Hazard Ratios
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CAP risk and smoking status 
Within COPD, CAP risk in current smokers (fully adj. HR 0.92 [0.82–1.02]) was compara-
ble to the risk in never smokers (reference; Figure 3; Table S5, Supplemental material). 
Former smoking COPD patients had a lower risk (fully adj. HR 0.81 [0.73–0.90]). Current 
smokers had a significantly higher CAP risk as compared to former smokers (p<0.001). 
CAP risk increased by older age (fully adj. HR aged 60–79, 2.26 [2.00–2.57]; aged ≥80, 
6.06 [4.86–7.55]) and female gender (fully adj. HR 1.30 [1.22–1.39]). The level of airflow 
obstruction showed a trend toward increased CAP risk for very severe obstruction (fully 
adj. HR 1.30 [0.98–1.73]) in comparison to mild obstruction (reference). A sub analysis 
was performed by smoking status, stratified for level of airflow obstruction (Table S6, 
Supplemental material). No clear trend of increased risk by severity of airflow obstruc-
tion was observed within never, current or former smokers. 
 
 
Figure 3. Risk of CAP in patients with COPD, stratified by age, gender, smoking status and the level of airflow 
obstruction. 
Notes: Adjusted for age, gender, BMI, antipsychotics, acid suppressants, immunosuppressants, influenza 
vaccination, pneumococcal vaccination, ICS, coronary artery disease, heart failure, diabetes mellitus, cerebro-
vascular disease, dementia, malignancy, chronic renal disease, chronic liver disease and smoking status. 
Abbreviations: BMI, body mass index; CAP, community-acquired pneumonia; ICS, inhaled corticosteroids. 
 
Within controls, CAP risk was highest in current smokers (fully adj. HR 1.23 [1.13–1.34]), 
while the risk in former smokers (fully adj. HR 1.07 [0.99–1.16]) was comparable with 
the risk in never smokers (reference; Table S7, Supplemental material). Older age (fully 
adj. HR aged 60–79 years, 2.54 [2.23–2.90]; aged ≥80 years, 8.85 [7.10–11.00]) and 
female gender (fully adj. HR 1.26 [1.18–1.35]) showed increased CAP risk. 
  
0.5 1.0 1.5 2.0 2.5 3.0 3.5 4.0 4.5 5.0 5.5 6.0 6.5 7.0 7.5 8.0
60-79 years vs. 40-59 years
80+ years vs. 40-59 years
Females vs. Males
Current smoking vs. Never smoking
Former smoking vs. Never smoking
≥50 - <80 %pred. vs. ≥80 %pred.
≥30 - <50 %pred. vs. ≥80 %pred.
<30 %pred. vs. ≥80 %pred.
Fully adjusted Hazard Ratios
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DISCUSSION 
COPD patients had a fourfold increased CAP risk in comparison with matched controls. 
Current smoking had no additional impact on CAP risk in COPD. In controls, CAP risk was 
elevated in current smokers. The risk of CAP increased in both COPD patients and con-
trols with older age and female gender. 
CAP risk and IRs 
COPD patients had higher CAP IRs and increased CAP risk compared to controls, in line 
with former research4,25. The observed IR in COPD patients was higher than reported by 
Müllerova et al5 (22.4/1000 person-years), but in accordance with the incidence report-
ed by DiSantostefano et al26 (30.9/1000 person-years). In controls, Capelastegui et al27 
observed an IR of 3.1/1000 adults per year, while our observed IR was twice as high 
(6.8/1000 person-years). 
A possible explanation of the higher IRs observed, might be the rising incidence in Euro-
pean countries28. A number of factors are associated with this phenomenon: popula-
tions grow older, and lifestyle factors and comorbid conditions related to CAP become 
more prevalent28. Older age might also be a potential factor in our study, as the average 
age was 67 years. This was also shown by Millett et al29 with an incidence of 8.0/1000 
person-years in controls ≥65 years old. 
Gender differences appeared, as females had a slightly larger CAP risk than males. This 
is in contrast with former research2,30,31. Reasons for increased risk in females could not 
be further delineated in this study, but clearly warrant further research. Changes in 
female lifestyle and risk behaviour have been reported in previous decades and might 
represent important factors32,33. Furthermore, former research showed that respiratory 
symptoms were more often reported by females than males34, with higher hospitaliza-
tion incidences in studies concerning milder CAP cases35,36. 
Smoking status and CAP risk 
Current smoking was associated with increased CAP risk in controls, in line with former 
research37–39. Smoking has been related to structural changes in the respiratory tract 
and a decrease in immune response40, which might result in microbial invasion of the 
bronchial tree, triggering CAP. 
In COPD patients, CAP risk was comparable between never and current smokers. It was 
expected that, in accordance with controls, current smokers were at increased CAP risk. 
However, Müllerova et al5 also observed no difference in CAP risk between non-
smoking and current smoking COPD patients. Moreover, Myint et al41 observed a larger 
4CAP risk in COPD by smoking status 
 71 
proportion of current smokers in COPD without CAP than in CAP–COPD. Maybe, inaccu-
rate recording of smoking status by general practitioners influenced the present results, 
although smoking is a QOF indicator, rewarding general practitioners to record patients’ 
smoking status every year when diagnosed with COPD. However, smoking is the major 
risk factor of COPD, but the majority of persistent smokers do not develop COPD. This 
suggests that the vulnerability to cigarette smoke varies between individuals. The 
mechanisms behind this are at the moment not completely understood42. Never smok-
ers may also develop COPD, but by a different pathway than exposure to smoking43, for 
example, by occupational/environmental exposures, alpha-1-antitrypsin deficiency or 
due to factors early in life which affect the respiratory health in the long-term44. Patho-
physiological differences between subgroups of COPD might contribute to the observed 
differences in CAP risk. Besides, it is likely that a combination of factors is responsible 
for disease development, or not. For example, smoking has been associated with CAP 
development, but is also associated with a lower socioeconomic status, poor diet, alco-
hol consumption and reduced physical activity45, which, in turn, are also risk factors for 
CAP4. Furthermore, there are theoretically three general mechanisms related to the 
increased CAP risk of smoking: 1) tobacco-induced physiological and structural changes, 
2) tobacco-induced increase in bacterial virulence, 3) tobacco-induced dysregulation of 
immune function8. These three mechanisms are also key features in COPD, and proba-
bly the smoking-effect related to both the development of CAP and COPD, does not 
sum-up. Overall, many mechanisms might be associated with the observed results, but 
further research is warranted to explore exact pathways involved. 
We also observed no difference concerning severity of airflow obstruction stratified by 
smoking status and CAP risk. IRs increased with worse airflow obstruction, but only 
showing a trend toward increased risk in very severe airflow obstruction. Conflicting 
results were reported before, some observing increased CAP risk in severe and very 
severe airflow obstruction46, while others observed no difference in CAP risk by airflow 
obstruction41. There may be reverse causation underlying this lack of relationship; those 
with worse airflow obstruction stopped smoking, while others continued their smoking 
habits. However, this is less likely, as smoking status over time was taken into account, 
correcting for possible confounding. Furthermore, never and current smoking COPD 
patients had a comparable risk, which stresses the fact that the observed results are not 
due to smoking cessation. 
Strengths and limitations 
The current study includes a large population-based cohort study, providing anonymous 
longitudinal medical records of primary care patients12,47. This study design makes the 
current results generalizable to a larger population. In addition, by taking smoking sta-
tus over time into account, the results are representative of real life setting. 
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In contrast, several methodological issues could have influenced the results. First, pri-
mary care databases rely on the quality of information included in records12. This de-
pends on the accuracy of individuals responsible for entering data. However, inclusion 
of a large number of patients will minimize potential bias. Second, we did not use spi-
rometry to confirm COPD diagnosis, as this was available for only one-third of patients. 
Misclassification of exposure is likely to be non-differential and may have led to a bias 
toward null48. This implies that the fourfold increased risk of CAP in COPD versus non-
COPD may have been underestimated. In addition, CAP diagnosis was not confirmed by 
chest X-ray, but based on clinical features, probably causing CAP overestimation49. This 
may have led to a non-differential misclassification of the outcome and a bias toward 
the null value. However, it has a small impact on our main findings: the true HR of CAP 
among smokers versus non-smokers in COPD would have been lower than the non-
significant 8% reduced risk, and will still not support our main hypothesis that smoking 
increases the risk of CAP in COPD. In addition, ICS use was not separately analysed, but 
only included as a potential confounder, as this would go beyond the primary aim of the 
objective. However, ICS risk in CAP is of high interest, often showing an increased risk, 
although probably depending on the specific ICS and dose50. 
Clinical implications 
The results of the present analyses highlight the fact that CAP remains a major health 
issue, impacting both socially and economically51. Smoking cessation is an important 
aspect in the management of CAP and especially in control subjects, this strategy might 
be beneficial and lead to a decreased risk to develop CAP38. In contrast, for patients 
with COPD, this association seems less clear, but as earlier described, further research is 
necessary to assess mechanisms associated with the increased risk to develop CAP. For 
clinical practice it remains important to not underestimate the impact of CAP in patients 
with COPD. The management of CAP is at the moment focused on treating the disease, 
and prevention by vaccination51, while prevention of lifestyle factors, such as smoking, 
alcohol consumption and bodyweight, is at least as important4,38,39,52,53. 
Conclusion 
COPD patients have a fourfold increased risk to develop CAP, independent of smoking 
status. Identification of factors related with the increased risk of CAP in COPD is war-
ranted, in order to improve the management of patients at risk. 
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SUPPLEMENTAL MATERIAL 
Table S1. Read codes to define COPD 
Read code Medical code Clinical event Read term 
66YM.00 11287  382901  Chronic obstructive pulmonary disease annual review 
H3...00  1001  338812  Chronic obstructive pulmonary disease 
H3...11  998  205995  Chronic obstructive airways disease 
66YB.00 9520  161278  Chronic obstructive pulmonary disease monitoring 
H312200 1446  153677  Acute exacerbation of chronic obstructive airways disease 
66Yf.00 28743  81666  Number of COPD exacerbations in past year 
H36..00 10863  52387  Mild chronic obstructive pulmonary disease 
H3z..00  5710  50568  Chronic obstructive airways disease NOS 
H3y1.00 7884  48220  Chron obstruct pulmonary dis wth acute exacerbation, unspec 
H37..00 10802  46111  Moderate chronic obstructive pulmonary disease 
66YL.00 18621  45740  Chronic obstructive pulmonary disease follow-up 
H32..00 794  44748  Emphysema 
66YL.11 18476  30033  COPD follow-up 
H31..00 3243  24068  Chronic bronchitis 
H38..00 9876  21178  Severe chronic obstructive pulmonary disease 
8H2R.00 11019  11033  Admit COPD emergency
66Yd.00 19106  5350  COPD accident and emergency attendance since last visit 
66Ye.00 19003  4720  Emergency COPD admission since last appointment 
H31z.00 15157  3461  Chronic bronchitis NOS 
66YB000 102685  1499  Chronic obstructive pulmonary disease 3 monthly review 
66YB100 103007  1470  Chronic obstructive pulmonary disease 6 monthly review 
14OX.00 96931  1448  At risk of chronic obstructive pulmonary diseas exacerbation 
H39..00 93568  1355  Very severe chronic obstructive pulmonary disease 
H312100 14798  1157  Emphysematous bronchitis 
H3y..00 12166  1113  Other specified chronic obstructive airways disease 
H312.00 27819  1014  Obstructive chronic bronchitis 
H32z.00 33450  862  Emphysema NOS 
H3z..11  37247  794  Chronic obstructive pulmonary disease NOS 
H310.00 25603  560  Simple chronic bronchitis 
H320.00 26306  410  Chronic bullous emphysema 
66Yi.00 46036  390  Multiple COPD emergency hospital admissions 
14B3.12 103494  363  History of chronic obstructive pulmonary disease 
H311.00 11150  309  Mucopurulent chronic bronchitis 
8BP8.00 100123  152  Antibiotic therapy for acute pulmonary exacerbation 
H320z00 23492  77  Chronic bullous emphysema NOS 
H312z00 44525  64  Obstructive chronic bronchitis NOS 
H32yz00 16410  54  Other emphysema NOS 
H32y.00 40788  47  Other emphysema 
Hyu3100 65733  47  [X]Other specified chronic obstructive pulmonary disease 
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Read code Medical code Clinical event Read term 
H311000 40159  45  Purulent chronic bronchitis 
H310z00 61118  33  Simple chronic bronchitis NOS 
H311z00 61513  25  Mucopurulent chronic bronchitis 
H313.00 24248  24  Mixed simple and mucopurulent chronic bronchitis 
H3A..00 104608  22  End stage chronic obstructive airways disease 
H31y.00 66043  18  Other chronic bronchitis 
H31yz00 68066  15  Other chronic bronchitis NOS 
H320200 60188  14  Giant bullous emphysema 
H320000 56860  10  Segmental bullous emphysema 
H320100 68662  10  Zonal bullous emphysema 
H3y..11 67040  7  Other specified chronic obstructive pulmonary disease 
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Table S2. Read codes to define pneumonia 
Read code Medical code Clinical event Read term 
H25..11 16287 1.368 chest infection - unspecified bronchopneumonia 
H26..11 19400 517 chest infection - pneumonia due to unspecified organism 
H22..11 22795 452 chest infection - other bacterial pneumonia 
H20..11 9389 304 chest infection - viral pneumonia 
H270.11 29457 131 chest infection - influenza with pneumonia 
H21..11 29166 71 chest infection - pneumococcal pneumonia 
H23..11 30653 62 chest infection - pneumonia organism OS 
H2B..00 104121 1.358 community acquired pneumonia 
H26..00 572 152.581 pneumonia due to unspecified organism 
H23..00 25694 1.404 pneumonia due to other specified organisms 
H231.00 1576 3.638 pneumonia due to mycoplasma pneumoniae 
H223.00 12423 781 pneumonia due to streptococcus 
H224.00 5612 416 pneumonia due to staphylococcus 
H22y200 12061 568 pneumonia - legionella 
H23z.00 34251 320 pneumonia due to specified organism NOS 
H201.00 31269 240 pneumonia due to respiratory syncytial virus 
H220.00 23546 202 pneumonia due to klebsiella pneumoniae 
H221.00 30591 170 pneumonia due to pseudomonas 
H222.00 37881 97 pneumonia due to haemophilus influenzae 
H202.00 36675 36 pneumonia due to parainfluenza virus 
H22y.00 50867 79 pneumonia due to other specified bacteria 
H200.00 67836 30 pneumonia due to adenovirus 
H223000 63858 22 pneumonia due to streptococcus, group B 
H222.11 48804 19 pneumonia due to haemophilus influenzae 
H22y100 45425 2 pneumonia due to proteus 
H22y000 65419 12 pneumonia due to escherichia coli 
Hyu0B00 98381 13 {X} pneumonia due to other specified infectious organisms 
H22y011 60299 6 e. coli pneumonia 
H233.00 17025 107 chlamydial pneumonia
A022200 58896 16 salmonella pneumonia 
A54x400 47973 12 herpes cimplex pneumonia 
H25..00 886 81.043 bronchopneumonia due to unspecified organism 
H21..00 1849 33.743 lobar (pneumococcal) pneumonia 
H260.00 9639 9.071 lobar pneumonia due to unspecified organism 
H261.00 3683 8.061 basal pneumonia due to unspecified organism 
H232.00 73735 3 pneumonia due to pleuropneumonia like organisms 
H2z..00 6094 25.862 pneumonia or influenza NOS 
H2…00 10086 11.512 pneumonia and influenza 
H270.00 15912 369 influenza with pneumonia 
H270z00 35745 55 influenza with pneumonia NOS 
H270100 62632 7 influenza with pneumonia, influenza virus identified 
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Read code Medical code Clinical event Read term 
H2y..00 11849 4.971 other specified pneumonia or influenza 
H28..00 5324 6.049 atypical pneumonia 
H20..00 5202 4.455 viral pneumonia 
H20z.00 14976 2.153 viral pneumonia NOS 
H20y.00 33478 154 viral pneumonia NEC 
Hyu0800 52520 12 {X} other viral pneumonia 
H22z.00 23095 2.636 bacterial pneumonia NOS 
H22yz00 43884 233 pneumonia due to bacteria NOS 
H22..00 28634 1.402 other bacterial pneumonia 
Hyu0A00 63763 17 {X} other bacterial pneumonia 
A3By.00 41721 14 other specified bacterial infection 
H56y100 4910 998 interstitial pneumonia 
H24y200 27519 137 pneumonia with pneumocystis carinii 
H24y700 23726 107 pneumonia with varicella 
H243.00 30437 107 pneumonia with whooping cough 
H24..00 40498 105 pneumonia with infectious diseases EC 
H24y.00 69782 11 pneumonia with other infectious diseases EC 
H24yz00 70559 4 pneumonia with other infectious diseases EC NOS 
H24z.00 66362 7 pneumonia with infectious diseases EC NOS 
H243.11 35082 86 pneumonia with pertussis 
H246.00 34274 45 pneumonia with aspergillosis 
H24y000 61623 40 pneumonia with actinomycosis 
H26000 8318 3.513 Lung consolidation 
H263.00 38065 893 Pneumonitis, unspecified 
A521.00 25462 417 Varicella pneumonitis 
H240.00 41034 135 pneumonia with measles 
A551.00 32172 94 postmeasles pneumonia 
H530300 35189 67 abscess of lung with pneumonia 
H22yx00 52384 3 pneumonia due to other aerobic gram-negative bacteria
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Table S3. Read codes to define smoking 
Read code Pegasus code Clinical event Read term 
1371.00 33 6470929 Never smoked tobacco 
137..00 54 2502551 Tobacco consumption 
137L.00 60 2304618 Current non-smoker 
137S.00 90 3052739 Ex smoker 
137P.00 93 2676385 Cigarette smoker 
137K.00 776 229539 Stopped smoking 
1376.00 1822 21119 Very heavy smoker - 40+cigs/d 
137P.11 1823 248966 Smoker 
1374.00 1878 306129 Moderate smoker - 10-19 cigs/d 
SM7z.11 2758 4192 Smoke inhalation 
1375.00 3568 180120 Heavy smoker - 20-39 cigs/day 
9OO..12 7130 31688 Stop smoking monitoring admin. 
8CAL.00 7622 2065441 Smoking cessation advice 
67A3.00 10184 1096 Pregnancy smoking advice 
13p..00 10211 66778 Smoking cessation milestones 
137R.00 10558 298165 Current smoker 
8HTK.00 10742 28366 Referral to stop-smoking clinic 
9N2k.00 11356 80957 Seen by smoking cessation advisor 
9N4M.00 11527 12018 DNA - Did not attend smoking cessation clinic 
1371.11 11788 486937 Non-smoker 
137G.00 12240 122363 Trying to give up smoking 
137T.00 12878 22138 Date ceased smoking 
1372.11 12941 63145 Occasional smoker 
137..11 12942 29304 Smoker - amount smoked 
137J.00 12943 44369 Cigar smoker 
1373.00 12944 192364 Light smoker - 1-9 cigs/day 
137M.00 12945 44090 Rolls own cigarettes 
137F.00 12946 184203 Ex-smoker - amount unknown 
137H.00 12947 42546 Pipe smoker 
137Q.11 12951 4825 Smoking restarted 
137Q.00 12952 5262 Smoking started 
9OO1.00 12953 34338 Attends stop smoking monitor. 
ZV4K000 12954 77 [V]Tobacco use 
1379.00 12955 102459 Ex-moderate smoker (10-19/day) 
137A.00 12956 63329 Ex-heavy smoker (20-39/day) 
1378.00 12957 67388 Ex-light smoker (1-9/day) 
1372.00 12958 45508 Trivial smoker - < 1 cig/day 
137B.00 12959 14127 Ex-very heavy smoker (40+/day) 
137Z.00 12960 5648 Tobacco consumption NOS 
1377.00 12961 17473 Ex-trivial smoker (<1/day) 
137Y.00 12963 3136 Cigar consumption 
137C.00 12964 6648 Keeps trying to stop smoking 
137X.00 12965 2300 Cigarette consumption 
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Read code Pegasus code Clinical event Read term 
137V.00 12966 2268 Smoking reduced 
137a.00 12967 4160 Pipe tobacco consumption 
8H7i.00 18573 52913 Referral to smoking cessation advisor 
67H1.00 18926 2697 Lifestyle advice regarding smoking 
9OOA.00 19485 8032 Stop smoking monitor.chck done 
137O.00 19488 2476 Ex cigar smoker 
9OOZ.00 21637 6887 Stop smoking monitor admin.NOS 
137N.00 26470 4026 Ex pipe smoker 
9OO..00 28834 15149 Anti-smoking monitoring admin. 
137c.00 30423 2733 Thinking about stopping smoking
137d.00 30762 5336 Not interested in stopping smoking 
137b.00 31114 4532 Ready to stop smoking 
9OO..11 32083 1482 Stop smoking clinic admin. 
E251.00 32687 2802 Tobacco dependence 
137W.00 32973 117 Chews tobacco 
13p0.00 34126 24577 Negotiated date for cessation of smoking 
13p5.00 38112 6814 Smoking cessation programme start date 
9OO3.00 40417 725 Stop smoking monitor default 
9OO2.00 40418 2940 Refuses stop smoking monitor 
8CAg.00 41042 333 Smoking cessation advice provided by community pharmacist 
137e.00 41979 358 Smoking restarted 
9OO4.00 42722 10208 Stop smoking monitor 1st lettr 
137g.00 46300 2262 Cigarette pack-years 
137f.00 46321 36 Reason for restarting smoking 
13WK.00 52503 230 No smokers in the household 
9OO7.00 53101 490 Stop smoking monitor verb.inv. 
9OO8.00 58597 395 Stop smoking monitor phone inv 
9OO5.00 60720 159 Stop smoking monitor 2nd lettr 
137h.00 62686 1277 Minutes from waking to first tobacco consumption 
9OO9.00 63901 15 Stop smoking monitoring delete 
9OO6.00 66387 17 Stop smoking monitor 3rd lettr 
E251z00 68658 242 Tobacco dependence NOS 
E251100 70746 12 Tobacco dependence, continuous 
E251300 72706 115 Tobacco dependence in remission 
745H.00 74907 12882 Smoking cessation therapy 
745H000 81440 1883 Nicotine replacement therapy using nicotine patches 
745H200 85247 375 Nicotine replacement therapy using nicotine inhalator 
745H100 85975 222 Nicotine replacement therapy using nicotine gum 
745H300 89464 98 Nicotine replacement therapy using nicotine lozenges 
745Hz00 90522 261 Smoking cessation therapy NOS 
745Hy00 91708 38 Other specified smoking cessation therapy 
745H400 94958 214 Smoking cessation drug therapy 
E251000 95610 2 Tobacco dependence, unspecified 
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Table S4. Stratum-specific risk of CAP in patients with COPD compared to matched controls, stratified by age, 
gender and smoking status 
 CAP  IRa Age and gender adjusted  
HR (95% CI) 
Fully adjusted  
HR (95% CI)b   n = 7 730 COPD non-COPD 
Non-COPD 3 911  6.75 reference reference 
COPD 3 819 32.00  4.67 (4.47-4.89) 4.51 (4.27-4.77) 
By age (years)c        
40-59 817 28.03 5.40 5.39 (4.89-5.94) 4.97 (4.40-5.62) 
60-79 2 234 30.06 6.29 4.67 (4.41-4.96) 4.48 (4.16-4.82) 
80+ 768 48.30 11.75 3.93 (3.56-4.33) 4.08 (3.61-4.60) 
By genderd      
Males 1 939 29.50 6.18 4.49 (4.21-4.78) f 4.52 (4.19-4.89) g 
Females 1 880 36.69 7.39 4.90 (4.60-5.22) f 4.61 (4.25-5.00) g 
By smoking statuse     
Never 509 39.51 6.40 5.47 (4.98-6.01) 5.25 (4.75-5.80) h 
Current 1 758 34.03 7.82 4.86 (4.59-5.14) 4.94 (4.65-5.26) h 
Former 1 552 28.31 6.78 4.28 (4.03-4.54) 4.26 (4.00-4.55) h 
a IR/1000 person-years. b Adjusted for age, gender, BMI, antipsychotics, acid suppressants, immunosuppres-
sants, influenza vaccination, pneumococcal vaccination, ICS, coronary artery disease, heart failure, diabetes 
mellitus, cerebrovascular disease, dementia, malignancy, chronic renal disease, chronic liver disease and 
smoking. c Non-COPD of the same age category as reference. d Non-COPD of the same gender as reference. e 
Non-COPD with the same smoking status as reference. f Adjusted for age. g Adjusted for age, BMI, antipsy-
chotics, acid suppressants, immunosuppressants, influenza vaccination, pneumococcal vaccination, ICS, 
coronary artery disease, heart failure, diabetes mellitus, cerebrovascular disease, dementia, malignancy, 
chronic renal disease, chronic liver disease and smoking. h Adjusted for age, gender, BMI, antipsychotics, acid 
suppressants, immunosuppressants, influenza vaccination, pneumococcal vaccination, ICS, coronary artery 
disease, heart failure, diabetes mellitus, cerebrovascular disease, dementia, malignancy, chronic renal disease 
and chronic liver disease. Abbreviations: CAP, community acquired pneumonia; COPD, Chronic Obstructive 
Pulmonary Disease; IR, incidence rate; HR, hazard ratio; ICS, inhaled corticosteroids. 
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Table S5. Risk of CAP in patients with COPD, stratified by age, gender, smoking status and the level of airflow 
obstruction 
 CAP  IRa Age and gender adjusted 
HR (95% CI) 
Fully adjusted HR (95% 
CI)b  n = 3 819 
By age (years)     
40-59 817 28.03 reference reference 
60-79 2 234 30.06 2.16 (1.91-2.45) 2.26 (2.00-2.57) 
80+ 768 48.30 6.18 (4.99-7.66) 6.06 (4.86-7.55) 
By gender     
Males 1 939 29.50 reference reference 
Females 1 880 36.69 1.31 (1.23-1.39)c 1.30 (1.22-1.39)d 
By smoking status     
Never 509 39.51 reference reference 
Current 1 758 34.03 0.87 (0.78-0.96) 0.92 (0.82-1.02)e 
Former 1 552 28.31 0.77 (0.70-0.86) 0.81 (0.73-0.90)e 
By FEV1         
≥80 %pred. 355 12.68 reference reference 
≥50 - <80 %pred. 627 12.72 0.93 (0.81-1.06) 0.93 (0.82-1.06) 
≥30 - <50 %pred. 266 14.33 1.03 (0.87-1.20) 1.09 (0.93-1.29) 
<30 %pred. 61 17.70 1.21 (0.92-1.59) 1.30 (0.98-1.73) 
a IR/1000 person-years. b Adjusted for age, gender, BMI, antipsychotics, acid suppressants, immunosuppres-
sants, influenza vaccination, pneumococcal vaccination, ICS, coronary artery disease, heart failure, diabetes 
mellitus, cerebrovascular disease, dementia, malignancy, chronic renal disease, chronic liver disease and 
smoking. c Adjusted for age. d Adjusted for age, BMI, antipsychotics, acid suppressants, immunosuppressants, 
influenza vaccination, pneumococcal vaccination, ICS, coronary artery disease, heart failure, diabetes mellitus, 
cerebrovascular disease, dementia, malignancy, chronic renal disease, chronic liver disease and smoking. e 
Adjusted for age, gender, BMI, antipsychotics, acid suppressants, immunosuppressants, influenza vaccination, 
pneumococcal vaccination, ICS, coronary artery disease, heart failure, diabetes mellitus, cerebrovascular 
disease, dementia, malignancy, chronic renal disease and chronic liver disease. Abbreviations: CAP, communi-
ty acquired pneumonia; COPD, Chronic Obstructive Pulmonary Disease; IR, incidence rate; HR, hazard ratio; 
FEV1, forced expiratory volume in 1 second; %pred., percentage of predicted; ICS, inhaled corticosteroids. 
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Table S6. Risk of CAP in patients with COPD, stratified by the level of airflow obstruction within each smoking 
category 
 CAP IRa Age and gender adjusted  
HR (95% CI) 
Fully adjusted  
HR (95% CI)b n = 3 819 
Never smoking 509    
≥80 %pred. 46 12.15 reference reference 
≥50 - <80 %pred. 73 15.86 1.22 (0.96-1.56) 1.17 (0.81-1.70) 
≥30 - <50 %pred. 29 21.87 1.57 (1.08-2.27) 1.61 (1.01-2.56) 
<30 %pred. 3 16.21 1.23 (0.40-3.84) 1.40 (0.44-4.51) 
Current smoking 1 758    
≥80 %pred. 158 14.58 reference reference 
≥50 - <80 %pred. 267 12.65 0.86 (0.75-0.99) 0.81 (0.67-0.99) 
≥30 - <50 %pred. 113 13.45 0.93 (0.77-1.13) 0.91 (0.71-1.16) 
<30 %pred. 31 19.65 1.32 (0.92-1.89) 1.30 (0.88-1.93) 
Former smoking 1 552    
≥80 %pred. 151 11.29 reference reference 
≥50 - <80 %pred. 287 12.17 0.95 (0.83-1.09) 0.99 (0.81-1.21) 
≥30 - <50 %pred. 124 14.04 1.05 (0.87-1.28) 1.16 (0.91-1.48) 
<30 %pred. 27 16.04 1.11 (0.76-1.64) 1.21 (0.79-1.85) 
a IR/1000 person-years. b Adjusted for age, gender, BMI, antipsychotics, acid suppressants, immunosuppres-
sants, influenza vaccination, pneumococcal vaccination, ICS, coronary artery disease, heart failure, diabetes 
mellitus, cerebrovascular disease, dementia, malignancy, chronic renal disease and chronic liver disease. 
Abbreviations: CAP, community acquired pneumonia; COPD, Chronic Obstructive Pulmonary Disease; IR, 
incidence rate; HR, hazard ratio; %pred., percentage of predicted; ICS, inhaled corticosteroids. 
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Table S7. Risk of CAP in matched control subjects, stratified by age, gender and smoking status 
 CAP IRa Fully adjusted HR (95% CI)b 
 N = 3 911 
By age (years)    
40-59 819 5.40 reference 
60-79 2221 6.29 2.54 (2.23-2.90) 
80+ 871 11.75 8.85 (7.10-11.00) 
By gender    
Males 1890 6.18 reference 
Females 2021 7.39 1.26 (1.18-1.35)c 
By smoking status    
Never 2003 6.40 reference 
Current 1130 7.82 1.07 (0.99-1.16)d 
Former 778 6.78 1.23 (1.13-1.34)d 
a IR/1000 person-years. b Adjusted for age, gender, BMI, antipsychotics, acid suppressants, immunosuppres-
sants, influenza vaccination, pneumococcal vaccination, ICS, coronary artery disease, heart failure, diabetes 
mellitus, cerebrovascular disease, dementia, malignancy, chronic renal disease, chronic liver disease and 
smoking. c Adjusted for age, BMI, antipsychotics, acid suppressants, immunosuppressants, influenza vaccina-
tion, pneumococcal vaccination, ICS, coronary artery disease, heart failure, diabetes mellitus, cerebrovascular 
disease, dementia, malignancy, chronic renal disease, chronic liver disease and smoking. d Adjusted for age, 
gender, BMI, antipsychotics, acid suppressants, immunosuppressants, influenza vaccination, pneumococcal 
vaccination, ICS, coronary artery disease, heart failure, diabetes mellitus, cerebrovascular disease, dementia, 
malignancy, chronic renal disease and chronic liver disease. Abbreviations: CAP, community acquired pneu-
monia; COPD, Chronic Obstructive Pulmonary Disease; IR, incidence rate; HR, hazard ratio; ICS, inhaled corti-
costeroids. 
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ABSTRACT 
Background: Spontaneous sputum production occurs in a subset of COPD patients; 
however, its clinical relevance has not been established. Differences in health status and 
clinical outcomes between patients with and without positive sputum cultures are un-
known. 
Objectives: To compare clinical characteristics and health status of spontaneous sputum 
producers with a positive culture (SC+) and negative culture (SC-) with non-sputum 
producers (NP) in a cohort of COPD patients referred for pulmonary rehabilitation. 
Methods: In total, 518 clinically stable patients with mild-to-very severe COPD were 
recruited (mean age 64.1±9.1 years, 55.6% males, forced expiratory volume in 1 second 
48.6%±20.0% predicted). Health status was measured using COPD Assessment Test, St. 
George’s Respiratory Questionnaire, and the Clinical COPD Questionnaire. Symptoms of 
anxiety and depression were assessed using the Hospital Anxiety and Depression Scale. 
Exercise capacity was measured using the 6-minute walking distance. Spontaneously 
expectorated sputum was cultured for microbiology. 
Results: Almost one-third of patients spontaneously produced sputum (n=164, 31.7%). 
Despite comparable lung function, SC+ reported more frequent exacerbations than NP 
(≥2 exacerbations <1 year: 43 [81.1%] vs. 179 [50.6%], p<0.001). COPD Assessment Test 
total score and the Clinical COPD Questionnaire total score were significantly worse in 
SC+ than NP (23.9±6.1 vs. 21.1±6.7, p=0.012; 3.1±1.0 vs. 2.5±1.0, p=0.002; respectively). 
Hospital Anxiety and Depression Scale-D score was significantly higher in SC+ than NP 
(8.7±4.1 vs. 7.2±4.3, p=0.046). 
Conclusion: Spontaneous sputum production is common in COPD. Particularly, patients 
with positive cultures have worse health status and more symptoms of depression. 
Impact on disease progression and long-term outcomes remain to be established. 
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INTRODUCTION 
COPD is a life-threatening lung disease and is the fourth leading cause of death world-
wide1. It is known that COPD has a great impact on a patient’s life. Symptoms frequently 
reported by patients with COPD are dyspnoea, wheezing, cough, and sputum produc-
tion2. 
For many years, the concept chronic bronchitis (CB) has been investigated in patients 
with COPD. The proportion of patients reporting CB, defined as chronic productive 
cough, varies from 24.5%3 to 82%4. Research concerning CB focused mainly on disease 
progression3,4, with reduced forced expiratory volume in 1 second (FEV1) and Tiffeneau 
index (ratio FEV1/forced vital capacity [FVC]) as end points, in comparison to non-
persistent sputum producers3,4. Furthermore, different studies observed an increase in 
the number of exacerbations3,4 and hospitalizations4, as well as a higher mortality risk5. 
Subsequently, a reduced quality of life6 and functional exercise capacity3 have been 
previously reported. 
Not all patients have symptoms of productive cough; some have only increased mucus 
production. Mucus hypersecretion (MH) is characterized by an increase in mucin-
producing cells, leading to increased mucus secretion7. CB and MH can simultaneously 
exist, although Caramori et al.8 concluded that there was no link between symptoms of 
CB and mucus production. MH was related to FEV1 decline, hospitalization
9, and exac-
erbation frequency10. Contrary results have been published concerning the association 
with mortality11. 
Although data are available on CB and MH, little is known about the association of spon-
taneous sputum production at any moment and health status and other clinical out-
comes in patients with COPD. Especially, the potential impact of sputum microbiology 
on these outcomes might be clinically relevant because a substantial proportion of 
stable patients with COPD are colonized with bacteria12, which is associated with in-
creased daily symptoms13 and exacerbation frequency14. Banerjee et al.15 reported a 
worse health status in stable COPD patients with a positive sputum culture compared to 
patients without bacterial pathogens in sputum. These last data were limited because 
the focus of the research was different, and substantial information is lacking (e.g., no 
mean values, only p-values). 
Therefore, the aim of the present study was to increase understanding of the impact of 
spontaneous sputum production on health status and clinical characteristics in patients 
with COPD, after stratification between those with and without positive sputum cul-
tures. 
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MATERIALS AND METHODS 
The current analyses were based on data collected as part of the COPD, health status, 
and comorbidities (Chance) study, an observational monocenter study16. The rationale 
and design of the study have been previously published16. Chance was approved on 
April 23, 2012 by the local ethics committee of the Maastricht University Medical Cen-
tre+, the Netherlands (MEC 11-3-070). The authors confirm that all on going and related 
trials are registered (NTR3416, registered at www.trialregister.nl). All patients gave 
written informed consent. 
Study population 
Stable patients with COPD referred for pulmonary rehabilitation (PR) to CIRO, a Center 
of Expertise for Chronic Organ Failure, were consecutively recruited between April 23, 
2012 and September 24, 2014 and were included in the current analyses. Patients were 
classified as COPD based on post-bronchodilator FEV1/FVC <0.7 according to the Global 
Initiative for Obstructive Lung Disease (GOLD)1. COPD Assessment Test (CAT) total score 
was used as symptom measure for the combined COPD assessment1. When CAT score 
was missing, the modified Medical Research Council score was used instead1. Stable 
was defined as not having a registered exacerbation in the past 4 weeks. Patients with a 
history of other respiratory diseases, having undergone lung surgery, or with a malig-
nancy within the last 5 years were excluded from the study17. 
Study procedures 
Patients were measured during an inpatient pre-rehabilitation assessment. Clinical 
characteristics were assessed as described before16. Exacerbation history and hospital 
and ICU admission were based on the medical report and patient recall. CB was defined 
as the presence of chronic cough and sputum production for at least 3 months a year, 
for two consecutive years1. Disease-specific health status was assessed by CAT18, the 
Clinical COPD Questionnaire (CCQ)19, and the COPD-specific version of the St George’s 
Respiratory Questionnaire (SGRQ-C)20. CAT items on cough and phlegm were stratified 
based on the number of points reported by patients, with a cut off of ≥3 points. Besides, 
the following minimum clinically important differences (MCID) were taken into account: 
≥2 points CAT21, ≥0.4 points CCQ22, and ≥4 points SGRQ-C23. Symptoms of anxiety and 
depression were measured using the Hospital Anxiety and Depression Scale (HADS)24. 
Exercise capacity was assessed by the 6-minute walking distance (6MWD)25. Moreover, 
laboratory data including inflammatory parameters and blood gas analysis were collect-
ed. All patients were asked to produce spontaneous sputum if possible. Sputum sam-
ples were cultured to obtain the microbial aetiology. Patients were categorized into two 
subgroups: non-sputum producers (NP) and sputum producers (SP), with the last group 
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stratified by culture result; SP with a negative culture (SC-) and SP with a positive cul-
ture (SC+). 
Statistical analysis 
SPSS version 20.0 (IBM Corporation, Armonk, NY, USA) was used for data analyses. Vari-
ables were tested for normality using the skewness and kurtosis statistics. Continuous 
data are presented as mean ± standard deviation or median (interquartile range), while 
categorical data are presented as counts and percentages. Subgroups were compared 
using one-way analysis of variance and post hoc Bonferroni test, Kruskal–Wallis test for 
k- and 2-independent samples, or chi-square test, as appropriate. A p-value <0.05 was 
considered to be statistically significant. 
RESULTS 
In total, 518 clinically stable patients with COPD were recruited (mean age 64.1±9.1 
years, 55.6% males, FEV1 48.6%±20.0% pred; Table S1). Of these, 164 patients (31.7%) 
produced a spontaneous sputum sample during their PR assessment. When comparing 
NP with SP, SP had a higher number of males, were more often classified as COPD GOLD 
D, were more frequent exacerbators, had more hospitalizations, and the prevalence of 
CB was higher (Table S1). 
To see whether these differences between NP and SP could be explained by the sputum 
microbiology, Table 1 gives an overview of the baseline characteristics of NP, SC+, and 
SC-. A positive sputum culture was obtained in 53 patients (32.3%) with a sample. SC+ 
were more often males compared with NP, and more frequently classified as COPD 
GOLD D. No discrimination based on culture result could be made for the number of 
exacerbations in the year prior to assessment and symptoms of CB, although there was 
a trend toward increased exacerbations (p=0.058) and symptoms of CB (p=0.061) in SC+ 
vs. SC-. In patients with CB (n=167), 78 patients produced a spontaneous sputum sam-
ple (46.7%). No differences were observed in medication use between the defined sub-
groups (Table S2). 
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Table 1. Baseline characteristics of NP vs. SC- vs. SC+ 
 NP (n=354) SC- (n=111) SC+ (n=53) p-value 
Age (years) 63.8±9.1 64.3±9.2 65.5±8.9 0.466 
Male sex  184 (52.0) 68 (61.3) 36 (67.9)# 0.037 
BMI (kg/m2) 26.1±5.8 26.2±5.4 27.0±6.4 0.622 
COPD GOLD 
A 
B 
C 
D 
 
13 (3.7)
162 (45.8) 
7 (2.0) 
172 (48.6) 
 
4 (3.6) 
36 (32.4) 
3 (2.7) 
68 (61.3) 
 
2 (3.8) 
8 (15.1) 
- 
43 (81.1)# 
<0.001 
 
 
 
 
Current smoker 72 (20.4) 32 (28.8) 10 (18.9) 0.362 
Pack years* 40.0 (30.0-50.0) 40.0 (25.0-50.0) 41.0 (31.0-51.0) 0.350 
FEV1 (% predicted) 49.0±20.0 48.7±19.2 45.6±21.4 0.525 
FEV1/FVC (Tiffeneau) 37.9±12.1 36.8±11.8 36.5±13.8 0.579 
RV (% predicted) 163.0±51.6 155.1±46.3 160.7±53.6 0.372 
TLC (% predicted) 117.9±17.1 116.2±17.5 113.7±20.0 0.226 
DLCO (% predicted) 49.5±17.5 50.2±16.9 46.2±15.8 0.391 
LTOT 82 (23.2) 24 (21.6) 19 (35.8) 0.103 
PaCO2 (kPa)* 5.2 (4.7-5.6) 5.1 (4.7-5.6) 5.3 (4.9-5.9) 0.340 
PaO2 (kPa)* 9.6 (8.7-10.4) 9.3 (8.3-10.3) 9.4 (8.4-10.4) 0.397 
Exacerbations (<1 year) 
0 
1 
≥ 2 
 
101 (28.5) 
74 (20.9) 
179 (50.6) 
 
23 (20.7) 
17 (15.3) 
71 (64.0)# 
 
4 (7.5) 
6 (11.3) 
43 (81.1)# 
<0.001 
 
 
 
Hospitalizations (<1 year) 
0 
1 
≥ 2 
 
204 (57.6) 
87 (24.6) 
63 (17.8) 
 
57 (51.4) 
23 (20.7) 
31 (27.9) 
 
23 (43.4) 
14 (26.4) 
16 (30.2) 
0.061 
 
 
 
ICU admissions (<1 year)† 
0 
1 
≥ 2 
 
312 (92.9) 
21 (6.3)
3 (0.9) 
 
100 (95.2) 
4 (3.8) 
1 (1.0) 
 
51 (98.1) 
1 (1.9) 
- 
0.597 
 
 
Symptoms of CB 89 (26.1) 46 (45.5)# 32 (61.5)# <0.001 
mMRC‡ 
0 
1 
2 
3 
4 
 
7 (2.0) 
62 (17.7) 
134 (38.2) 
82 (23.4) 
66 (18.8) 
 
3 (2.8) 
16 (14.7) 
42 (38.5) 
28 (25.7) 
20 (18.3) 
 
- 
7 (13.5) 
17 (32.7) 
17 (32.7) 
11 (21.2) 
0.825 
 
 
 
 
Notes: Data are presented as mean±SD, median (interquartile range), or n (%). a p<0.05 compared to NP; b not 
normally distributed; c missing NP: n=18; SC-: n=6; SC+: n=1; d missing NP: n=3; SC-: n=2; SC+: n=1.  
Abbreviations: BMI, body mass index; COPD, Chronic Obstructive Pulmonary Disease; GOLD, Global initiative 
for chronic Obstructive Lung Disease; FEV1, forced expiratory volume in 1 second; FVC, forced Vital capacity; 
RV, residual volume; TLC, total lung capacity; DLCO, diffusing capacity for carbon monoxide; LTOT, long-term 
oxygen therapy; CB, chronic bronchitis; mMRC, modified Medical Research Council; ICU, intensive care unit; 
SD, standard deviation; NP, non-sputum producers; SC+, sputum producers with a positive culture; SC-, spu-
tum producers with a negative culture. 
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Health status, depression, and anxiety 
Health status using CAT total, cough and phlegm score, SGRQ-C total and symptom 
score, and CCQ-total score were worse in SP compared to NP (Table S3), although the 
differences did not exceed the MCID for all total scores. The sputum microbiology was 
discriminating in CAT total (Figure 1) and CCQ total (Figure 1), with worse scores in SC+ 
compared with NP (23.9±6.1 vs. 21.1±6.7, p=0.012; 3.1±1.0 vs. 2.5±1.0, p=0.002; re-
spectively). CAT cough and phlegm (Figure 1) and SGRQ-C symptom score (Figure 1) 
were increased in both SC+ and SC- compared with NP (Table S4). SGRQ-C total score 
was not significantly different anymore when taking the sputum microbiology into ac-
count, although the MCID was reached comparing SC+ with NP (65.4±16.1 vs. 
60.0±17.0). Additionally, the MCID was reached for SGRQ-C impact comparing SC+ with 
NP (53.8±21.6 vs. 48.4±20.7). A significant difference between SC+ and SC- was ob-
served in CAT phlegm (3.1±1.1 vs. 2.5±1.3, p=0.020) and a MCID in SGRQ-C symptom 
score (71.3±17.5 vs. 66.0±18.2; Table S4). 
When stratifying CAT cough and phlegm items based on reported scores, a significantly 
larger proportion of SC+ and SC- reported scores ≥3 points compared with NP (38 
[74.5%] vs. 66 [60.6%] vs. 162 [47%], p<0.001; 38 [74.5%] vs. 55 [50.5%] vs. 134 [38.8%], 
p<0.001; respectively). 
Symptoms of depression by the HADS score (Figure 1F) were more often observed in 
SC+ compared to NP (8.7±4.1 vs. 7.2±4.3). When comparing groups based on the pro-
portion of patients with an elevated score on health status or symptoms of anxiety and 
depression, no significant differences appeared (Table S5). 
Exercise capacity 
Exercise capacity, assessed using the 6MWD, did not differ between NP and SP 
(424.8±124.7 vs. 422.3±124.1 m). 
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Figure 1. Health status of NP vs. SC- vs. SC+ by CAT total score (A), CAT cough and phlegm (B), SGRQ-C total 
score (C), SGRQ-C domain scores (D), CCQ total score (E), and HADS score (F). 
Notes: Data are presented as mean±SD. One-way ANOVA and post hoc Bonferroni test. *p<0.05 compared to 
NP. Abbreviations: CAT, COPD Assessment Test; SGRQ-C, St. George’s Respiratory Questionnaire; CCQ, Clinical 
COPD Questionnaire; HADS, Hospital Anxiety and Depression scale; SC-, sputum producers with a negative 
culture; SC+, sputum producers with a positive culture; SD, standard deviation; ANOVA, analysis of variance; 
NP, non-sputum producers. 
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Inflammatory parameters and microbial aetiology 
Table 2 shows the inflammatory parameters, with no differences between NP and SP. 
Table 2. Inflammatory parameters, by peripheral blood collection, of NP vs. SP 
 NP (n=354) SP (n=164) p-value 
CRP (mg/l)a 2.6 (0.9-7.0) 3.3.0 (1.1-8.0) 0.158 
Erythrocytes (10E12/l) 4.7±0.4 4.7±0.5 0.490 
Leucocytes (10E9/l) 8.0±2.3 8.3±2.5 0.153 
Granulocytes (%) 60.7±9.6 59.5±10.3 0.198 
Lymphocytes (%) 28.2±8.1 28.7±8.7 0.538 
Monocytes (%) 8.6±3.0 9.0±3.0 0.119 
Eosinophilic granulocytes (%)a,b 
≤2% 
>2% 
3.0 (2.0-4.0) 
86 (45.5) 
103 (54.5) 
3.0 (2.0-5.0) 
35 (39.3) 
54 (60.7) 
0.205 
0.332 
Notes: Data are presented as mean±SD, median (interquartile range), or n (%). a Not normally distributed; 
b n=278. Abbreviations: CRP, C-reactive protein; NP, non-sputum producers; SP, sputum producers; SD, stand-
ard deviation. 
 
The frequency of the detected pathogens in the 53 patients with positive culture is 
presented in Figure 2. Haemophilus influenzae was most frequently present (39.6%), 
followed by Pseudomonas aeruginosa (28.3%). Coinfections existed, as a total of eleven 
patients were positive for more than one pathogen. 
 
 
Figure 2. Microbial aetiology of sputum producers with a positive culture. 
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DISCUSSION 
The results of this study can be summarized as follows. Almost one-third of patients 
with COPD referred for PR were identified as being spontaneous sputum producers. 
Also, it was shown that patients with COPD who had a sputum sample with a positive 
culture had worse health status compared with NP. Moreover, these patients had a 
higher exacerbation frequency and more symptoms of CB. Thus, not the presence of 
spontaneous sputum production per se, but its microbiological characterization influ-
ences outcomes in these patients. 
Frequency of spontaneous sputum production 
Spontaneous sputum production at any moment was very common in the present study 
and was associated with increased CAT cough and phlegm scores and an increased 
frequency of CB. Previously, Putcha et al.5 observed that sputum alone, or in combina-
tion with cough, was reported by 43.1% of 5,887 patients with mild-to-moderate airflow 
obstruction in the Lung Health Study. A study focusing on symptom variability in 2,441 
stable patients with severe COPD showed that sputum was the second most experi-
enced symptom after breathlessness (63.6%)2. Although around 30% of these patients 
reported a low frequency of sputum production in the past 7 days, ~20% reported 
moderate and ~10% severe or extreme production2. Taking these proportions into con-
sideration, it must be concluded that sputum production is common in patients with 
COPD, highlighting the potential importance of this specific clinical profile. 
Impact on outcomes 
Health status is an important outcome in the management of COPD. Until now, studies 
showed that health status is worse in patients with symptoms of CB3,6,26, mostly based 
on SGRQ scores. The results support the finding that health status is worse in patients 
with sputum production, especially in those with a positive culture (CAT total and CCQ 
total), even when compared with patients with a negative culture (CAT phlegm and 
SGRQ-C symptom). So, it seems that sputum production influences the symptom do-
mains, while the sputum microbiology influences health status in general. Within the 
subgroup of patients with CB, however, health status was not affected by sputum cul-
ture. This suggests that sputum microbiology may be clinically relevant, especially in 
COPD patients with incidental sputum production. Although SGRQ-C total score and the 
domain score impact were not statistically significantly different, the difference ob-
served between patients with a positive sputum culture and those without sputum 
production exceeded the MCID. 
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Limited data are available concerning symptoms of anxiety and depression in relation to 
CB. Corhay et al.4 reported no difference in symptoms of depression comparing patients 
with and without CB. The current data showed no difference in anxiety scores, although 
a significantly higher depression score was observed in patients with a positive sputum 
culture. Whether treatment of CB can lead to a decrease in symptoms of depression is 
not known and need further research. 
It can be argued whether sputum production affects exercise capacity, as no differences 
were observed in 6MWD, as well as in SGRQ-C activity. Kim et al.6 made similar observa-
tions in patients with CB. However, this is not supported by others, who observed a 
reduced 6MWD in patients with CB compared to patients without3,26. In the population 
of this study, sputum production did not seem to affect exercise capacity at baseline, 
but it would be interesting to see whether sputum production affects long-term exer-
cise capacity. Moreover, the effect of sputum production on physical activities in daily 
life would be clinically relevant to investigate. 
Remarkably, no differences in inflammatory parameters of blood samples were ob-
served between NP and patients with sputum production. Although all patients were in 
a clinically stable state at time of assessment, a positive sputum culture may indicate 
microbial colonization. Indeed, worse outcomes were previously described in colonized 
patients with COPD concerning exacerbation frequency and daily symptoms, when 
compared with non-colonized patients13,14. Although the current study design does not 
allow to firmly establish colonization, it suggests that sputum microbiology, instead of 
sputum production per se, affects health status. 
The observed difference in frequency of sputum production between sexes might be 
explained by sex-related differences in reporting respiratory symptoms. Lamprecht et 
al.27 observed that females more often reported respiratory symptoms such as dysp-
noea and cough compared to males. In contrast, males more often reported sputum 
production27. This in accordance with other studies that observed the same differences 
between the sexes regarding the presence of CB3,6. 
Microbiological characterization 
The sputum microbiology confirms that H. influenzae and P. aeruginosa are pathogens 
frequently cultured in patients with COPD28. Especially, H. influenzae is observed in both 
stable state and during exacerbations29. P. aeruginosa is more often found in patients 
with most severely impaired lung function30. The effect of a specific aetiology on the 
outcomes cannot be studied as the subgroups would become too small. 
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Strengths and limitations 
The current study was based on a rather homogenous population of clinically stable 
patients with mild-to-severe COPD referred for PR. Therefore, differences in health 
status between subgroups are not expected to be associated with COPD-specific char-
acteristics. Subgroups had comparable baseline characteristics concerning their level of 
airflow obstruction, smoking status, and hospital admissions. 
Until now, most analyses3,4,6 were based on patients who reported CB. However, it is 
difficult to assess this phenotype objectively as this definition relies on patients’ percep-
tion of the symptoms and might be subject to recall bias. Studies that used sputum 
samples are few in number and are mainly focused on inflammatory parameters26. 
Moreover, no study differentiated patients with sputum samples based on their micro-
biological culture result. This is, to the best of our knowledge, the first study investigat-
ing differences between subgroups of patients with and without sputum production 
and with and without positive culture. Therefore, the current study increased the un-
derstanding of this specific subgroup of patients. 
However, some aspects need to be taken into consideration regarding the current 
study. Although characterized as a patient with CB, more than half of them could not 
produce sputum during their 3 days’ pre-rehabilitation assessment. No sputum induc-
tion was performed as part of the current study, so only patients with a spontaneous 
sample were included in the producer groups. Besides, SC+ were often classified as 
GOLD D and were frequent exacerbators, which could act as bias. However, it is known 
that patients with frequent exacerbations are more often colonized, which explains the 
present outcomes14. Moreover, no high-resolution computed tomography was per-
formed to identify bronchiectasis, which is associated with increased sputum produc-
tion31. 
Conclusion 
In conclusion, health status is worse in patients with COPD who spontaneously produce 
sputum, especially when having a positive culture. Exercise capacity does not seem to 
be affected by sputum production. Further research is necessary to investigate the 
influence of sputum production and microbiology in the long term, especially when 
looking at positive cultures in relation to disease progression and outcomes of PR. In-
sight into the clinical profile of this subgroup of patients may contribute to specific rec-
ommendations, as not sputum per se seems to influence clinical outcomes, but having a 
positive culture. 
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SUPPLEMENTAL MATERIAL 
Table S1. Baseline characteristics of the total study population and NP vs. SP 
 All (n=518) NP (n=354) SP (n=164) p-value 
Age (years) 64.1±9.1 63.8±9.1 64.7±9.1 0.321 
Male sex 288 (55.6) 184 (52.0) 104 (63.4) 0.015 
BMI (kg/m2) 26.2±5.8 26.1±5.8 26.5±5.7 0.527 
COPD GOLD 
A 
B 
C 
D 
 
19 (3.7) 
206 (39.8) 
10 (1.9) 
283 (54.6) 
13 (3.7) 
162 (45.8) 
7 (2.0) 
172 (48.6) 
 
6 (3.7) 
44 (26.8) 
3 (1.8) 
111 (67.7) 
0.001 
Current smoker 114 (22.1) 72 (20.4) 42 (25.6) 0.369 
Pack yearsa 40.0 (30.0-50.0) 40.0 (30.0-50.0) 40.0 (28.0-50.0) 0.803 
FEV1 (% predicted) 48.6±20.0 49.0±20.0 47.7±19.9 0.518 
FEV1/FVC (Tiffeneau) 37.5±12.2 37.9±12.1 36.7±12.4 0.300 
RV (% predicted) 161.0±50.7 163.0±51.6 156.9±48.6 0.210 
TLC (% predicted) 117.1±17.5 117.9±17.1 115.4±18.3 0.133 
DLCO (% predicted) 49.3±17.2 49.5±17.5 48.9±16.6 0.713 
LTOT 125 (24.1) 82 (23.2) 43 (26.2) 0.450 
PaCO2 (kPa)
a 5.2 (4.7-5.6) 5.2 (4.7-5.6) 5.2 (4.8-5.7) 0.276 
PaO2 (kPa)
a 9.5 (8.6-10.4) 9.6 (8.7-10.4) 9.3 (8.4-10.3) 0.176 
Exacerbations (<1 year) 
0 
1 
≥ 2 
 
128 (24.7) 
97 (18.7) 
293 (56.6) 
101 (28.5) 
74 (20.9) 
179 (50.6) 
 
27 (16.5) 
23 (14.0) 
114 (69.5) 
<0.001 
Hospitalizations (<1 year) 
0 
1 
≥ 2 
 
284 (54.8) 
124 (23.9) 
110 (21.2) 
204 (57.6) 
87 (24.6) 
63 (17.8) 
 
80 (48.8) 
37 (22.6) 
47 (28.7) 
0.018 
ICU admissions (<1 year)b 
0 
1 
≥ 2 
 
463 (93.9) 
26 (5.3) 
4 (0.8) 
312 (92.9) 
21 (6.3) 
3 (0.9) 
 
151 (96.2) 
5 (3.2) 
1 (0.6) 
0.347 
Symptoms of CB 167 (33.8) 89 (26.1) 78 (51.0) <0.001 
mMRCc 
0 
1 
2 
3 
4 
 
10 (2.0) 
85 (16.6) 
193 (37.7) 
127 (24.8) 
97 (18.9) 
7 (2.0) 
62 (17.7) 
134 (38.2) 
82 (23.4) 
66 (18.8) 
 
3 (1.9) 
23 (14.3) 
59 (36.6) 
45 (28.0) 
31 (19.3) 
0.775 
Notes: Data are presented as mean±SD, median (interquartile range), or n (%). a Not normally distributed; 
b missing n= 25 (NP n=18; SP n=7); c missing n=6 (NP n=3; SP n=3). p<0.05 NP vs. SP. Abbreviations: BMI, Body 
Mass Index; COPD, Chronic Obstructive Pulmonary Disease; GOLD, Global initiative for chronic Obstructive 
Lung Disease; FEV1, Forced Expiratory Volume in 1 sec.; FVC, Forced Vital Capacity; RV, residual volume; TLC, 
total lung capacity; DLCO, diffusing capacity for carbon monoxide; LTOT, long term oxygen therapy; mMRC, 
modified Medical Research Council; NP, non-sputum producers; SP, sputum producers. 
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Table S2. Medication use of NP vs. SC- vs. SC+ 
 NP (n=354) SC- (n=111) SC+ (n=53) p-value 
SABA 164 (46.3) 41 (36.9) 24 (45.3) 0.218 
SAMA 54 (15.3) 15 (13.5) 13 (24.5) 0.170 
SABA/SAMA  67 (18.9) 31 (27.9) 11 (20.8) 0.127 
LABA 94 (26.6) 28 (25.2) 9 (17.0) 0.327 
LAMA 247 (69.8) 84 (75.7) 38 (71.7) 0.486 
ICS 69 (19.5) 23 (20.7) 11 (20.8) 0.947 
ICS/LABA  238 (67.2) 77 (69.4) 39 (73.6) 0.628 
Oral corticosteroids 62 (17.5) 19 (17.1) 13 (24.5) 0.443 
Antibiotics 39 (11.0) 6 (5.4) 9 (17.0) 0.062 
Notes: Data are presented as n (%). Abbreviations: SABA, short-acting beta-agonist; SAMA, short-acting mus-
carinic antagonist; LABA, long-acting beta-agonist; LAMA, long-acting muscarinic antagonist; ICS, inhaled 
corticosteroids; NP, non-sputum producers; SC-, sputum producers with a negative culture; SC+, sputum 
producers with a positive culture. 
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Table S3. Health status and symptoms of anxiety and depression of NP vs. SP 
 NP (n=354)a SP (n=164)b p-value 
CAT total 21.1±6.7 22.6±6.5 0.020 
CAT cough 2.3±1.3 2.9±1.2 <0.001 
CAT phlegm 2.0±1.4 2.7±1.2 <0.001 
SGRQ-C total 60.0±17.0 63.5±18.0 0.036 
SGRQ-C symptom 59.0±18.9 67.7±18.1 <0.001 
SGRQ-C impact 48.4±20.7 52.3±22.0 0.055 
SGRQ-C activity 80.0±18.4 79.9±19.8 0.929 
CCQ total 2.5±1.0 2.9±1.0 0.001 
HADS-A 7.6±4.5 8.1±4.4 0.260 
HADS-D 7.2±4.3 8.2±4.4 0.022 
Notes: Data are presented as mean±SD. a Missing CAT n=9; SGRQ-C n=9; CCQ n=9; HADS n=10; b missing CAT 
n=4; SGRQ-C n=5; CCQ n=7; HADS n=8. Abbreviations: CAT, COPD Assessment Test; SGRQ-C, St. George’s 
Respiratory Questionnaire; CCQ, Clinical COPD Questionnaire; HADS, Hospital Anxiety and Depression scale; 
SD, standard deviation; NP, non-sputum producers; SC-, sputum producers with a negative culture; SC+, 
sputum producers with a positive culture. 
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Table S4. Health status and symptoms of anxiety and depression of NP vs. SC- vs. SC+ 
 NP (n=354)a SC- (n=111)b SC+ (n=53)c p-value 
CAT total 21.1±6.7 21.9±6.6 23.9±6.1d 0.013 
CAT cough 2.3±1.3 2.7±1.2d 3.1±1.1d <0.001 
CAT phlegm 2.0±1.4 2.5±1.3d 3.1±1.1d,e <0.001 
SGRQ-C total 60.0±17.0 62.6±18.8 65.4±16.1 0.070 
SGRQ-C symptom 59.0±18.9 66.0±18.2d 71.3±17.5d <0.001 
SGRQ-C impact 48.4±20.7 51.6±22.3 53.8±21.6 0.133 
SGRQ-C activity 80.0±18.4 79.1±21.3 81.6±16.2 0.723 
CCQ total 2.5±1.0 2.8±1.1 3.1±1.0d 0.001 
HADS-A 7.6±4.5 8.0±4.3 8.3±4.5 0.489 
HADS-D 7.2±4.3 8.0±4.5 8.7±4.1d 0.046 
Notes: Data are presented as mean±SD. a Missing CAT n=9; SGRQ-C n=9; CCQ n=9; HADS n=10; b missing CAT 
n=2; SGRQ-C n=2; CCQ n=4; HADS n=5; c missing CAT n=2; SGRQ-C n=3; CCQ n=3; HADS n=3; d p<0.05 com-
pared to NP; e p<0.05 compared to SC-. Abbreviations: CAT, COPD Assessment Test; SGRQ-C, St. George’s 
Respiratory Questionnaire; CCQ, Clinical COPD Questionnaire; HADS, Hospital Anxiety and Depression scale; 
SD, standard deviation; NP, non-sputum producers; SC-, sputum producers with a negative culture; SC+, 
sputum producers with a positive culture. 
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Table S5. Number of patients with elevated scores on health status and symptoms of anxiety and depression 
 All (n=518) NP (n=354) SC- (n=111) SC+ (n=53) p-value 
CAT (≥10) 477 (94.5) 326 (94.5) 102 (93.6) 49 (96.1) 0.812 
SGRQ-C (≥25) 489 (97.0) 334 (96.8) 105 (96.3) 50 (100) 0.413 
CCQ (≥1) 477 (95.0) 327 (94.8) 101 (94.4) 49 (98.0) 0.586 
HADS-A (≥8) 235 (47.0) 154 (44.8) 57 (53.8) 24 (48.0) 0.264 
HADS-D (≥8) 238 (47.6) 156 (45.3) 53 (50.0) 29 (58.0) 0.211 
Notes: Data are presented as n (%). Missing CAT n=13; SGRQ-C n=14; CCQ n=16; HADS n=18. Abbreviations: 
CAT, COPD Assessment Test; SGRQ-C, St. George’s Respiratory Questionnaire; CCQ, Clinical COPD Question-
naire; HADS, Hospital Anxiety and Depression scale; NP, non-sputum producer; SC-, sputum producers with a 
negative culture; SC+, sputum producers with a positive culture. 
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Impact of exacerbations on adherence and 
outcomes of pulmonary rehabilitation 
in patients with COPD 
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ABSTRACT 
Background and objective: Dropout or lack of response is an important issue in pulmo-
nary rehabilitation (PR), which underlines the need to identify predictors of dropout and 
response. Acute exacerbations (AEs) of COPD may influence dropout rates and PR re-
sponse. We aimed to assess differences in dropout and outcomes of PR between COPD 
with and without AEs. 
Methods: Clinically stable patients with moderate-to-very severe COPD (age 64.1±9.1 
years, 55.6% males, forced expiratory volume in 1s (FEV1) 48.6±20.0% predicted) were 
assessed during PR (inpatient and outpatient). Mild-to-moderate AEs were defined as 
‘the prescription of systemic glucocorticosteroids and/or antibiotics, following an acute 
increase in respiratory symptoms’. Severe AEs were defined as ‘a hospital admission 
due to an AE’. Health status was measured by COPD Assessment Test (CAT), COPD-
specific version of the St. George’s Respiratory Questionnaire (SGRQ-C) and Clinical 
COPD Questionnaire (CCQ). Symptoms of anxiety and depression were measured by 
Hospital Anxiety and Depression Scale (HADS). Exercise capacity was measured with the 
6-min walking test (6MWT) and constant work rate test (CWRT). 
Results: A total of 518 patients were assessed during a pre-rehabilitation assessment. 
Four hundred and seventy-six patients started PR, of whom 419 (88.0%) completed it. A 
larger proportion of patients who dropped out had a severe AE during PR (20.0% vs. 
3.5%, p<0.001). Completers with severe AE showed a deterioration in 6MWT, while 
completers without AE and with mild-to-moderate AE improved (−24.8 (95% CI: −94.0 
to 44.5) vs. 24.2 (95% CI: 16.0 to 32.5) vs. 25.1 (95% CI: 14.0 to 36.3) metres, p=0.042). 
No other significant differences were observed in outcomes comparing completers with 
and without AE during PR. 
Conclusion: Mild-to-moderate AEs do not affect dropout or response of PR, although 
severe AEs are associated with dropout. AEs should not lead to discontinuation of PR, as 
response is in general not affected. 
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INTRODUCTION 
COPD is a major health problem and a leading cause of morbidity and mortality. Pulmo-
nary rehabilitation (PR) is targeted at reducing symptoms, improving health status (HS) 
and increasing physical activity in persistently symptomatic patients1. Beneficial effects 
of PR have been described consistently2, although a subset of patients does not respond 
to PR3,4. Besides, 10–32% of patients do not complete PR5. 
Identification of factors associated with dropout and response of PR is of broad interest, 
whilst there is still limited data available. Dropout for medical reasons is frequently 
reported, mainly due to acute exacerbations (AEs)5,6. AEs are common features of the 
disease; in general, 1.53 episodes per patient per year have been reported (1.20/year 
for mild-to-moderate AEs; 0.33/year for severe AEs)7. Although AEs are recognized as an 
important factor of dropout in PR, research concerning the impact of AEs on dropout 
and outcomes is limited. Steele et al.8 investigated the impact of mild-to-moderate AEs 
during PR on dropout and PR outcomes, observing that almost one-third of dropout was 
due to AEs. No differences were observed between completers with and without AEs in 
outcomes of PR, except for change in 6-min walk distance, with AE patients having a 
larger improvement following PR compared with patients without AEs8. 
Although former research8 did not look at severe AEs, AEs resulting in hospitalization 
might play a major role in dropout and response. Besides, research is needed in larger 
samples to clarify the role of AEs in dropout and outcomes of PR, whilst it is expected 
that AEs, especially severe AEs, have a negative impact on completion and outcomes of 
PR. Therefore, we aimed to assess the impact of both mild-to-moderate as well as se-
vere AEs on dropout and outcomes of PR. 
METHODS 
Data were derived from the COPD, Health Status and Co-morbidities (Chance) Study, a 
longitudinal observational single-centre study9. The rationale and design of the study 
were published before9, as well as data concerning the responsiveness and minimum 
clinically important difference (MCID) estimates for COPD Assessment Test (CAT), Clini-
cal COPD Questionnaire (CCQ) and Hospital Anxiety and Depression Scale (HADS) in 
patients with COPD undergoing PR10. The Chance study was approved by the local ethics 
committee of Maastricht University Medical Centre+, The Netherlands (MEC11-3-
070/trialregister.nl NTR3416). All patients gave written informed consent. 
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Study population 
Stable COPD patients referred for PR to CIRO, a centre of expertise for patients with 
chronic organ failure in Horn, The Netherlands, were recruited between April 2012 and 
September 2014. Patients were classified as COPD based on post-bronchodilator forced 
expiratory volume in 1s (FEV1)/forced vital capacity (FVC) <0.7 according to the Global 
Initiative for Obstructive Lung Disease (GOLD)11. Stable was defined as not having a 
registered AE 4 weeks before pre-rehabilitation assessment. Patients with a history of 
other respiratory diseases, having undergone lung surgery or with a malignancy within 
the last 5 years were excluded9. 
Study procedures 
Patients were screened and included during an inpatient pre-rehabilitation assessment. 
Patients eligible for PR followed an inpatient rehabilitation programme of 8 weeks or an 
outpatient rehabilitation programme of 16 weeks4, both 40 sessions. A multidisciplinary 
team evaluated patients during the pre-rehabilitation assessment, in combination with 
the severity of the disease and co-morbid conditions, as well as the access to facilities 
nearby, and made a decision for inpatient or outpatient rehabilitation. After PR, pa-
tients were evaluated at end-assessment. 
Clinical characteristics were assessed as described before9. Disease-specific HS was 
assessed by CAT12, COPD-specific version of the St. George’s Respiratory Questionnaire 
(SGRQ-C)13 and CCQ14. MCIDs were taken into account: ≥2 points CAT15, ≥4 points 
SGRQ-C16 and ≥0.4 points CCQ15. Symptoms of anxiety and depression were measured 
with HADS17, MCID ≥1.5 points18. Exercise capacity was assessed by 6-min walking test 
(6MWT)19, MCID ≥30 m20, and constant work rate test (CWRT)21, MCID ≥100 s.22 Pa-
tients performed the CWRT at 75% of the predetermined peak work rate assessed at 
pre-rehabilitation assessment, for a maximum of 20 min. 
Mild-to-moderate AEs were defined as ‘prescription of systemic glucocorticosteroids 
and/or antibiotics following acute increase in respiratory symptoms’23. Severe AEs were 
defined as ‘admission to a hospital due to AE for (non)invasive ventilatory support 
and/or parenteral administration of medications’. When patients had both mild-to-
moderate and severe AE, patients were classified as having severe AE. AEs in the year 
prior to PR were assessed based on patient recall, following the same definitions. 
Patients were categorized into three subgroups: not started (not started PR), dropouts 
(dropped out PR) and completers (completed PR). 
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Statistical analysis 
SPSS version 22.0 (IBM Corp. Armonk, NY, USA) was used for data analyses. Continuous 
variables were tested for normality by skewness and kurtosis, presented as mean±SD or 
median (interquartile range), as appropriate. Categorical data are presented as counts 
(%). Mean change was expressed as mean (95% CI). Subgroups were compared by one-
way analysis of variance (ANOVA) and post hoc Bonferroni test, Kruskal-Wallis-test or 
chi-square test, as appropriate. PR response was analysed by paired samples t-test. A p-
value of <0.05 was considered to be statistically significant, with analyses corrected for 
multiple comparisons by Bonferroni. 
RESULTS 
A total of 518 stable COPD patients were assessed during pre-rehabilitation assessment 
and included into the study (Figure 1) (mean age: 64.1±9.1 years, 55.6% male, mean 
FEV1: 48.6±20.0% predicted, most classified as COPD GOLD B or D (Table S1, Supple-
mental material)). 
 
 
Figure 1. Flow diagram of the study time points. 
Notes: Reasons for dropout due to medical problems: musculoskeletal problems n = 5, 22.7%; cardiovascular 
problems n = 1, 4.5%; planned operation (i.e. rectum and cancer) n = 2, 9.1%; cancer diagnosis n = 1, 4.5%; 
physical problems not further specified n = 2, 9.1%; disease/medical problems not further specified n = 11, 50.0%. 
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Dropout 
Forty-two patients (8.1%) underwent baseline assessment, but did not start PR due to 
various reasons (Figure 1). Consequently, no post-rehabilitation data were available. Of 
those who started PR, 419 patients (88.0%) completed PR. Main reasons to dropout 
were medical problems (n = 22, 38.6%) and hospital admissions (n = 13, 22.8%; Figure 1). 
Table 1 presents baseline characteristics of patients who completed (n = 419), dropped 
out (n = 57) and not started PR (n = 42). No significant differences were observed between 
subgroups, only a trend towards more current smokers in dropouts (n = 21, 36.8%) and 
patients not started (n = 14, 34.1%), compared with completers (n = 79, 18.9%). 
Subgroups did not differ in the proportion of patients with one or more AEs in the year 
prior to pre-rehabilitation assessment, regardless AE severity (Table 2). However, drop-
outs had more often severe AE during PR compared with completers (n = 8, 20.0% vs. n = 
14, 3.5%, respectively), while the other way around for mild-to-moderate AE (n = 6, 15.0% 
vs. n = 154, 38.4%, respectively; p< 0.001). The setting of PR did not influence dropout. 
Table 1. Baseline characteristics of completers, dropouts and not started patients 
 Completers (n = 419) Dropouts (n = 57) Not started (n = 42) 
Age (years) 64.3±8.8 64.7±9.7 61.3±10.8 
Male gender (%) 232 (55.4) 34 (59.6) 22 (52.4) 
BMI (kg/m2) 26.2±5.7 26.7±6.6 25.5±5.8 
COPD GOLD (%)    
A 15 (3.6) 1 (1.8) 3 (7.1) 
B 174 (41.5) 17 (29.8) 15 (35.7) 
C 8 (1.9) - 2 (4.8) 
D 222 (53.0) 39 (68.4) 22 (52.4) 
Current smoker (%) 79 (18.9) 21 (36.8) 14 (34.1) 
Pack years† (number) 40.0 (30.0–50.0) 40.0 (35.0–52.5) 39.0 (26.3–50.0) 
FEV1 (% predicted) 48.9±20.0 46.2±20.1 48.9±20.3 
FEV1/FVC (%) 37.3±12.1 38.2±13.8 38.7±11.7 
Charlson co-morbidity index (%) 
1 
2 
3 
4 
5 
6 
10 
 
257 (61.3) 
98 (23.4) 
45 (10.7) 
13 (3.1) 
4 (1.0) 
2 (0.5) 
- 
 
27 (47.4) 
15 (26.3) 
10 (17.5) 
3 (5.3) 
- 
1 (1.8) 
1 (1.8) 
 
25 (59.5) 
13 (31.0) 
3 (7.1) 
1 (2.4) 
- 
- 
- 
Notes: Data are presented as mean±SD, median (interquartile range) or n (%). Corrected for multiple compari-
sons by Bonferroni correction, p<0.002. †Not normally distributed. Abbreviations: BMI, body mass index; 
COPD, Chronic Obstructive Pulmonary Disease; FEV1, forced expiratory volume in 1 s; FVC, forced vital capaci-
ty; GOLD, Global Initiative for Obstructive Lung Disease; SD, standard deviation. 
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Table 2. Mild-to-moderate and severe exacerbations in the year prior to pre-rehabilitation assessment and 
during PR of completers, dropouts and not started patients 
 Completers (n = 419) Dropouts (n = 57) Not started (n = 42) p-value 
AE 1 year prior to PR     
0 96 (22.9) 10 (17.5) 7 (16.7) Ns. 
≥1 mild-to-moderate 144 (34.4) 13 (22.8) 14 (33.3)  
≥1 severe 179 (42.7) 34 (59.6) 21 (50.0)  
AE during PR     
0 233 (58.1) 26 (65.0) 0 <0.001 
≥1 mild-to-moderate 154 (38.4) 6 (15.0) 0  
≥1 severe 14 (3.5) 8 (20.0)   
Setting of PR     
Inpatient 261 (62.3) 40 (70.2) 0 Ns. 
Outpatient 158 (37.7) 17 (29.8) 0  
Notes: Data are presented as n (%). Corrected for multiple comparisons by Bonferroni correction, p<0.006. 
Data on exacerbations during PR were missing for 17 dropouts. For 18 completers, it was known they had at 
least 1 exacerbation during PR, but not the exact amount and severity. Abbreviations: AE, acute exacerbation; 
PR, pulmonary rehabilitation. 
Response to PR 
Health status 
Table 3 displays HS scores of completers at pre-rehabilitation assessment, end-
assessment and change in scores between pre-rehabilitation and end-assessment. On 
average, HS improved in completers following PR (ΔCAT: −3.0 (95% CI−3.7 to −2.4) 
points; ΔSGRQ-C: −9.1 (95% CI: −10.5 to −7.7) points; ΔCCQ: −0.6 (95% CI: −0.7 to −0.5) 
points). This improvement was statistically significant and clinically relevant, as for all 
questionnaires the mean improvement exceeded the MCID (Table 3). When comparing 
inpatient and outpatient PR completers (Table S2, Supplemental material), outpatients 
had a significantly better HS, less symptoms of anxiety and depression and a significant-
ly better performance on the 6MWT and CWRT at pre-rehabilitation assessment. On 
average, this difference was exceeding the MCID for all outcomes, except for the CWRT. 
Response to PR was significantly lower in outpatients compared with inpatients on HS 
scores, symptoms of anxiety and depression and 6MWT. 
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Table 3. Health status, symptoms of anxiety and depression and exercise capacity of completers 
 Pre-rehabilitation† End-assessment‡ Δ p-value 
CAT total score 21.5±6.6 18.5±6.9 −3.0 (−3.7 to −2.4) <0.001 
SGRQ-C total score 60.1±17.1 51.0±17.4 −9.1 (−10.5 to −7.7) <0.001 
SGRQ-C symptom score 61.2±19.0 54.5±19.0 −6.6 (−8.4 to −4.7) <0.001 
SGRQ-C activity score 79.2±19.0 72.2±21.0 −7.2 (−8.8 to −5.5) <0.001 
SGRQ-C impact score 48.4±20.4 37.1±20.9 −11.2 (−13.0 to −9.4) <0.001 
CCQ total score 2.6±1.0 2.0±1.0 −0.6 (−0.7 to −0.5) <0.001 
HADS-A score 7.5±4.4 5.8±4.2 −1.7 (−2.1 to −1.3) <0.001 
HADS-D score 7.4±4.2 5.3±3.9 −2.1 (−2.5 to −1.8) <0.001 
6MWT (m) 431.1±123.7 457.4±122.1 22.9 (16.4 to 29.5) <0.001 
CWRT (s) 234.5 
(174.25–338.0) 
376.5 
(210.3–708.5) 
206.4 
(175.5–237.3) 
<0.001 
Notes: Data of pre-rehabilitation and end-assessment are presented as mean±SD or median (interquartile 
range). Change is presented as mean (95% CI). Corrected for multiple comparisons by Bonferroni correction, p 
< 0.005. 
†Missing: CAT n = 9; SGRQ-C n = 10; CCQ n = 10; HADS n = 12; 6MWT n = 2; CWRT n = 27. 
‡Missing: CAT n = 23; SGRQ-C n = 26; CCQ n = 34; HADS n = 38; 6MWT n = 16; CWRT n = 37. 
Abbreviations: 6MWT, 6-min walking test; CAT, COPD Assessment Test; CCQ, Clinical COPD Questionnaire; CI, 
confidence interval; CWRT, constant work rate test; HADS, Hospital Anxiety and Depression Scale; SD, stand-
ard deviation; SGRQ-C, COPD-specific version of the St. George’s Respiratory Questionnaire. 
 
Completers with mild-to-moderate and severe AE during PR had a mean improvement 
of at least the MCID on all HS scores, except for CCQ in patients with severe AE (Table 
4). Mean change in HS between completers with AE, regardless of severity, and com-
pleters without AE, was not statistically different or clinically relevant. The proportion of 
patients exceeding the MCID for CAT and SGRQ did not differ between completers with 
and without AE (Figure 2). The proportion of patients exceeding the MCID of CCQ was 
significantly lower in completers with severe AE (n = 3, 23.1%) than completers without 
AE (n = 125, 59.8%, p = 0.009) and completers with mild-to-moderate AE (n = 77, 56.2%, 
p=0.022; Figure 2). 
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Table 4. Change in health status, symptoms of anxiety and depression and exercise capacity of completers 
with and without AE during PR 
 Completers without 
AE† (n = 233) 
Completers with  
mild-to-moderate AE‡ 
(n = 154) 
Completers with 
severe AE§ (n = 14) 
p-value 
Δ CAT total score −3.4 (−4.2 to −2.5) −2.9 (−4.0 to −1.8) −2.2 (−4.9 to 0.6) Ns. 
Δ SGRQ-C total score −9.9 (−11.9 to −7.8) −8.5 (−10.6 to −6.5) −4.5 (−11.4 to 2.5) Ns. 
Δ SGRQ-C symptom score −7.8 (−10.4 to −5.2) −5.4 (−8.2 to −2.5) −4.0 (−12.6 to 4.6) Ns. 
Δ SGRQ-C activity score −7.9 (−10.3 to −5.5) −6.1 (−8.6 to −3.5) −2.3 (−8.3 to 3.8) Ns. 
Δ SGRQ-C impact score −11.8 (−14.3 to −9.3) −11.1 (−13.9 to −8.2) −5.8 (−16.1 to 4.4) Ns. 
Δ CCQ total score −0.7 (−0.8 to −0.5) −0.6 (−0.7 to −0.4) −0.1 (−0.4 to 0.3) Ns. 
Δ HADS-A score −1.7 (−2.2 to −1.2) −1.7 (−2.3 to −1.1) −0.6 (−2.4 to 1.2) Ns. 
Δ HADS-D score −2.1 (−2.7 to −1.6) −2.0 (−2.6 to −1.4) −2.0 (−4.1 to 0.1) Ns. 
Δ 6MWT (m) 24.2 (16.0 to 32.5) 25.1 (14.0 to 36.3) −24.8 (−94.0 to 44.5) 0.042¶ 
Δ CWRT (s) 229.2(186.2 to 272.1) 167.3 (120.7 to 213.9) 174.8 (−91.0 to 440.6) Ns. 
Notes: Change is presented as mean (95% CI). Corrected for multiple comparisons by Bonferroni correction. 
†Missing: CAT n = 18; SGRQ-C n = 20; CCQ n = 24; HADS n = 26; 6MWT n = 6; CWRT n = 16. 
‡Missing: CAT n = 12; SGRQ-C n = 14; CCQ n = 18; HADS n = 20; 6MWT n = 9; CWRT n = 19. 
§Missing: CAT n = 1; SGRQ-C n = 1; CCQ n = 1; HADS n = 1; 6MWT n = 2; CWRT n = 4. 
¶Completers with severe AE versus completers without AE p = 0.041; completers with severe AE versus com-
pleters with mild-to-moderate AE p = 0.040. 
Abbreviations: 6MWT, 6-min walking test; AE, acute exacerbation; CAT, COPD Assessment Test; CCQ, Clinical 
COPD Questionnaire; CI, confidence interval; CWRT, constant work rate test; HADS, Hospital Anxiety and 
Depression Scale; PR, pulmonary rehabilitation; SGRQ-C, COPD specific version of the St. George’s Respiratory 
Questionnaire. 
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Serum markers and clinical parameters 
HADS scores on average decreased in completers following PR (HADS-A Δ: −1.7 (95% CI: 
−2.1 to −1.3) points and HADS-D Δ: −2.1 (95% CI: −2.5 to −1.8) points, respectively; 
Table 3), exceeding the MCID. 
No significant difference was observed in mean change of HADS when comparing com-
pleters with and without mild-to-moderate or severe AE (Table 4). The mean improve-
ment of anxiety symptoms in completers with severe AE did not exceed the MCID 
(Δ: −0.6 (95% CI: −2.4 to 1.2) points). There was no significant difference in the propor-
tion of completers exceeding the MCID comparing completers with and without AE 
Figure 2. Percentage of patients exceeding the minimum clinically important difference (MCID) stratified by 
acute exacerbation (AE) severity.  
Notes: *p=0.009; p=0.022. COPD Assessment Test (CAT): n = 128 completers without AE (59.5%), n = 80 
completers with mild-to-moderate AE (55.9%), n = 7 completers with severe AE (53.8%). COPD-specific ver-
sion of the St. George’s Respiratory Questionnaire (SGRQ-C): n = 139 completers without AE (65.3%), n = 81 
completers with mild-to-moderate AE (57.4%), n = 6 completers with severe AE (46.2%). Clinical COPD Ques-
tionnaire (CCQ): n = 125 completers without AE (59.8%), n = 77 completers with mild-to-moderate AE (56.2%), 
n = 3 completers with severe AE (23.1%). Hospital Anxiety and Depression Scale (HADS)-A: n = 104 completers 
without AE (50.2%), n = 66 completers with mild-to-moderate AE (48.9%), n = 7 completers with severe AE 
(53.8%). HADS-D: n = 107 completers without AE (51.7%), n = 74 completers with mild-to-moderate AE 
(54.8%), n = 6 completers with severe AE (46.2%). 6-Min walk test (6MWT): n = 102 completers without AE 
(44.7%), n = 64 completers with mild-to-moderate AE (43.8%), n = 4 completers with severe AE (33.3%). 
Constant work rate test (CWRT): n = 117 completers without AE (53.9%), n = 65 completers with mild-to-
moderate AE (48.1%), n = 4 completers with severe AE (40.0%). , completers without AE; , completers 
with mild-to-moderate AE; , completers with severe AE. 
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regardless of severity (Figure 2; HADS-A n = 104 (50.2%), n = 66 (48.9%), n = 7 (53.8%), 
p>0.05; HADS-D n = 107 (51.7%), n = 74 (54.8%), n = 6 (46.2%), p>0.05, respectively). 
Exercise capacity 
On average, completers significantly increased the distance walked at 6MWT and sec-
onds performed on CWRT, comparing pre-rehabilitation with end-assessment (Δ: 22.9 
(95% CI: 16.4–29.5) metres; Δ: 206.4 (95% CI: 175.5–237.3) seconds, respectively; Table 
3). However, this mean change was not clinically relevant for 6MWT. 
Completers with severe AE on average decreased on 6MWT (Δ: −24.8 (95% CI: −94.0 to 
44.5) metres), while completers without and with a mild-to-moderate AE showed a 
mean improvement (Δ: 24.2 (95% CI: 16.0 to 32.5) metres; Δ: 25.1 (95% CI: 14.0 to 36.3) 
metres, respectively; Table 4). For CWRT, all subgroups showed a mean improvement, 
exceeding the MCID (Table 4), observing no significant difference in the proportion of 
completers with and without AE exceeding the MCID (Figure 2). 
DISCUSSION 
The current findings show that mild-to-moderate exacerbations do not affect dropout 
and response of PR, although severe exacerbations are associated with increased drop-
out. However, when completing PR after a severe exacerbation, patients generally re-
spond positively, although less pronounced. These results emphasize that disease insta-
bility during PR should not discourage patients and healthcare professionals from PR 
continuation. 
Around 8.0% of the study population did not start PR, a smaller number than observed 
by others5,24. Of the patients who started, 12.0% dropped out, in between the range 
(9.7–31.8%) as described by Keating et al.5 Reasons of dropout in our population were 
mainly medical problems and hospital admissions. These reasons are, besides motiva-
tional and psychological factors6, known factors accounting for a substantial proportion 
of dropouts6,24. Nevertheless, the present study observed no association between mild-
to-moderate exacerbations prior to and during PR, and dropout. The same for severe 
exacerbations prior to PR. However, the proportion of patients with severe exacerba-
tions during PR was significantly larger in dropouts compared with completers. This 
difference might even be larger as we consider that dropouts completed less sessions. 
Besides, data on exacerbations were missing for 17 dropouts. However, it is expected 
that these patients had no exacerbation, as assessment of exacerbations is a standard 
procedure during PR. So, exacerbations in the year prior to PR do not influence dropout, 
although severe exacerbations during PR are associated with dropout. These results are 
in line with Steele et al.8 
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Smoking status has been related to dropout3,24,25. Smoking status or pack-years was not 
different between subgroups, although there was a trend towards more current smok-
ers in not started patients and dropouts, compared with completers. Some clinicians 
have doubts of including smokers in PR. However, smoking cessation is an important 
aspect in COPD management, and often offered during PR1. On the other hand, smoking 
is related to skeletal muscle dysfunction, affecting the oxygen delivery and the ability of 
the mitochondria to use oxygen26. This might have negative consequences on PR out-
comes, although comparable outcomes have been reported in smokers and non-
smokers25,27. Based on the latter, current smokers should not be withheld from PR. 
In general, patients made progress following PR, with a mean improvement exceeding 
the MCID for HS, HADS and CWRT. These results are not surprising, as the benefits of PR 
have been described frequently2. Moreover, these results confirm that especially pa-
tients who are limited and/or having recent and frequent exacerbations are admitted to 
PR. The setting of PR appeared to influence the outcomes. However, a lower response 
in outpatients was expected, as these patients had less room for improvement following 
the significantly better HS and better performance on exercise capacity at pre-
rehabilitation assessment. 
Completers with AE during PR, regardless of severity, performed comparable on CAT, 
SGRQ-C, HADS and CWRT as completers without AE. This was also seen in the percent-
age of patients exceeding the MCID for these measures. These results are in line with 
Steele et al.8 Probably, patients are monitored closely when following PR, resulting in 
fast and adequate treatment28. 
Conversely, mean change in distance walked at 6MWT significantly differed between 
completers with severe AE and completers without or with mild-to-moderate AE. Com-
pleters with severe AE on average deteriorated on the 6MWT, while others showed a 
mean improvement. On the other hand, the amount of patients exceeding the MCID of 
the 6MWT was comparable between completers with and without AE, regardless of 
severity. The amount of patients exceeding the MCID of CCQ was significantly lower in 
completers with severe AE than in completers without or with mild-to-moderate AE. 
Exacerbations, especially those resulting in hospitalizations, are known to have a detri-
mental impact on patients’ outcomes, partly supporting these findings29,30. 
What is now the consequence for clinical practice following the current results? As 
mentioned before, severe exacerbations are associated with dropout. However, the 
current analysis and former research showed beneficial effects of PR in these patients, if 
they are able to restart PR31,32. Given these data, we believe that patients who are hos-
pitalized for an exacerbation during PR, should be motivated to return and complete PR. 
Probably, the programme should be adjusted, depending on the specific patient, for 
example extension of programme duration, providing a less or more intensive pro-
gramme. Besides, continuing rehabilitation during the admission is recommended31. 
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Neuromuscular electrical stimulation (NMES) is a feasible and effective intervention to 
prevent skeletal muscle function deterioration in patients with severe exacerbations33. 
Early start of NMES during admission, and continuation during PR are probably good 
options to prevent deterioration after initial gain during PR. Troosters et al.31 showed 
that resistance training applied during an admission has favourable effects on quadri-
ceps muscle force. Another favourable effect of both interventions might be that pa-
tients stay motivated to finish their initial PR. So, in-hospital rehabilitation during severe 
exacerbations may be an effective bridge between hospitalization and PR continuation. 
Furthermore, facilitating care for acute respiratory failure in an inpatient setting might 
be a way to avoid hospitalizations and offer the possibility to continue PR during exac-
erbations. Training with non-invasive ventilation is promising, and might also be benefi-
cial in patients with severe exacerbations, but well-designed studies are needed34. 
Furthermore, it is important to offer ‘strategies’ to prevent hospitalizations. Besides 
optimal medication treatment, a possible ‘strategy’ can be education of exacerbation 
management. Self-management has found to be effective in reducing emergency de-
partment visits and hospital admissions35, by teaching patients to monitor signs and 
symptoms, and provide them with action plans and skills to improve health-enhancing 
behaviours. Eventually, patients will be his own expert in identifying and managing 
exacerbations36. 
There are some methodological considerations that should be taken into account. The 
study included a population of well-characterized moderate-to-very severe COPD pa-
tients. A subset of outcome measures was studied independently, while Spruit et al.4 
suggests a multidimensional response measure, allowing more insight into the multidi-
mensional effects of exacerbations on PR. Besides, data on exacerbations were un-
derreported or missing for a small proportion of patients, especially from patients reha-
bilitating in an outpatient setting. We expect that this small proportion of lacking data 
did not influence results. Additionally, exact data on the amount of completed session 
were not available, but would be interesting to study. This also in light of programme 
extension, and the effect on outcomes. Furthermore, it would be interesting to follow-
up dropouts to study the amount of exacerbations over the same time period. Overall, 
precaution is necessary when interpreting the results, as the subgroup of severe exa-
cerbators is quite small. Further research in a larger cohort is recommended. 
In conclusion, while mild-to-moderate AEs do not affect dropout or outcomes of PR, 
severe exacerbations are associated with increased dropout. However, AEs should not 
lead to discontinuation of PR, as response is generally not affected. 
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SUPPLEMENTAL MATERIAL 
Table S1. Baseline characteristics of the total population 
 All (n=518) 
Age (years) 64.1±9.1 
Male gender 288 (55.6) 
BMI (kg/m2) 26.2±5.8 
COPD GOLD 
A 
B 
C 
D 
 
19 (3.7) 
206 (39.8) 
10 (1.9) 
283 (54.6) 
Current smoker 114 (22.1) 
Pack years* 40.0 (30.0-50.0) 
FEV1 (% pred.) 48.6±20.0 
FEV1/FVC 37.5±12.2 
Charlson comorbidity index 
1 
2 
3 
4 
5 
6 
10 
 
309 (59.7) 
126 (24.3) 
58 (11.2) 
17 (3.3) 
4 (0.8) 
3 (0.6) 
1 (0.2) 
Notes: Data are presented as mean±SD, median (interquartile range) or N (%).*Not normally distributed. 
Abbreviations: BMI, Body Mass Index; COPD, Chronic Obstructive Pulmonary Disease; GOLD, Global initiative 
for chronic Obstructive Lung Disease; FEV1, Forced Expiratory Volume in 1 sec.; FVC, Forced Vital Capacity. 
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ABSTRACT 
Background: Different types of specimens have been used to assess the respiratory 
microbiome in COPD. However, no consensus on suitable specimens to use in clinical 
practice has been reached, while the use of the respiratory microbiome as diagnostic 
tool is of great interest. 
Objective: To determine the patient-specific and specimen-specific signatures of the 
respiratory microbiome, using the IS-pro technology, in specimens from different ana-
tomical locations in the respiratory tract, in order to asses similarities/differences be-
tween the different sampling locations as well as between different patients. 
Methods: 11 patients with mild-to-moderate COPD (mean age 72.3±8.0 years, 81.8% 
males, forced expiratory volume in 1 second 74.5±17.9 %pred.) were assessed. A throat 
swab, spontaneous sputum sample, bronchial aspirate and bronchoalveolar lavage 
(BAL) were collected. Specimens were analysed by the IS-pro technology, a 16S-23S 
rDNA interspace(IS)-region-based profiling method. Alpha-diversity was measured to 
assess the diversity within a specific specimen. Beta-diversity was measured to assess 
similarities between IS-profiles of the defined specimens within and between patients. 
Results: BAL specimens had a significantly lower alpha-diversity than sputum and throat 
(2.9±0.5 vs. 3.4±0.4 vs. 3.6±0.3, respectively; p<0.05). A principal coordinate analysis 
revealed a segregation of upper and lower respiratory specimens, while sputum and 
throat had a significantly lower beta-diversity compared to BAL and bronchial aspirate 
(p<0.05). Interestingly, we observed a higher level of microbiome similarity within dif-
ferent respiratory specimens of an individual (0.4±0.2), than within a particular type of 
respiratory specimen between individuals (0.5±0.1, p<0.001). 
Conclusion: Both, the alpha and beta diversity differ between different anatomical loca-
tions of the respiratory tract. However, the respiratory microbiome contains a patient-
specific signature in all respiratory specimens, which is more pronounced than the spec-
imen-specific signature. 
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INTRODUCTION 
Chronic Obstructive Pulmonary Disease (COPD) is a leading cause of death and morbidi-
ty worldwide1. Patients with COPD are prone to exacerbations most often triggered by 
respiratory infections, and their airways are often colonised with microorganisms2. Up 
to now, laboratory analysis of bacterial pathogens in respiratory specimens was based 
on culture-dependent techniques. However this excludes unculturable micro-organisms 
which form a large proportion of the respiratory microbiome3. Shifts in this microbiome 
have already been associated with disease; it was shown that Rhinovirus infection in 
COPD patients was associated with increased bacterial load and a change in microbiome 
composition4. Moreover, differences in the respiratory microbiome in relation to dis-
ease severity have been observed, as well as changes in the respiratory microbiome 
during COPD exacerbations5-7. However, it is still unclear whether a core microbiome 
exists across individuals, certain disease (pheno)types, or within single individuals. In 
addition, the possible influence of the clinical specimen, thus the anatomical location, is 
largely unknown. The use of the respiratory microbiome in clinical practice is of increas-
ing interest, and could develop into an important diagnostic tool, although comprehen-
sive evidence in this field is still largely lacking. 
The IS-pro technology seems to be suitable for a clinical laboratory in analysing the respir-
atory microbiome and microbial shifts based on a predefined algorithm. In order to use 
this technique in clinical practice, it is important to define suitable types of specimens. 
Until now, different sampling techniques have been used to assess the respiratory micro-
biome: (induced) sputum8, bronchial aspirate8, bronchoalveolar lavage (BAL)8,9, bronchial 
mucosa8 and surgical specimens from lung transplants9. Specimens of the upper respira-
tory tract are expected to be contaminated with oropharyngeal flora, and to be composed 
of a different respiratory microbiome than specimens of the lower respiratory tract8. On 
the other hand, these specimens have the advantage of being non-invasive which allows 
longitudinal follow-up10,11. For clinical practice, it is important to have patient friendly 
techniques providing sufficient information for adequate management. Therefore, we 
aimed to determine the patient-specific and specimen-specific signatures of the respirato-
ry microbiome, using the IS-pro technology, in specimens from different anatomical loca-
tions in the respiratory tract, in order to asses similarities or differences between the 
different sampling methods as well as between different patients. 
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MATERIALS AND M.ETHODS 
The Maastricht Respiratory Microbiome Study (MRMS-study) is a study performed at 
the Maastricht University Medical Centre (MUMC+), Maastricht, the Netherlands. The 
study was approved by the medical ethical committee of Maastricht (MEC141117), and 
registered at www.trialregister.nl (NTR5369). All patients gave written informed consent 
before study entry. 
Study population 
COPD patients with all grades of severity could be included in the MRMS-study. They 
were eligible to participate if they had a respiratory physician-based diagnosis of COPD, 
as defined by the Global initiative for chronic Obstructive Lung Disease (GOLD)12, and 
were planned to undergo a bronchoscopy for a non-infectious indication. Patients with 
chronic use of oral corticosteroids >10mg/day were excluded. 
Study procedures 
Patients were screened and included into the study at the outpatient clinic for respiratory 
medicine of the Maastricht University Medical Centre, the Netherlands. Patient characteris-
tics were collected including demographic variables, Charlson comorbidity index13, clinical 
data (e.g. vaccination status and saturation) and smoking status. Furthermore, information 
regarding the number of acute exacerbations (AEs) during the last year, as well as the 
amount of hospitalisations due to AEs in the last year were recorded (patient recall). Dis-
ease-specific health status was assessed with the COPD Assessment Test (CAT)14 and the 
level of dyspnoea according to the modified Medical Research Council (mMRC)15. The most 
recent lung function assessment was recorded (including post-bronchodilator forced expir-
atory volume in 1 second (FEV1) and forced vital capacity (FVC)).  
All patients were planned to undergo bronchoscopy. Before bronchoscopy, a throat 
swab (BD ESwab 220245, Sparks USA) and a spontaneous sputum sample were collect-
ed. During bronchoscopy, first a bronchial aspirate was collected, followed by a BAL 
sample. Bronchoscopy was performed by an experienced lung physician. Both, bron-
chial aspirate and BAL were taken at the medial segment of the middle lobe (10cc NaCl 
0.9%; 50cc NaCl 0.9%; respectively). If the primary abnormality was located at the mid-
dle lobe, specimens were collected at the lingula instead. Only patients who had all 
different types of specimens collected, were included in the current analysis. 
IS-pro procedure 
The throat swab was collected in standard transport medium. Upon arrival in the lab 
the swab was mixed during 5’, then the swab was discarded and the remaining 
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transport medium was directly stored at -80°C. Bronchial aspirates and BAL were mixed 
with sputolysin (0.1xtotal volume) till homogeneity and immediately stored at -80°C. 
Sputum samples were diluted with sterile PBS (1:1), sputolysin (0.1xtotal volume (spu-
tum+PBS)) was added and homogenized, and immediately stored at -80°C. For DNA 
isolation: 100 µl of throat swab medium, 250 µl of bronchial aspirate or BAL solution 
and 200 µl of sputum solution was used. DNA isolation of all specimens was performed 
by routine DNA isolation in the MagNA Pure 96 automated DNA isolation instrument 
using the MagNA Pure MP 96 DNA and viral NA Large volume kit following manufactur-
er’s instructions (Roche Molecular Diagnostics ltd.). The IS-pro technology was used on 
a phylum specific profiling level with a standardized protocol, as previously described by 
Budding et al.16 for the phyla Firmicutes, Actinobacteria, Fusobacteria, Verrucomicrobia 
(FAFV), Bacteriodetes and Proteobacteria following standard manufacturer’s recom-
mendations (IS-Diagnostics, Amsterdam, The Netherlands). In brief, DNA was amplified 
on a thermal cycler T3000 (Biometra GmbH, Göttingen, Germany) using fluorescently 
labelled phylum-specific primers, after which the PCR products were further analysed 
on a ABI Prism 3500 Genetic Analyzer (Applied Biosystems Carlsbad, California, USA). All 
data were pre-processed with the IS-pro proprietary software suite (IS-Diagnostics, 
Amsterdam, The Netherlands) and were subsequently visualized with the Spotfire soft-
ware package (TIBCO, Palo Alto, CA, USA). Hierarchical clustering of IS-profiles, visual-
ized in a heat map Plot, was performed using the Unweighted Pair Group Method with 
Arithmetic Mean (UPGMA). 
Statistical analysis 
Baseline characteristics of patients were assessed with SPSS version 23.0. Continuous 
variables were tested for normality by Skewness and Kurtosis, presented as 
mean±standard deviation or median (interquartile range), as appropriate. Categorical 
data are presented as counts (%). Statistical analyses were performed on the detected 
fragments as determined by the proprietary software developed for IS-pro analysis. 
One-way ANOVA and post-hoc Tukey HSD test were performed to assess the alpha-
diversity between types of specimens, using the Shannon wiener index. The alpha-
diversity measures the diversity within a specific specimen, with other words, how 
many different types of sequences are present in one specimen. A principal coordinate 
analysis (PCoA) was used to explore variation and patterns in the microbiome composi-
tion between the types of specimens. The beta-diversity was analysed using cosine 
distance. It is a term for the comparison of types of specimens to each other, and pro-
vides a measure of the distance or dissimilarity between types of specimens. To assess 
similarities between IS-profiles of the defined specimens within and between patients, a 
hierarchical clustering heat map plot was performed. Further statistical analyses were 
performed using two-sided student t-test, additional correction was applied using Bon-
ferroni in the analysis of within- and between-groups using QIIME 1.8.0. 
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RESULTS 
In total, 11 patients with mild-to-moderate COPD were included into the current analy-
sis. Clinical characteristics are presented in Table 1. Patients were on average 72 years 
old, half were former and half current smokers, and nearly half of the patients were 
classified as COPD GOLD IIB. Disease-specific health status, assessed by the CAT, was on 
average 14.4 points, indicating a moderate impact of respiratory symptoms. The level of 
dyspnoea measured by mMRC was low in most patients. 
Table 1. Baseline characteristics 
 COPD patients (n=11) 
Age (years) 72.3±8.0 
Male gender 9 (81.8) 
BMI (kg/m2) 24.2 (23.3-27.4) 
Smoking status 
Former 
Current 
 
5 (45.5) 
6 (54.5) 
Pack years 33.8 (21.6-60.0) 
Years stop smoking 9.0 (1.6-25.0) 
Vaccination status 
Influenza 
Pneumococcal  
 
7 (63.6) 
1 (9.1) 
Charlson comorbidity index 3.1±2.0 
FEV1 %pred. 74.5±17.9 
FEV1/FVC 52.6±15.0 
COPD assessment 
IA 
IB 
IIB 
IIC 
 
3 (27.3) 
2 (18.2) 
5 (45.5) 
1 (9.1) 
Number of patients with 
AE in last 3 months 
AE in last year 
Hospitalisation due to AE in last year 
 
4 (36.4) 
5 (45.5) 
1 (9.1) 
CAT total score 14.4±7.9 
mMRC score 
0 
1 
2 
3 
4 
 
3 (27.3) 
5 (45.5) 
1 (9.1) 
1 (9.1) 
1 (9.1) 
Notes: data are presented as mean±SD, median (interquartile range) or n (%). Abbreviations: AE, acute exac-
erbation; BMI, body mass index; CAT, COPD Assessment Test; COPD, Chronic Obstructive Pulmonary Disease; 
FEV1, Forced Expiratory Volume in 1 second; FVC, Forced Vital Capacity; mMRC, modified Medical Research 
Council. 
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FAFV are most abundant in respiratory specimens 
In total, 44 microbiome profiles from the respiratory samples of 11 patients were gen-
erated by IS-pro. At the phylum level, 49% of the detected bacteria species belonged to 
the FAFV, whereas the Bacteriodetes comprised 26% and the Proteobacteria 25% of the 
bacteria found amongst all respiratory isolates. The two most abundant IS-fragments, 
with a fragment size of 321 and 297 bp (both belonging to the group of FAFV), were 
found in respectively 66 and 61% of all clinical specimens. The three most abundant 
fragments (third fragment with a size of 289 bp) all belonged to bacteria of the family of 
Streptococcaceae and were identified in respectively 9, 11 and 10 out of the 11 pa-
tients. 
Alpha-diversity 
The alpha-diversity, as assessed by the one-way ANOVA, showed a statistically signifi-
cant effect of specimens of all phyla (Figure 1; p=0.005), with 3 degrees of freedom for 
the error term and an F statistic of 5.0. As the corresponding p-value of the F statistic is 
lower than 0.05, this suggests that one or more specimens are significantly different 
with regard to their respiratory microbiome composition. Post-hoc analyses (Tukey HSD 
test, 40 degrees of freedom for the error term) showed that BAL and throat specimens 
(2.9±0.5 vs. 3.6±0.3, p=0.004), as well as BAL and sputum specimens (2.9±0.5 vs. 
3.4±0.4, p=0.044) significantly differed from each other. On the phylum level, there 
were no statistical significant differences in alpha-diversity between Bacteriodetes and 
FAFV. However, the one-way ANOVA showed a statistically significant difference 
amongst the Proteobacteria in clinical specimens (p<0.001). Further post-hoc Tukey 
HSD analyses showed that only bronchial aspirate compared to sputum (1.5±0.7 vs. 
2.1±0.4), and sputum compared to throat (2.1±0.4 vs. 2.5±0.4) did not show any signifi-
cant difference. All other combinations were significantly different, in which bronchial 
aspirate and BAL had a p-value of <0.05 (1.5±0.7 vs. 0.6±0.8) and all other combinations 
had a p-value of <0.01. 
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Figure 1. Shannon wiener index of all phyla, Bacteriodetes, FAFV and Proteobacteria, stratified by respiratory 
specimen. 
Notes: ** p<0.001; * p<0.05. 
Beta-diversity  
A PCoA analysis showed that, in general, the most distal respiratory tract specimens 
(BAL and bronchial aspirate) clustered apart from the more proximal respiratory tract 
specimens (sputum and throat swabs; Figure 2). This indicates that the beta-diversity is 
different between the more proximal and more distal respiratory tract specimens. 
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Figure 2. Principal Coordinate Analysis 
 
In order to further examine the differences between the four respiratory specimens, 
the beta-diversity distances of each of the types of specimens were calculated and plot-
ted (Figure 3). As expected, throat specimens were most homogeneous followed by 
sputum, bronchial aspirate and BAL specimens. Samples from the same location (within-
types of specimens) were significantly more similar to each other, than samples from 
different locations (between-types of specimen; p=0.001; Figure 3A). Independent anal-
ysis of the different types of specimens showed that throat differed significantly from 
BAL (p=0.003) and bronchial aspirate (p<0.001) but not from sputum (p=0.210), where-
as sputum in itself was also significantly different from BAL (p=0.047) and bronchial 
aspirate (p=0.009; Figure 3B). This confirmed the finding of the PCoA analysis that 
showed that the lower respiratory tract specimens (BAL and bronchial aspirate) were 
significantly different from those of the relatively higher respiratory tract specimens 
(sputum and throat swabs). 
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Figure 3. Distance of beta-diversity 
Notes: A. Between-specimen vs. Within-specimen; B. Bronchial aspirate vs. BAL vs. Sputum vs. Throat; C. 
Within-specimen vs. Within-patient. ** p<0.001; * p<0.05. 
Patient specific clustering 
The hierarchical clustering heat map plot revealed a patient-specific clustering (Figure 
4). As expected, the upper (sputum and throat) and lower (BAL and bronchial aspirate) 
respiratory tract specimens also clustered. This finding was confirmed on the raw data 
set, indicating the strength of this finding. 
In three out of the eleven patients, all types of respiratory specimens clustered together 
(Figure 4), whereas there were three patients in which 75% of the types of specimens 
clustered and five patients in which only two types of specimens clustered. Sputum and 
throat specimens clustered in 100% of the patients. To further analyse whether this 
patients-specific signature is more important than the specimen-specific signature that 
we identified earlier, we performed a student t-test between the within-types of speci-
mens and within-patients beta-diversity distances (Figure 3C). Interestingly, the similari-
ty of specimens within individual patients (0.4±0.2) was significantly higher from that of 
the specific types of specimens between patients (0.5±0.1; p<0.001). 
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DISCUSSION 
In this study, throat swabs, spontaneous sputum samples, bronchial aspirates and BAL 
fluids of 11 patients with COPD were analysed for microbiome composition. Our find-
ings indicate that there are differences in the microbiome composition between the 
lower and upper respiratory tract, but also that all types of respiratory specimens con-
tain a patient-specific signature. 
Abundance and alpha-diversity 
In alignment with previous research8,17-19, we observed that approximately half of the 
detected fragments belonged to FAFV, with the Streptococcaceae family being the most 
abundant. Streptococcaceae is a well-known bacterial family of the respiratory tract and 
often observed in both patients with COPD as well as ‘healthy’ controls17,20,21. 
When focussing on the alpha-diversity, a significant difference in Shannon wiener index 
was observed between the different types of specimens analysed. Especially BAL had a 
significantly lower diversity compared to sputum and throat specimens. This pattern 
was probably due to the microbial diversity observed between types of specimens in 
the Proteobacteria. As expected, the lower respiratory specimens harboured a lower 
diversity of Proteobacteria. However, previous research also showed colonisation by 
Proteobacteria of the lower respiratory tract in patients with COPD2,22. Colonization of 
the lower airways in patients with COPD implies a vicious cycle of among others epithe-
lial cell damage, mucus hypersecretion and inflammatory cell infiltration, promoting 
further dysfunction of host defences and bacterial adherence and growth23. Neverthe-
less, still much remains unknown about colonization and associated mechanisms, as 
well as the relationship with disease severity. Overall, our findings are supported by 
Carbera-Rubio and colleagues8, who also observed a distinct alpha-diversity in upper 
and lower respiratory samples, although they observed a larger diversity in the lower 
respiratory samples.  
Beta-diversity and patient-specific clustering 
The current study confirms distinct clustering of lower and upper respiratory speci-
mens8, as shown by the PCoA analysis and significant differences observed in the beta-
diversity. It is expected that specimens of the same region of the respiratory tract are 
more alike to each other, than specimens of different regions. This was also demon-
strated in lung explants; there seemed to be marked regional differences in the respira-
tory microbiome within a patient9, which may be very important for our understanding 
of respiratory health and disease. 
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When hierarchically clustering the respiratory microbiome in a heat map plot, we ob-
served patient-specific clustering. A higher level of microbiome similarity (expressed as 
lower beta-diversity) was observed within an individual, compared to a specific type of 
respiratory specimen between individuals. This finding suggests that upper respiratory 
specimens may be representative for microbiome analysis, which would make collection 
of samples considerably easier. However, we should interpret this result with caution, 
as longitudinal research is necessary in order to assess shifts in the respiratory microbi-
ome. At the moment, we assessed the respiratory microbiome in stable state, while 
changes in the respiratory microbiome are expected to occur during exacerbation. How 
this affects types of specimens and the level of microbiome similarity is currently un-
known. 
Charlson and coworkers24 described in healthy subjects that different types of respirato-
ry specimens within an individual were more similar to each other than they were to a 
particular specimen type between individuals. In other words, types of specimens with-
in one subject were more closely related to their own specimen, than to those of any 
other subject24. Comparable results were observed by Dickson et al.25, who also looked 
at different respiratory specimens in healthy subjects. Overall, these results support the 
patient-specific signature of the respiratory microbiome. By our knowledge, this is the 
first study to investigate the patient-specific signature in patients with COPD. Cabrera-
Rubio and colleagues8 assessed different respiratory specimens, but only focussed on 
the alpha-diversity and the specimen-specific signature, while it would be interesting to 
also investigate the patient-specific signature. 
Clinical implications 
This study provides promising results for respiratory microbiome analysis in clinical 
practice. Sputum samples and especially throat swabs are non-invasive procedures, 
easy to collect from patients. This way of sampling may increase the use of respiratory 
microbiome analysis in clinical practice. However, we should interpret these results with 
caution, as longitudinal studies and sampling during exacerbations are required to sup-
port our recent findings. Until now, a limited number of studies were conducted in 
patients with COPD exacerbation5,10,26. Overall, these studies showed a significant het-
erogeneity of the microbial composition at both baseline and during exacerbation in 
patients with COPD26. Moreover, they observed changes in the microbial composition 
during and after an exacerbation, with diverse effects of antibiotic versus corticosteroid 
treatment5,10. At the moment, usage of the respiratory microbiome in clinical practice is 
challenging, but insights into the microbial patterns of patients, and change of these 
patterns over time, might play a role in a better understanding of the pathophysiology 
of COPD exacerbations in the near future. 
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Methodological considerations 
There are some methodological issues that should be taken into consideration when 
interpreting the current analyses. First, the population of patients with COPD is relative-
ly small. Analyses need to be expanded to a larger population. Moreover, the current 
population existed of mild-to-moderate patients with COPD. It would be interesting to 
perform comparable analyses in severe-to-very severe patients with COPD, and to pos-
sibly assess patients based on clinical characteristics as frequent exacerbators, and 
patients with a high burden of respiratory symptoms. Second, the current study includ-
ed patients who were planned to undergo a bronchoscopy for a non-infectious indica-
tion. However, the influence of the different indications to undergo bronchoscopy on 
the respiratory microbiome are currently unknown. Although patients were clinically 
stable at the time of sampling, one third of our patients had an exacerbation in the 
previous three months and the possible effects of previous use of antibiotics and/or oral 
corticosteroids on microbiome diversity remain unknown in the current study. Finally 
we used the IS-pro technology for our study16; the discriminatory power of this method 
is high, even below the species level for some species. This technology can be used in 
different ways. We used this method for pattern recognition and phylum level analysis 
for putative use in routine diagnostics. Microbial pattern analysis might be an easy way 
to follow up patients in clinical practice and sufficient to predict or monitor exacerba-
tions of COPD. 
Conclusion 
In conclusion, the respiratory microbiome in patients with COPD contains a patient-
specific signature in all types of respiratory specimens, which is more pronounced than 
the specimen-specific signature. In future, respiratory microbiome analysis might be 
possible on upper respiratory samples, which are much easier to collect compared to 
lower respiratory tract samples. Longitudinal studies also covering COPD exacerbations 
are required, in order to advance the understanding of the respiratory microbiome. Our 
study provides a new approach to such much-needed studies. 
  
7Respiratory specimen validation for microbiome analysis in COPD 
 139 
REFERENCES 
1. Lopez-Campos JL, Tan W, Soriano JB. Global burden of COPD. Respirology. 2016;21(1):14-23. 
2. Marin A, Monso E, Garcia-Nunez M, et al. Variability and effects of bronchial colonisation in patients with 
moderate COPD. The European respiratory journal. 2010;35(2):295-302. 
3. Dickson RP, Erb-Downward JR, Prescott HC, Martinez FJ, Curtis JL, Lama VN, et al. Analysis of culture-
dependent versus culture-independent techniques for identification of bacteria in clinically obtained 
bronchoalveolar lavage fluid. J Clin Microbiol. 2014;52(10):3605-13. 
4. Molyneaux PL, Mallia P, Cox MJ, et al. Outgrowth of the Bacterial Airway Microbiome following Rhinovi-
rus Exacerbation of Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2013. 
5. Huang YJ, Sethi S, Murphy T, et al. Airway microbiome dynamics in exacerbations of chronic obstructive 
pulmonary disease. J Clin Microbiol. 2014;52(8):2813-23. 
6. Galiana A, Aguirre E, Rodriguez JC, et al. Sputum microbiota in moderate versus severe patients with 
COPD. The European respiratory journal. 2014;43(6):1787-90. 
7. Garcia-Nunez M, Millares L, Pomares X, et al. Severity-related changes of bronchial microbiome in chron-
ic obstructive pulmonary disease. J Clin Microbiol. 2014;52(12):4217-23. 
8. Cabrera-Rubio R, Garcia-Nunez M, Seto L, et al. Microbiome diversity in the bronchial tracts of patients 
with chronic obstructive pulmonary disease. J Clin Microbiol. 2012;50(11):3562-8. 
9. Erb-Downward JR, Thompson DL, Han MK, et al. Analysis of the lung microbiome in the "healthy" smoker 
and in COPD. PLoS One. 2011;6(2):e16384. 
10. Wang Z, Bafadhel M, Haldar K, et al. Lung microbiome dynamics in COPD exacerbations. The European 
respiratory journal. 2016;47(4):1082-92. 
11. Cameron SJ, Lewis KE, Huws SA, et al. Metagenomic Sequencing of the Chronic Obstructive Pulmonary 
Disease Upper Bronchial Tract Microbiome Reveals Functional Changes Associated with Disease Severity. 
PLoS One. 2016;11(2):e0149095. 
12. Vogelmeier CF, Criner GJ, Martinez FJ, et al. Global Strategy for the Diagnosis, Management, and Preven-
tion of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary. Am J Respir Crit Care 
Med. 2017;195(5):557-82. 
13. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal 
studies: development and validation. Journal of chronic diseases. 1987;40(5):373-83. 
14. Jones PW, Harding G, Berry P, et al. Development and first validation of the COPD Assessment Test. The 
European respiratory journal. 2009;34(3):648-54. 
15. Bestall JC, Paul EA, Garrod R, et al. Usefulness of the Medical Research Council (MRC) dyspnoea scale as 
a measure of disability in patients with chronic obstructive pulmonary disease. Thorax. 1999;54(7):581-6. 
16. Budding AE, Hoogewerf M, Vandenbroucke-Grauls CM, et al. Automated Broad-Range Molecular Detec-
tion of Bacteria in Clinical Samples. J Clin Microbiol. 2016;54(4):934-43. 
17. Einarsson GG, Comer DM, McIlreavey L, et al. Community dynamics and the lower airway microbiota in 
stable chronic obstructive pulmonary disease, smokers and healthy non-smokers. Thorax. 2016. 
18. Pragman AA, Kim HB, Reilly CS, et al. The lung microbiome in moderate and severe chronic obstructive 
pulmonary disease. PLoS One. 2012;7(10):e47305. 
19. Zakharkina T, Heinzel E, Koczulla RA, et al. Analysis of the airway microbiota of healthy individuals and 
patients with chronic obstructive pulmonary disease by T-RFLP and clone sequencing. PLoS One. 
2013;8(7):e68302. 
20. Hilty M, Burke C, Pedro H, et al. Disordered microbial communities in asthmatic airways. PLoS One. 
2010;5(1):e8578. 
21. Morris A, Beck JM, Schloss PD, et al. Comparison of the respiratory microbiome in healthy nonsmokers 
and smokers. Am J Respir Crit Care Med. 2013;187(10):1067-75. 
22. Finney LJ, Ritchie A, Pollard E, et al. Lower airway colonization and inflammatory response in COPD: a 
focus on Haemophilus influenzae. International journal of chronic obstructive pulmonary disease. 
2014;9:1119-32. 
Chapter 7 
 140 
23. Patel IS, Seemungal TA, Wilks M, et al. Relationship between bacterial colonisation and the frequency, 
character, and severity of COPD exacerbations. Thorax. 2002;57(9):759-64. 
24. Charlson ES, Bittinger K, Haas AR, et al. Topographical continuity of bacterial populations in the healthy 
human respiratory tract. Am J Respir Crit Care Med. 2011;184(8):957-63. 
25. Dickson RP, Erb-Downward JR, Freeman CM, et al. Spatial Variation in the Healthy Human Lung Microbi-
ome and the Adapted Island Model of Lung Biogeography. Annals of the American Thoracic Society. 
2015;12(6):821-30. 
26. Huang YJ, Erb-Downward JR, Dickson RP, et al. Understanding the role of the microbiome in chronic 
obstructive pulmonary disease: principles, challenges, and future directions. Translational research: the 
journal of laboratory and clinical medicine. 2017;179:71-83.  
  141 
8 
General discussion 
  

8General discussion 
 143 
GENERAL DISCUSSION 
Chronic Obstructive Pulmonary Disease (COPD) is a highly prevalent disease, causing 
significant morbidity and mortality worldwide1. Symptoms such as dyspnoea, cough and 
sputum production are often experienced by patients with COPD, limiting them in their 
daily functioning2. These symptoms are also related to acute respiratory events, includ-
ing infections and exacerbations2. Although, respiratory infections such as community 
acquired pneumonia (CAP) have been studied frequently in patients with COPD3, the 
impact of COPD on outcomes and clinical parameters of CAP remains uncertain. Fur-
thermore, limited evidence is available concerning the influence of airway microbiology 
and exacerbations in patients with COPD on clinical outcomes and the effects of (non-) 
pharmacologic interventions, including pulmonary rehabilitation. Meanwhile, new 
techniques for microbiome analysis have been introduced4, but the clinical implication 
of the choice of respiratory samples in patients with COPD is insufficiently addressed. 
This thesis investigated the impact of respiratory infections and exacerbations on COPD 
outcomes and the clinical perspective of respiratory samples used for respiratory mi-
crobiome analysis. In this chapter, the main findings of this thesis will be discussed. 
RESPIRATORY INFECTIONS AND COPD 
Respiratory infections are ranked the greatest single contributor to the overall burden 
of disease in the world5; this relates to a high disease as well as economic burden6. In 
patients with COPD, a higher prevalence is observed, as these patients appear to be 
more susceptible for respiratory infections7. This was confirmed by our research per-
formed in chapter 4, where we observed a substantial higher incidence of CAP in pa-
tients with COPD compared to matched control subjects, resulting in a fourfold in-
creased risk of developing CAP. These numbers emphasize the importance of research 
in this field, to improve disease management focussed on prevention and treatment. 
Although many studies have been performed in the field of CAP and COPD, results con-
cerning the impact of COPD on outcomes in patients with CAP remain controversial. 
Chapter 2 discussed the differences in outcomes of CAP patients with and without con-
current COPD in the CAPNETZ population. Patients with COPD appeared to have more 
severe CAP, as expressed by the CURB-score. Furthermore, they had a longer length of 
stay, and disturbances in gas exchange were more pronounced in patients with COPD. 
These results are comparable with earlier findings8,9. Interestingly, conflicting results 
have been observed for short- and long-term mortality10. We demonstrated in the 
CAPNETZ population increased short- and long-term mortality rates in patients with 
COPD, when compared to non-COPD patients with CAP. However, when adjusted for 
other possible confounders, COPD was not related to CAP mortality. Possibly, patients 
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with COPD may seek medical care earlier, be admitted to the hospital sooner and re-
ceive more attention from physicians. Overall, intensive care unit (ICU)-admission and 
older age were independently related to both short- and long-term mortality. Older age 
as risk factor for all-cause mortality in patients with COPD is not surprising11, and fre-
quently reported in COPD patients identified with CAP7,12. COPD patients admitted to 
the ICU have been observed to present with more severe CAP and frequently comorbid-
ities are present, which has been related to increased mortality rates13. Probably, a 
combination of factors influences the disease outcome. Close follow-up of, for example, 
comorbid conditions is important14. Other possible mechanisms described to be associ-
ated with increased mortality rates in patients with COPD, included the presence of 
resistant bacteria and reduced pulmonary reserve15. Moreover, there is much debate 
about the role of inhaled corticosteroids (ICS) in relation to an increased CAP risk in 
COPD16. However, evidence is controversial concerning the impact of ICS on outcomes 
in CAP, as some showed a protective effect17, while others observed no impact18,19. 
Possibly, the specific kind of ICS and the dosage play a role in this20. Though, the Euro-
pean Medicines Agency completed a review and observed no difference in the risk of 
pneumonia between different products21. Well-designed research is necessary to identi-
fy the precise relationship of ICS with CAP and its role in outcomes within patients with 
COPD. 
To target treatment of CAP in patients with COPD, it is important to focus on the micro-
biology of CAP. In chapter 3 we observed a distinct microbiological pattern in CAP pa-
tients with COPD, compared to CAP patients without COPD. As confirmed by our study, 
Haemophilus influenzae is frequently detected in patients with COPD22-25, both in stable 
and acute phase. Normally, H. influenzae colonises the nasopharynx, and is related to 
upper respiratory tract infections. Infection of the lower respiratory tract is less com-
mon, because host immune responses prevent the spread to the lower respiratory 
tract20. This implies, that in patients with COPD, certain host immune mechanisms are 
impaired. Another pathogenic bacterium often detected in both patients with COPD 
and CAP is Streptococcus pneumoniae26,27. In the CAPNETZ population, this was the 
most frequently detected pathogen in CAP patients without COPD and together with H. 
influenzae, the most identified pathogen in COPD patients with CAP. We aimed to inves-
tigate the impact of specific pathogens on outcomes of CAP, but the detection rate was 
unfortunately too low to draw conclusions. Forstner and colleagues22 observed in CAP-
cases, not specifically specified to patients with COPD, that 30- and 90-day mortality 
rates between CAP patients with H. influenzae detection and patients with other or 
unknown aetiology, were comparable. Similar results were observed by Capelastegui et 
al.28, showing no difference in 30-day mortality between patients with conventional 
bacteria, atypical bacteria, viral infection and mixed infection. On the other hand, pa-
tients infected with conventional bacteria frequently had severe sepsis and septic 
shock, and were significantly more often hospitalised and admitted to an ICU than the 
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other subgroups28. Large, well-designed studies are needed to investigate the impact of 
specific pathogens on outcomes of clinical infection. Insight in the latter might optimise 
CAP management in general, but also for specific subgroups of patients with concomi-
tant comorbidities as COPD. 
Besides the patients with a detected pathogen, there is a large subset of patients who 
had clinical signs of CAP, but culture techniques failed to obtain a bacterial aetiology. 
Unfortunately, identification of pathogens is still challenging. Culture-dependent tech-
niques are at the moment the golden standard for microbiological analysis, but lack the 
detection of many pathogens25,29. Additionally, this technique is not helpful when anti-
biotic treatment is already started. Often, the treatment is empirical, which might in-
duce treatment failure as well as antibiotic resistance. Besides, there are some clinical 
consequences: patients without pathogen detection are difficult to treat, have the 
highest mortality rate and also appear to have more severe CAP (chapter 3)30. Possibly, 
these pneumonias were caused by viral infections, which are expected to cause up to 
25% of CAP cases and are often accompanied by a secondary bacterial infection, espe-
cially S. pneumoniae31,32. Influenza and rhinovirus are the viruses most frequently de-
tected33. Mortality rates of patients with a viral infection were not significantly higher, 
but bacterial co-infection has been associated with an increased short-term mortality 
risk32. In the last decades, vaccination is recommended for vulnerable patient groups, in 
order to prevent influenza and pneumococcal infection34. Vaccination aims to reduce 
the risk of adverse outcomes, as risk of CAP, hospitalisation and mortality. Clearly, the 
incidence of these pathogens decreased, and prevention can be as high as 60-80% if the 
vaccine matches the circulating strain35,36. In patients with COPD, there is an increased 
risk of inadequate immune response following vaccination, showing lower efficacy per-
centages36. 
Furthermore, there is at the moment limited understanding of the impact of bacterial 
pathogens in the airways in the absence of an acute infection. Worse outcomes have 
been reported for H. influenzae colonisation: increased airway and systemic inflamma-
tion, frequent exacerbations and a poorer health status20,37. Additionally, pathogenic 
colonisation in general in patients with COPD has been associated with a clinically signif-
icant increase in daily symptoms38. This strengthens the need for research on daily 
symptoms and its impact on disease features. Chapter 5 partly focussed on this aspect, 
and will be discussed in the next paragraph. 
The current insights emphasize that physicians and other health care professionals 
should not underestimate the impact of CAP in patients with COPD. A shift towards 
prevention of respiratory infections is needed, as treatment of these infections be-
comes increasingly harder due to antibiotic resistance. Besides vaccination as preven-
tion method (as mentioned above)34, there are some modifiable lifestyle factors related 
to an increased CAP risk. The most well-known preventable risk factor associated with 
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CAP is smoking39, which in turn is one of the main risk factors for COPD. It is often diffi-
cult to determine the specific influence of smoking in the development of CAP in pa-
tients with COPD, due to this dual pathway. We examined in chapter 4 the effect of 
smoking in a large population of patients with COPD in comparison with matched con-
trol subjects. As described earlier in this paragraph, patients with COPD had an in-
creased CAP risk compared to matched controlled subjects. Current smoking was asso-
ciated with an increased risk of CAP in healthy subjects, as expected. Mechanisms such 
as tobacco-induced physiological and structural changes, and increase in bacterial viru-
lence and dysregulation of immune function are related to this observed association40. 
In patients with COPD, we expected to see a comparable association. However, the risk 
of CAP was comparable between never and current smoking COPD. While this finding 
was unexpected, it was confirmed by other research in this field12,41. The mechanisms 
behind this observation are not yet clear. Maybe, smoking does not induce the risk of 
CAP in patients with COPD, as this risk is already augmented due to the underlying dis-
ease itself. The smoking effect does not sum up. On the other hand, pathophysiological 
aspects might be related to the comparable risk in never smokers. The development of 
COPD in these patients is not smoking-related, but for example by occupational or envi-
ronmental exposures, alpha1-antitrypsin deficiency or factors early in life which effect 
the respiratory health in long-term42,43. 
Other lifestyle factors associated with CAP risk are alcohol consumption and body 
weight39. It appeared that consumption of ≤40 g alcohol daily protects against CAP 
compared to no alcohol consumption. On the other hand, consumption of >40 g alcohol 
daily was associated with an increased risk. Hence, moderate alcohol consumption 
seems to have some beneficial effects. The same applies for body weight, showing an 
increased risk in underweight patients, but a reduced risk in overweight patients. These 
results underline that a balance in lifestyle factors, which can be effected by patients 
themselves, is still a good way to reduce CAP risk. For patients with COPD, the relation-
ship with CAP is complex and is not as straight forward as in healthy subjects. Still, these 
factors are also important to take into account for patients with COPD, as these lifestyle 
factors are not only related to CAP risk, but many health problems. Probably, patients 
with COPD are more vulnerable to changes, and pursuing a healthy life style is im-
portant for their overall disease burden. 
EXACERBATIONS IN COPD 
Respiratory symptoms play an important role in the life of patients with COPD. There-
fore, assessment of symptoms is part of the international disease stratification for 
COPD34. Symptoms are increased in patients with bacterial airway colonisation38 and 
have a major impact on the daily functioning44. Moreover, they are the key feature of 
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exacerbations, as these events are defined as ‘an acute worsening of respiratory symp-
toms that result in additional therapy’34. In addition to pharmacotherapy, pulmonary 
rehabilitation (PR), defined as ‘a comprehensive intervention based on thorough patient 
assessment followed by patient-tailored therapies that include, but are not limited to, 
exercise training, education, self-management intervention aiming at behaviour change, 
designed to improve the physical and psychological condition of people with chronic 
respiratory disease and to promote the long-term adherence to health-enhancing be-
haviours’, is targeted to reduce respiratory symptoms in patients with COPD34. Besides 
reduction of respiratory symptoms, PR has been shown to improve quality-of-life and 
exercise tolerance of patients with COPD45. 
The second most experienced symptom reported by patients with COPD was sputum 
production44. In chapter 5 we were interested whether patients with sputum produc-
tion, and especially a positive culture result, indicative for bacterial colonisation, are 
clinically different from those without sputum production and/or a negative culture 
result before start of PR. We observed that a substantial proportion of patients with 
COPD produced sputum during a pre-rehabilitation assessment. Of these, almost one 
third had a positive culture. It appeared that patients with a positive sputum culture had 
a worse health status based on the CAT total score and CCQ total score, and had more 
symptoms of depression than patients who did not produce sputum. Our results are an 
addition to research performed in patients with chronic bronchitis46,47. Chronic bronchi-
tis is defined as ‘the presence of chronic cough and sputum production for at least 3 
months a year, for two consecutive years’34. Objectively diagnosing chronic bronchitis is 
complex and subject to patient recall. The definition covers no incidental cough and 
sputum, while many patients experience those symptoms without meeting the criteria. 
A recent study of Deslee and colleagues48 assessed cough and sputum in the past 7 
days. They showed that current cough was associated with health related quality of life 
impairment48. It appeared that cough alone was a stronger predictor than chronic bron-
chitis, or current sputum production. Hence, we should be aware of the fact that inci-
dental cough and sputum production in patients with COPD also impacts on health 
related outcomes, especially health status. Providing patient centred care through a 
holistic and dynamic approach is needed, to focus on patients’ needs and values49. 
Exacerbations are important events in the course of COPD34. They negatively impact 
health status and exercise capacity, and are associated with disease progression, hospi-
tal admission and mortality50-52. Key features of exacerbations include increased airway 
inflammation, increased mucous production and marked gas trapping, resulting in 
symptoms as dyspnoea, sputum, cough and wheezing. While there is currently a paucity 
of data on the effects of PR on exacerbation risk, post-exacerbation PR has been shown 
to reduce the risk of exacerbation readmissions53,54. Additionally, exacerbations are 
reported to be one of the most common reasons of drop out during PR55. We did a 
similar observation in chapter 6: having at least one severe exacerbation during PR was 
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associated with increased dropout. Mild-to-moderate exacerbations were more often 
identified in completers. By our knowledge, we were the first to stratify exacerbations 
by severity, highlighting the fact that especially exacerbations resulting in a hospitalisa-
tion, had a negative effect on completion of PR. Nevertheless, it remains a challenge to 
foresee the impact of exacerbations on dropout in the long-term. The effect of an exac-
erbation might last longer, even though dropout was reported by a different cause. 
When we focussed on outcomes of PR, stratified by exacerbation severity, we observed 
a mean improvement on health status scores, symptoms of anxiety and depression and 
exercise capacity in completers without an exacerbation and those with at least one 
mild-to-moderate exacerbation. These mean improvements exceeded the minimal 
clinically important difference, except for the 6-minute walking test. The beneficial 
effects of PR have been described more often56, and our results confirmed the valuable 
addition of PR in patients with COPD, even when having a mild-to-moderate exacerba-
tion. Completers with at least one severe exacerbation, had in general comparable 
results, but the improvement was not significant. Still, these patients should be encour-
aged to complete PR. It would be very interesting to compare completers with a severe 
exacerbation, with those who dropped out after a severe exacerbation. Staying stable 
over time, and not showing a large deterioration following PR, is in these patients a 
result that should be fostered. 
We believe, the shift from treatment of exacerbations towards prevention is desired. 
Prevention involves different aspects, including non-pharmacological and pharmacolog-
ical options. Next to PR, one of the key concepts is smoking cessation. Former smokers 
appeared to have a reduced risk of exacerbations, when compared with current smok-
ers57. Furthermore, as discussed before, vaccination is recommended in patients with 
COPD, as the majority of exacerbations are triggered by bacterial and viral infections58. 
Vaccination has been shown to reduce the rate of exacerbations59,60. Moreover, there is 
a legion of pharmacological options associated with reduced exacerbation risk, but 
more evidence in this field is necessary61,62. Another aspect, which is involved in all of 
the before mentioned interventions, is self-management. Self-management training 
aims to ‘help patients acquire and practise the skills they need to carry out disease-
specific medical regimens, to guide changes in health behaviour and to provide emo-
tional support to enable patients to adjust their roles for optimal function and control of 
their disease’63. An international expert group stated that ‘besides developing skills, 
enhancing the patient’s motivation to actually execute these skills on a daily basis is an 
essential component of a COPD self-management intervention’64. Multi-component 
COPD self-management programs are promising, but the effect on outcomes var-
ies63,65,66. Overall, compliance remains a huge challenge in all proposed interventions. 
Likewise, it is important to concentrate on the individual patient, as COPD is a very het-
erogeneous disease, and interventions should be adapted to specific needs of a patient. 
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RESPIRATORY MICROBIOME 
Following the impact of acute respiratory events in patients with COPD, and the short-
comings of research in the field of microbiology in patients with COPD, new techniques 
are desired to understand mechanisms and overcome pressing issues related to respira-
tory infections and exacerbations. Microbiome analysis is promising in gaining insight in 
patterns of the microbial environment and its role in the development and prevention 
of respiratory infections and exacerbations. 
First, it is important to identify which respiratory specimens are sufficient to assess the 
respiratory microbiome for clinical practice in patients with COPD. By now, only one 
study compared specimens from different regions of the respiratory tract67. Cabrera-
Rubio and colleagues observed a distinct microbial environment in the upper respirato-
ry tract as compared to the lower respiratory tract in patients with COPD67. Lower res-
piratory tract specimens were more diverse, and clustered together concerning their 
microbial composition. Contrary, upper respiratory specimens were less diverse and 
expected to be contaminated by the oropharynx67. Hence, the implementation of res-
piratory microbiome analysis in clinical practice is depending the accessibility to obtain 
respiratory specimens. Molyneaux and co-workers suggested to use sputum for micro-
biome analysis, as it allows prolonged sampling over time to assess changes in the res-
piratory microbiome, and avoids invasive sampling68. Because there is some discussion 
regarding the different sample types, we performed a research to compare the clinical 
implication of specimens from different regions in the lung (chapter 7). We specifically 
focussed on the patient-specific as well as the specimen-specific signatures of the res-
piratory microbiome, to assess similarities/differences between different sampling loca-
tions as well as between different patients. In general, the alpha-diversity (specimen-
specific signature – diversity within a specific specimen) significantly differed between 
upper and lower respiratory specimens, as a result of Proteobacteria. This pattern was 
also observed by former research67, concluding that upper respiratory specimens were 
not representative for the respiratory microbiome. Therefore, we also assessed the 
beta-diversity between and within specimens (distance or dissimilarity between types of 
specimens). The beta-diversity of the upper respiratory specimens was significantly 
lower than that of lower respiratory specimens, suggesting that upper respiratory spec-
imens were more alike each other between patients. However, the patient-specific 
signature in relation to the different types of specimens remained unclear. Thus, a hier-
archical clustering heat map plot was performed and showed a patient-specific cluster-
ing, which was also confirmed by a significantly lower within-patients beta-diversity in 
comparison with the within-types of specimens beta-diversity. A higher level of micro-
biome similarity was observed within an individual. Unfortunately, no comparable re-
search had been performed within patients with COPD, only within healthy individuals, 
showing comparable results69,70. Overall, our findings indicated that there are differ-
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ences in the microbiome composition between upper and lower respiratory tract spec-
imens, but also suggests that the patient-specific signature in all respiratory specimens 
was more pronounced than the specimen-specific signature. The latter must be inter-
preted with caution, as this is the first research performed including the beta-diversity 
and assessing the patient-specific signature in patients with COPD. Clearly, more well-
designed research, in larger study populations, is necessary to confirm our findings. 
Moreover, we should take into mind that COPD is a highly heterogeneous disease, 
which makes it difficult to draw firm conclusions across the research performed71. 
Additionally, it would be very interesting to perform longitudinal research, in order to 
assess the respiratory microbiome over time, taking into account possible shifts in the 
respiratory microbiome due to disease alterations. As discussed before, respiratory 
infections and exacerbations are highly prevalent in patients with COPD and have a 
tremendous impact on a patients wellbeing. Molyneaux and colleagues68 investigated 
the effect of rhinovirus infection on the respiratory microbiome. They observed an 
increase of bacterial burden in patients with COPD, driven by a significant outgrowth of 
Haemophilus influenzae, suggesting that rhinovirus infection altered the respiratory 
microbiome and may precipitate secondary bacterial infections68. Others observed a 
reduction in alpha-diversity following COPD exacerbation72. Furthermore, medication 
might influence the respiratory microbiome, especially antibiotic and corticosteroid use 
are of interest. Evidence in this field is conflicting, as some observed72 a decreased al-
pha-diversity in subjects treated with corticosteroids alone and an increasing alpha-
diversity trend in patients treated with antibiotics alone or in combination with steroids. 
While an opposite trend was observed by others73. Generally, before we can oversee 
the precise role of the respiratory microbiome in patients with COPD more research is 
necessary, although results are promising. 
CLINICAL IMPLICATIONS AND FUTURE DIRECTIONS 
This thesis described different aspects of respiratory infections and exacerbations in 
patients with COPD. Both conditions negatively impact on disease outcomes and thus 
have important clinical implications. First, it is important to distinguish between respira-
tory infections in patients with COPD and COPD exacerbations74. Although both events 
present with comparable symptoms, they result in different treatment options. Misuse 
of antibiotics has consequences for future treatment options75. Besides, prevention 
should play a key role, including among others vaccination and pursuing a healthy life-
style. Second, assessing the microbiology in stable and disease state provides insight in 
airways colonisation, which is often present and possibly drives physicians into the 
wrong direction. Third, assessment of comorbidities is essential, not only in stable state, 
but also in disease state. It has been observed that patients with COPD present with 
8General discussion 
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many comorbidities76,77, highlighting the need for a personalised approach in the man-
agement of the disease. Fourth, pulmonary rehabilitation might play a substantial role 
in the latter. This intervention is multi-component and patient-centred, showing in 
general positive effects, even when interrupted by a COPD exacerbation. Nevertheless, 
COPD is a complex disease with a large heterogeneity between patients, which makes 
research and development of interventions necessary, but also challenging. Microbiome 
analysis is promising in understanding the role of the respiratory microbiome in health 
and disease, but further research is clearly needed. 
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SUMMARY 
Chronic Obstructive Pulmonary Disease (COPD), characterised by persistent respiratory 
symptoms and airflow limitation, is one of the leading causes of death worldwide with a 
high economic and societal burden. COPD is a very heterogeneous disease, which 
makes the management complex. The disease is featured by acute events, impacting on 
health related quality of life, exercise capacity and activities of daily living. These acute 
events can be discriminated in respiratory infections, including community acquired 
pneumonia (CAP), and exacerbations (AECOPD). Although both disease conditions pre-
sent with comparable symptoms, discrimination is important for prevention strategies, 
treatment options and outcomes. Therefore the current thesis aimed to better under-
stand both disease conditions as well as to provide recommendations for which speci-
mens to use for respiratory microbiome analysis (Chapter 1). 
To optimise disease management, it is important to gain insight into both disease condi-
tions. Chapter 2 and 3 aimed to assess the prevalence of COPD in CAP patients, as well 
as to determine characteristics and the bacterial aetiology of patients with COPD com-
pared to non-COPD patients. A large observational study revealed that CAP patients 
with COPD were significantly older, more often current or former smokers, with more 
severe CAP, compared to non-COPD patients with CAP. Different bacterial pathogens 
were observed in patients with and patients without COPD, which advocates the use of 
different treatment options. Besides, worse outcomes were observed in patients with 
COPD; higher mortality rates and longer length of hospital stay. Older age and admis-
sion to an intensive care unit were observed to be related to short- and long-term mor-
tality for patients with CAP, independent of COPD. Bacterial pathogen detection 
seemed to be important, as patients without pathogen detection had more severe CAP 
and higher mortality rates. Overall, these chapters suggest that insight into characteris-
tics of patients with COPD and the aetiology underlying CAP might contribute to better 
management and treatment of patients. 
Since smoking is the most important risk factor to develop COPD, and is also related to 
an increased risk of developing CAP, chapter 4 studied the impact of smoking on the risk 
to develop CAP in patients with COPD compared to patients without COPD. This study 
showed that current smoking is not related to an increased risk to develop CAP in pa-
tients with COPD, while this is the case in patients without COPD. Interestingly, current 
smoking patients with COPD had a comparable risk to develop CAP as never smoking 
patients with COPD. Which mechanisms underlie this observation is currently unknown 
and needs further investigation. 
One of the main symptoms related to COPD is sputum production. This symptom is also part 
of the definition of AECOPD, and frequently reported by patients. In chapter 5 the influence 
of sputum production and sputum aetiology on patient characteristics, health status and 
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exercise capacity was assessed in a population of patients with stable COPD who were re-
ferred for pulmonary rehabilitation (PR). Almost one-third of the patients with stable COPD 
produced a spontaneous sputum sample, with a positive culture related to a worse health 
status compared to patients who did not produce spontaneous sputum. Besides, patients 
with a positive sputum culture had a higher exacerbation frequency before PR and reported 
more often symptoms of chronic bronchitis. This study makes us aware of specific clinical 
profiles of patients with COPD, which is important in order to develop specific recommenda-
tions following the general management of patients with COPD. 
Next to CAP, patients with COPD are susceptible to acute exacerbations of the disease. 
AECOPD are often subject of research, but still much remains unclear due to the heter-
ogenic character of this event. In chapter 6 the impact of AECOPD, stratified by severity, 
on pulmonary rehabilitation (PR) was determined. This research observed that even 
though patients were having a mild-to-moderate AECOPD during PR, positive results 
were achieved at the end of PR. Unfortunately, patients with severe AECOPD during PR 
had on average no improvement of health related quality of life, symptoms of anxiety 
and depression and exercise capacity. However, these results also showed no overall 
decline in outcomes, which might be considered as a benefit. This should however, be 
investigated by comparing a group of patients with severe AECOPD during PR who fin-
ished PR, with a comparable group who did not finish PR. Still, it is important to moti-
vate and encourage patients to complete PR even though exacerbating, as the benefits 
of PR have been convincingly demonstrated in the past. 
Overall, the before mentioned results highlight the fact that a lot more research is neces-
sary in the field of respiratory infections and exacerbations in patients with COPD. In the 
last few years, respiratory microbiome analysis is positioned as a promising technique to 
overcome pressing questions. Chapter 7 aims to provide a recommendation on which 
respiratory specimens to use for respiratory microbiome analysis in patients with COPD. 
Different respiratory specimens were assessed, of both the upper and lower respiratory 
tract. In general, the alpha and beta diversity differed between the respiratory speci-
mens, but the patient-specific signature in the respiratory specimens was more pro-
nounced than the specimen-specific signature. So, different respiratory specimens of one 
subject are more alike to each other than similar respiratory specimens of other subjects. 
This observation makes respiratory microbiome research in the future easier, as less 
invasive sampling techniques might be sufficient enough for clinical practice. 
In conclusion, this thesis discussed various concepts of respiratory infections, exacerba-
tions and the respiratory microbiome in patients with COPD (Chapter 8). Many steps are 
needed to understand the different disease conditions and to optimize treatment and 
overall management. Respiratory microbiome analysis is challenging, as well as promis-
ing to understand the development of COPD. Possibly non-invasive sampling techniques 
can be used to assess the respiratory microbiome for clinical practice. 
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SAMENVATTING 
Chronisch obstructieve longziekten (COPD), gekarakteriseerd door persisterende respi-
ratoire symptomen en luchtwegobstructie, is één van de belangrijkste doodsoorzaken 
wereldwijd, met een hoge economische en sociale last. COPD is een heterogene ziekte, 
wat het management rondom de ziekte complex maakt. De ziekte wordt gekenmerkt 
door acute gebeurtenissen, welke van invloed zijn op de gezondheidsgerelateerde kwa-
liteit van leven, de inspanningscapaciteit en activiteiten van het dagelijkse leven. Deze 
acute gebeurtenissen kunnen worden onderscheiden in respiratoire infecties, onder 
andere een longontsteking opgelopen buiten het ziekenhuis (CAP), en longaanvallen 
(AECOPD). Ondanks dat beide ziektecondities gepaard gaan met vergelijkbare sympto-
men, is het belangrijk om onderscheid te maken tussen beide condities in het kader van 
preventiestrategieën, behandelingsmogelijkheden en uitkomsten. Daarom had het 
huidige proefschrift tot doel om beide ziektecondities beter te begrijpen en aanbevelin-
gen te geven voor welk respiratoir monster het best gebruikt kan worden voor respira-
toir microbioom analyse (Hoofdstuk 1). 
Voor het optimaliseren van het management rondom COPD, is het belangrijk om inzicht 
te krijgen in beide ziektecondities. Hoofdstuk 2 en 3 hadden tot doel de prevalentie van 
COPD in CAP patiënten te bepalen, alsook het vaststellen van karakteristieken en de 
bacteriële etiologie van patiënten met COPD vergeleken met niet-COPD patiënten. Uit 
een grote observationele studie bleek dat CAP patiënten met COPD significant ouder 
waren, vaker huidige of voormalige rokers, met ernstiger CAP, in vergelijking met niet-
COPD patiënten met CAP. Verschillende bacteriële pathogenen werden gevonden in 
patiënten met en zonder COPD, wat het belang aangeeft van verschillende behandelop-
ties. Bovendien bleken patiënten met COPD slechtere uitkomsten te hebben; hogere 
sterftecijfers en een langer verblijf in het ziekenhuis. Oudere leeftijd en opname op een 
intensive care afdeling werden gerelateerd aan korte- en lange termijn mortaliteit in 
CAP patiënten, onafhankelijk van COPD. Detectie van bacteriële pathogenen lijkt be-
langrijk, omdat patiënten zonder detectie van pathogenen ernstiger CAP en hoger sterf-
tecijfers hadden. Over het algemeen suggereren deze hoofdstukken dat inzicht in karak-
teristieken van patiënten met COPD en de etiologie van CAP mogelijk bijdragen aan een 
beter management en behandeling van patiënten. 
Omdat roken de belangrijkste risicofactor is voor het ontwikkelen van COPD, en ook 
verband houdt met een verhoogd risico op het ontwikkelen van CAP, werd in hoofdstuk 
4 de invloed van roken op het risico om CAP te ontwikkelen bij COPD-patiënten in ver-
gelijking met patiënten zonder COPD onderzocht. Dit onderzoek toonde aan dat huidig 
roken niet gerelateerd is aan een verhoogd risico op CAP bij patiënten met COPD, ter-
wijl dit wel het geval is bij patiënten zonder COPD. Interessant is dat de huidige rokers 
met COPD een vergelijkbaar risico op het ontwikkelen van CAP hadden ten opzichte van 
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nooit-rokende patiënten met COPD. Welke mechanismen ten grondslag liggen aan deze 
observatie is momenteel onbekend en zal verder onderzocht moeten worden. 
Een van de belangrijkste symptomen gerelateerd aan COPD is sputumproductie. Dit 
symptoom maakt ook deel uit van de definitie van AECOPD en wordt vaak gemeld door 
patiënten. In hoofdstuk 5 werd de invloed van sputumproductie en de etiologie van het 
sputum op patiëntkarakteristieken, gezondheidsstatus en inspanningscapaciteit onder-
zocht in een populatie van patiënten met stabiel COPD die werden verwezen voor long-
revalidatie (PR). Bijna een derde van de patiënten met stabiel COPD produceerde spon-
taan sputum, met een positieve kweek gerelateerd aan een slechtere gezondheidssta-
tus vergeleken met patiënten die geen spontaan sputum produceerde. Bovendien had-
den patiënten met een positieve sputumkweek een hogere AECOPD frequentie voor PR 
en meldden ze vaker symptomen van chronische bronchitis. Deze studie maakt ons 
bewust van specifieke klinische profielen van patiënten met COPD, wat belangrijk is om 
specifieke aanbevelingen te ontwikkelen volgend op het algemene management van 
patiënten met COPD.  
Naast CAP zijn patiënten met COPD ook gevoelig voor longaanvallen. AECOPD zijn vaak 
onderwerp van onderzoek, maar er is nog steeds veel onduidelijkheid vanwege het 
heterogene karakter van deze ziekteconditie. In hoofdstuk 6 werd de impact van AE-
COPD, gestratificeerd naar ernst, op longrevalidatie (PR) onderzocht. Uit dit onderzoek 
bleek dat hoewel patiënten een mild tot matige AECOPD hadden tijdens PR, er aan het 
einde van de PR positieve resultaten werden behaald. Helaas hadden patiënten met 
ernstige AECOPD tijdens PR gemiddeld geen verbetering van de gezondheidsgerela-
teerde kwaliteit van leven, symptomen van angst en depressie, en inspanningscapaci-
teit. Deze resultaten lieten echter ook geen algemene daling van resultaten zien, wat als 
een vooruitgang kan worden beschouwd. Dit moet echter worden onderzocht in een 
groep patiënten met ernstig AECOPD die PR afronden in vergelijking met een vergelijk-
bare groep patiënten die PR beëindigden. Toch is het belangrijk om patiënten met een 
AECOPD te blijven motiveren en aan te moedigen PR te voltooien, gezien de voordelen 
van PR in het verleden dikwijls overtuigend zijn aangetoond.  
Al met al wijzen de eerder genoemde resultaten erop dat veel meer onderzoek nodig is 
op het gebied van luchtweginfecties en longaanvallen bij patiënten met COPD. In de 
laatste paar jaar is respiratoire microbioom analyse gepositioneerd als een veelbelo-
vende techniek om prangende vragen te beantwoorden. Hoofdstuk 7 heeft tot doel een 
aanbeveling te geven over welk respiratoir monster gebruikt kan worden voor respira-
toire microbioom analyse bij patiënten met COPD. Verschillende monsters werden 
onderzocht, zowel van de bovenste als de onderste luchtwegen. Over het algemeen 
verschilden de alfa- en betadiversiteit tussen de respiratoire monsters, maar het pati-
ent-specifieke signatuur in de respiratoire monsters was meer uitgesproken dan het 
monster-specifieke signatuur. Verschillende respiratoire monsters van één persoon 
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lijken dus meer op elkaar dan vergelijkbare respiratoire monsters van verschillende 
personen. Deze observatie maakt onderzoek naar het respiratoire microbioom in de 
toekomst eenvoudiger, omdat minder invasieve technieken voldoende kunnen zijn voor 
de klinische praktijk. 
Concluderend besprak dit proefschrift verschillende concepten van luchtweginfecties, 
longaanvallen en het respiratoire microbioom bij patiënten met COPD (Hoofdstuk 8). Er 
zijn veel stappen nodig om de verschillende ziektecondities te begrijpen en de behande-
ling en het algemene management te optimaliseren. Analyse van het respiratoire mi-
crobioom is een uitdaging, evenals dat het een veelbelovende techniek is om het ont-
staan van COPD te begrijpen. Het is mogelijk dat niet-invasieve technieken gebruikt 
kunnen worden om het respiratoire microbioom in de klinische praktijk toe te passen. 
  
   
  167 
 
Valorisation 
  
   
Valorisation 
 169 
VALORISATION 
This thesis includes a series of studies to broaden our knowledge of respiratory infec-
tions, exacerbations and the respiratory microbiome in patients with Chronic Obstruc-
tive Pulmonary Disease (COPD). Practical implications are described in various chapters 
of this thesis, in order to make this knowledge suitable and available for clinical practice. 
In the current chapter, these studies and their outcomes are further positioned in a 
broader economical and societal framework, in order to transfer the scientific 
knowledge described into clinical practice, as well as to put the findings into future 
perspective. 
RELEVANCE 
COPD is a chronic disease, with a high morbidity and mortality, which affects many 
people. Research in the field of COPD is necessary, in order to gain insight into disease 
development and management. It is known that the prevalence of community acquired 
pneumonia (CAP) in patients with COPD is remarkably higher compared to controls, and 
that subgroups of patients with COPD are susceptible to COPD exacerbations. Both 
disease conditions influence socially and economically, which warrants the fact that a 
lot of obstacles need to be taken. 
The first part of this thesis focussed mainly on the impact of COPD with concomitant 
CAP on various health related outcomes. Adverse outcomes are more frequent and 
more severe in patients with COPD, for example a longer length of hospital stay and 
higher mortality rates. Targeted diagnostics of patients during hospitalisation play an 
important role, including microbiological sampling. Especially, the last should be a key 
component of the management of hospitalised CAP-COPD patients, as therapy can be 
better targeted to the spectrum of pathogens, which has the potential to reduce un-
necessary coverage, increase antimicrobial efficiency and also reduce the economic 
burden. 
Next to CAP, patients with COPD are vulnerable to COPD exacerbations. The concept of 
COPD exacerbations is still incompletely understood, since there is no clear definition 
yet. In the second part of this thesis, the impact of exacerbations on disease related 
outcomes following pulmonary rehabilitation was assessed. The results made clear that 
pulmonary rehabilitation has a positive effect on health status and exercise capacity, 
even when exacerbating mildly-to-moderately during the course of treatment. These 
results emphasise that completing pulmonary rehabilitation is essential, even for pa-
tients with a severe exacerbation. 
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Following the research questions and outcomes of the first two parts of this thesis, it 
became clear, that many steps should be taken to broaden our knowledge, in order to 
really understand what are the particular pathophysiologic features of the respiratory 
system of patients with COPD. Therefore, the last part of this thesis is especially rele-
vant for the future. Respiratory microbiome analysis is a central component in this and 
is expected to contribute to finding answers to health-related questions. Until now, the 
focus is on gaining insight into the microbial composition of the lungs in both health and 
disease. But, for the future, it has the potential to provide guidance in prevention of the 
disease and acute disease conditions, as well as treatment of the latter. 
TARGET GROUPS 
Health care professionals 
The main target group of this thesis are respiratory physicians, who are involved in the 
care of patients with COPD. Besides, for other health care providers, such as physician 
assistants, nurse practitioners and respiratory nurses, this thesis provides important 
clinical implications. Insight into respiratory infections is important to guide the man-
agement of patients with COPD. Therefore, microbiological sampling is an essential part 
of disease management. Moreover, insight into the microbiology involved in acute con-
ditions of the disease can trigger pharmaceutical companies to develop new treatment 
options. 
On the other hand, we also suggest a shift from treatment towards prevention. Para-
medics such as occupational therapists, physiotherapists and dieticians are expected to 
motivate and stimulate patients to maintain or gain a healthy lifestyle. Even when 
chronically ill, delaying disease progression can often be accomplished by healthy life-
style. Furthermore, health care professionals need to create a supportive environment 
and are encouraged to improve a patient’s performance. 
Patients with COPD 
Unfortunately, patients with COPD do not directly benefit from the research performed 
for this thesis. However, patients are always the main target, as research questions 
arise from problems patients encounter. By performing this research, our knowledge is 
extended, and might result in further research and recommendations for patients with 
COPD. One direct key message for patients with COPD is the fact that patients should 
not be withheld from completing pulmonary rehabilitation when exacerbating. For 
both, patients and health care professionals, this should result in motivation and faith 
that even after an acute event, encouraging results can be accomplished. Second, it is 
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worth mentioning, that we observed promising results for microbiome analysis with 
non-invasive sampling. Non-invasive sampling makes it easier to perform microbiome 
analysis in clinical practice, but also makes it easier to perform research in this field. We 
hope our research provides the basis for future research projects more directly targeted 
to clinical implementation and application. 
ACTIVITIES AND PRODUCTS 
The findings of this thesis have led to several activities in the field of expertise. The 
results of chapter 2 to 6 have been presented during the European Respiratory Society 
(ERS) Congress in 2013 (Barcelona, Spain), 2014 (Munich, Germany), 2015 (Amsterdam, 
the Netherlands) and 2016 (London, United Kingdom). Furthermore, the findings have 
been translated into original manuscripts, published in different scientific international 
journals. Besides, results have been presented at different meetings and courses orga-
nized by CIRO, the Maastricht University Medical Centre and other institutions. Follow-
ing these activities, the current findings have been distributed and may hopefully inspire 
future research. 
FUTURE PERSPECTIVE 
For the near future, it is important to distinguish between CAP and exacerbations in 
patients with COPD. Both acute events present with comparable symptoms and sub-
stantially impact on the disease, although treatment options differ. The disease condi-
tions are often mixed in clinical practice, while it is expected that clear definitions would 
positively contribute to both the societal and economical field, as disease management 
can be optimised. 
Second, respiratory microbiome analysis has a lot of potential, but is still in its infancy, 
and comprises many aspects which remain to be studied. Especially the technique used 
for microbiome analysis in this thesis needs to be further explored. Until now, respirato-
ry microbiome analysis changed our perspective concerning the microbial composition 
of the lungs. In future, microbiome analysis has the potential to shed light on the devel-
opment of disease and its relationship with health and disease alterations by advanced 
microbiology. This hopefully leads to new products such as medication, and techniques 
to prevent disease and/or disease alterations. 
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DANKWOORD 
Het dankwoord… het leukste, maar misschien ook wel het lastigste gedeelte van dit 
proefschrift om te schrijven. Ten eerste wil ik benadrukken dat het schrijven van dit 
proefschrift nooit was gelukt zonder de steun en hulp van heel veel mensen. Promove-
ren lukt alleen als je onderdeel bent van één groot team. Een woord van dank aan allen 
die, in welke vorm dan ook, een bijdrage hebben geleverd aan dit proefschrift en mij 
hebben gesteund en geïnspireerd! 
Mijn grootste dank gaat uit naar de vrijwillige deelnemers die tijd hebben vrijgemaakt 
om deel te nemen aan alle onderzoeken die in dit proefschrift staan beschreven. Wat 
vond ik het vaak lastig om mensen te vragen of ze een paar minuten tijd voor me had-
den en of ze hun vrije tijd wilden besteden aan mijn onderzoek. Ik heb veel respect voor 
al deze vrijwilligers, die vaak naast hun ziek zijn ook nog de puf en zin hadden om deel 
te nemen aan onderzoek. 
Een hartelijk woord van dank aan professor Wouters. Uw inzichten en kritische feed-
back hebben mijn proefschrift naar een hoger niveau getild. Tevens bedankt voor het 
gestelde vertrouwen in mij. Ik ben blij dat ik een jaar deel mocht uitmaken van het 
MUMC-team. Dank ook aan Ingrid Augustin, dat ik van jullie beiden de kans heb gekre-
gen om mijn promotieonderzoek binnen CIRO te doen. 
Beste Frits en Gernot, zonder jullie was dit alles nooit tot stand gekomen. Jullie hebben 
mij professioneel begeleid en zijn op en top betrokken geweest bij mijn proces. Jullie 
vertrouwen, optimisme en enthousiasme heb ik nodig gehad om een minder geijkt 
promotietraject te kunnen voltooien. Tevens heb ik door jullie vertrouwen in mij en de 
goede woordjes, die jullie voor mij gedaan hebben een jaar lang ervaring mogen op-
doen in Maastricht. Heel erg bedankt voor deze kans. Beste Gernot, ik had graag nog 
wat jaren met je samengewerkt, maar deze kans kon je natuurlijk niet laten liggen. Ik 
wens je heel veel succes in je verdere toekomst. Beste Frits, ook aan onze samenwer-
king is helaas een einde gekomen. Ik had gehoopt nog velen jaren met jou samen te 
werken en van gedachten te wisselen. Ik ben blij met de nieuwe uitdaging die ik aanga, 
maar was ook heel graag onderdeel gebleven van het team Longziekten/CIRO. Hopelijk 
kunnen we nog een aantal mooie projecten afronden. 
Beste co-auteurs, bedankt voor jullie kritische blik en waardevolle feedback. Dear co-
authors, thank you for your critical input and valuable feedback. Frank en Annemariek 
heel veel dank voor jullie hulp bij het CPRD-paper, zonder jullie was het niet gelukt. 
Dank aan alle leden van de beoordelingscommissie van dit proefschrift. Voorzitter Prof. 
Wesseling, Prof. Muris en Dr. Bergmans, dank voor jullie kritische beoordeling en goed-
keuring van dit proefschrift. Dear Prof. Stolz and Dr. Hurst, thank you for your critical 
assessment and approval of this thesis. 
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Mijn geweldige en lieve collega’s… Sarah, Dionne S, Jeannet, Carmen, Wai-Yan, Fiona, 
Nienke, Anouk, Yvonne, Cindy, Rafael, Coby en Vasislis… wat heb ik een geweldige tijd 
gehad!. Zonder jullie was het nooit zo leuk geweest. Ik heb jullie vaak van het werk 
gehouden (nogmaals sorry), maar ik was altijd blij jullie weer te zien. Wat hebben we 
veel gelachen, mooie momenten meegemaakt en natuurlijk niet te vergeten de vele 
kilo’s lekkers die we samen verorberd hebben. Daarnaast bewonder ik het begrip voor 
en het vertrouwen in elkaar. Ontzettend bedankt voor de mooie tijd die we samen had-
den/hebben! Fiona, bedankt dat ik al mocht proeven aan het promoveren door jou bij 
te staan. Een hele eer waar ik trots op ben. 
Beste Riny en Annie, wat heb ik genoten van jullie. Altijd goedgemutst en behulpzaam. 
Jullie zijn toppers in het rekruteren van deelnemers. Ik hoop dat jullie beiden van een 
mooi welverdiend pensioen genieten! Miriam, bedankt voor je statistische inzichten en 
adviezen. 
Jacqueline, Marleen, Hilde, Nancy, Dorien, Erna en Guido, het hoekje van Maastricht. 
Gelukkig mocht ik een jaartje langer genieten van onze gangpraatjes en heb ik voor 
even het team mogen versterken. Jullie hebben mijn dagen in Maastricht veraange-
naamd en kleur gegeven. Bedankt voor de gezelligheid, jullie praktische inzichten, be-
grip en vertrouwen! Succes met alle ontwikkelingen en kansen die er liggen. 
De dames van de microbiologie, Marlies en Marie-Louise, Carla, Birke en Charlotte: 
bedankt voor jullie geduld met mij, de ‘niets-van-microbiologie-afwetende’ promoven-
da. Ik heb in 4 jaar tijd heel veel geleerd over microbiologie, maar moet eerlijk beken-
nen dat ik nog steeds een ‘groentje’ ben. Ik heb veel respect voor jullie werk. Een speci-
aal woord van dank aan Marlies voor de privélessen over het microbioom en Marie-
Louise voor al het lab-werk. 
Alle overige CIRO en MUMC collega’s, ontzettend bedankt voor jullie medewerking en 
begrip. CIRO voelt als een kleine familie en ik vind het fijn hier deel van te zijn geweest. 
Marianne en Kitty bedankt voor jullie lessen in longfunctie. De longartsen en assistenten 
in Maastricht wil ik danken voor het enthousiasmeren van patiënten en jullie uitleg en 
hulp bij de bronchoscopieën: heel leerzaam. Annemarie, Conny, Esther, Gerrie, Ilse, 
Margeret, Mieke, Willy, Paul en Marie-José: bedankt voor de fijne samenwerking en 
jullie interesse in mijn werk. 
Arjen, Eline, Frank, Inge, Josien, Martijn, Nicol, Quinten en Vivian, bedankt voor jullie 
vriendschap. Ik geniet altijd van ons stichtelijke ‘weekendje weg’ naar Banneux. Anja, 
Jolanda, Sharon en Stéphanie, wat ben ik gezegend met deze unieke vriendinnen! Nooit 
gedacht dat we na het afronden van onze opleiding HBO-V nog zo’n hechte groep zou-
den zijn. We hebben in al die jaren al vele mooie momenten mogen meemaken met 
elkaar. Ik hoop dat onze eetavondjes nog lang standhouden. Anja en Susan, bedankt 
voor jullie altijddurende vriendschap. Dat we in de toekomst nog veel van elkaar en 
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onze gezinnen mogen genieten. Dames van HV IASON/HV MIC, jullie zorgden voor de 
wekelijkse ontspanning, zowel sportief als sociaal. 
Ger, Yvonne, Richard, Diana, Raoul, Renske en Boukje, wat fijn dat ik deel mag uitmaken 
van jullie familie. Bedankt voor jullie interesse in mijn werk. 
Mijn paranimfen, Jeannet en Eline. Jeannet: jij bent onze vaste waarde op kantoor en 
hebt geen idee wat je voor ons allemaal betekent! Je bent altijd geïnteresseerd in ie-
dereen, zowel persoonlijk als werkinhoudelijk. Blijf jezelf en zo behulpzaam als je bent. 
Heel veel succes met je opleiding en wie weet, ooit een promotie  
Pap en mam, danke! Wat mos ich toch zonder uch. Bedank veur uch sjteun en vertroe-
we. Sorry veur ’t mótte loestere nao al die eindeloze verhaole van mich. Helaas zal dat 
neet verandere nao ‘t aafronde van mien promotie, dus väöl sjterkte  Eline en Arjen, 
mien groate zus en klein breurke… Eline, auch doe höbs väöl mótte aanhuère, meh 
waors altied begripvol. Dank veur dien interesse in mien werk en de gezellige oetsjtep-
kes, ich kin mich gein betere zus indinke! Arjen, mèt dich kin ich zoa väöl lache! Af en 
toe haols te ós ‘t blood onder de negel oet, meh soms zou ich wille get miè van dien 
nonchalance te höbbe. Gelukkig is Caroline noe ouch ónderdeil van de familie en kint ‘t 
dich e bitsje in toom houte. Ich kom gaer thoes en kin uch neet misse. Oma, danke veur 
uch interesse in mien ‘sjtudie’. Ich hoop dat veer nog ein aantal jaore van uch maoge 
genete in gooi gezondheid. 
Michael, danke veur al dien geduld en leefde! ’t Is neet altied gemekkelek mèt mich te 
leve. Hopelek höbbe veer nog gans get jaore um vanein en Funs te genete. 
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Dionne Braeken is geboren op 13 juni 1987 in Houthem St.-Gerlach. In 2004 behaalde 
zij haar HAVO-diploma aan het Stella Maris college te Meerssen. In hetzelfde jaar startte 
zij met de studie HBO-verpleegkunde aan de Hogeschool Zuyd Heerlen, welke ze in 
2008 met goed gevolg afrondde. Vervolgens heeft ze een jaar gewerkt als verpleegkun-
dige in Zorgcentrum Vroenhof, gecombineerd met een cursus statistiek en methodiek 
als voorbereiding op een master opleiding. In 2009 startte ze met de master Gezond-
heidswetenschappen aan de Universiteit Maastricht. Na haar afstuderen in 2010 heeft 
ze twee jaar gewerkt als onderzoeksmedewerkster bij GALA, een onderdeel van het 
Hart- en Vaat Centrum in het MUMC+ te Maastricht. Het laatste half jaar heeft ze dit 
werk gecombineerd met een baan als ARBO-verpleegkundige bij EASE travel clinic. Van-
af oktober 2012 is ze gestart met haar promotieonderzoek bij CIRO te Horn op het ge-
bied van respiratoire infecties, exacerbaties en het respiratoire microbioom bij patiën-
ten met COPD onder leiding van Prof. Dr. Emiel F.M. Wouters, Dr. Frits Franssen en 
Prof. Dr. Gernot Rohde. De resultaten van dit promotieonderzoek werden gepresen-
teerd op verschillende internationale congressen en resulteerde in 2013 in een Young 
Scientist Award van de European Respiratory Society (ERS). In 2017 is Dionne werkzaam 
geweest als wetenschappelijk onderzoekster in het MUMC+ voor de afdeling Longziek-
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werkzaam als trombosevigilantie functionaris in het MUMC+. Dionne is getrouwd met 
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